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Abstract
Large animal species, such as cattle, sheep and pigs, have great potential value to scientific
research. This is due to their physiological similarity to humans, meaning they make excel-
lent disease models in addition to their inherent agricultural value. However, the efficiency
with which such animals can be created has been a critical barrier to their use in bioscience.
Research into creating genetically modified large animals has not progressed as rapidly as re-
search on smaller mammals, such as mice, for two main reasons. Firstly, technologies such
as pluripotent stem cells, which are well established in rodents, are lacking for large animals.
Secondly, large animals cannot produce as many offspring within a given time frame as mice or
rats. This, combined with the low efficiencies and lack of precision of current transgenic meth-
ods, severely reduces the likelihood of obtaining an animal with a desired genotype within a
viable amount of time.
Recently, new tools known as ’genome editors’ have been developed to facilitate genetic
modification of animals. The vastly enhanced efficiency of these editors in comparison to pre-
vious gene targeting methods, combined with the fact that genome editors do not require marker
genes to be used, mean that creating genetically modified livestock is now far more feasible.
This thesis investigates whether two types of genome editor, TALENs and CRISPR/Cas9, can
be used to produce genetically modified large animals for a range of applications.
Genome editors were combined with interspecific blastocyst complementation techniques to
produce chimeric rodents where the haematopoietic system is partially or fully derived from
the donor cells. This work was carried out with a long-term aim of producing chimeric animals
which could produce human organs suitable for transplantation. Initial blastocyst complement-
ation experiments were carried out by injecting murine ESCs into wildtype rat blastocysts.
One animal resulting from these injections showed chimerism in several tissues. Further ex-
periments were carried out using rat ESCs and mouse blastocysts which were either Runx1-/-
xiv
or Rag1-/-, however no additional chimeras were identified. In addition to these experiments,
TALENs and sgRNAs were designed against Runx1 and Rag1 in sheep and pigs in order to
create a large animal model for future blastocyst complementation experiments.
Increasing animal productivity is a key step in meeting the demands of an increasing global
population and tackling future food insecurities. TALENs and sgRNAs for use in the CR-
ISPR/Cas9 system were created to target the myostatin gene in sheep. Myostatin is a negative
regulator of muscle growth and animals which acquire natural inactivating mutations in both
myostatin alleles exhibit a well-characterised double-muscled phenotype, where total muscle
mass is about 20% greater than that of a wildtype animal. Embryo microinjections were car-
ried out using both types of genome editor and two edited lambs were produced, one from each
editor. The TALEN-edited lamb was mosaic for a deletion of arginine 283 which, upon further
analysis of the muscle, did not appear to cause a significant phenotype. The CRISPR-edited
lamb was heterozygous for a 20bp deletion, causing the formation of a premature stop codon
and severe truncation of the mature myostatin protein. Based on data from other myostatin-
knockout animals, including the Belgian Blue cattle breed, this truncated protein is not thought
to be functional. To determine if this is indeed the case, the CRISPR-edited lamb is now part
of a breeding programme to amplify the edited allele.
To discover if genome editors could be applied to create disease-resistant animals, the project
focused on foot and mouth disease. Through a literature search and bioinformatic analysis
of the bovine and porcine proteomes, three host genes which are cleaved by the virus were
identified; eIF4A1, eIF4G1 and IKBKG. TALENs were designed to bind and cut at the FMDV
protease cleavage sites in all three genes in order to disrupt protease cleavage and reduce viral
replication by slowing viral disruption of the host translation and innate immune response
pathways. Although none of the TALENs showed any signs of activity, this thesis sets out
some potential directions for future work.
In conclusion, this thesis shows that, despite some technical issues, genome editors are a
promising technology for the creation of genetically modified livestock.
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Lay Summary
Genetic modification (GM) is the process by which the DNA of a living organism is altered to
produce a desired characteristic, such as resistance to disease. This technique has many poten-
tial applications in different areas of science; from microbiology to plant science. However,
established GM methods are notoriously inefficient and therefore can only really be applied
to cases where enough offspring will be produced that there is a good chance of getting the
desired modified organism.
Genome editors are a recently developed and easy-to-use GM method, with efficiencies far
higher than those previously used. This means that animals which give birth to relatively few
offspring, such as sheep and cattle, can now be genetically modified with a reasonable chance
of success. This thesis explores several potential uses of GM livestock species. Firstly, we
attempt to create animals which cannot produce blood, with the intention of “rescuing” these
animals by injecting them with human blood cells and establishing them as a future source of
human blood for transfusion. We also investigate the possibility of increasing the productivity
of livestock, by increasing the amount of muscle on animals bred for meat and by making
animals resistant to foot and mouth disease, which can be a major cause of financial loss for
farmers.
The work in this thesis shows that it is possible to produce GM livestock animals with a
relatively high efficiency. However, much of the research presented here ran into technical
problems, demonstrating that there is plenty of scope for genome editors to be better understood
and refined before they reach their maximum potential.
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The ability to alter the genetic information contained within an organism has become a key
part of scientific research in the last 50 years and is seen by some as part of the solution to
global socio-economic issues, such as climate change and food security. The two key methods
required to produced a transgenic organism are the ability to create a desired DNA molecule
and the ability to insert this molecule into a cell or organism, both of which were first published
in 1972. The bacterium Escherichia coli was the first organism to be successfully transformed
with exogenous DNA (Cohen et al., 1972) and was soon followed by the report of the first
recombinant DNA molecule, created by adjoining DNA molecules from the virus SV40 and
the E. coli gal operon (Jackson et al., 1972). The production of recombinant DNA molecules
improved with the introduction of restriction enzymes to construct plasmid molecules (Cohen
et al., 1973), a technique which is still central to molecular cloning today.
Eukaryotic cells were transformed for the first time using the same principles behind those
of bacterial transformation (Szybalska and Szybalski, 1962, Graham and van der Eb, 1973,
Hinnen et al., 1978). The transformation of ribosomal RNA genes from Xenopus into E. coli
showed that eukaryotic genes could be expressed in prokaryotic cells (Morrow et al., 1974), an
observation that was later exploited to create bacteria which produced the regulatory hormone
somatostatin (Itakura et al., 1977), leading to the use of transgenic organisms as bioreactors
producing molecules of scientific and medical value.
The mouse was the one of the first multicellular organisms to be genetically modified by
the injection of SV40 DNA into the blastocoel of mouse blastocysts (Jaenisch and Mintz,
1974). Analysis of animals resulting from the injections showed the presence of SV40 DNA
in tissues of 34% of the adult mice analysed. Pronuclear injection allowed donor DNA to be
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stably integrated into recipient genomes and passed down to descendants through the germline
(Gordon and Ruddle, 1981). Since then, other multicellular organisms such as plants (Bevan
et al., 1983), nematodes (Stinchcomb et al., 1985), insects (Rubin and Spradling, 1982), fish
(Maclean and Talwar, 1984), birds (Bosselman et al., 1989) and large mammals such as pigs,
sheep and primates (Hammer et al., 1985, Chan et al., 2001) have been successfully genetically
modified by microinjection.
The isolation and culture of ES cells (Evans and Kaufman, 1981, Thomson et al., 1998, Buehr
et al., 2008) and production of iPS cells (Takahashi and Yamanaka, 2006) has provided another
route to producing genetically modified animals (Thomas and Capecchi, 1987, Doetschman
et al., 1987, Tong et al., 2010, Okita et al., 2007). However, this resource is only available for
a select number of species, such as mice and rats. Although iPS lines showed initial promise
in providing suitable pluripotent cells for large animals transgenics, the lack of suitable culture
conditions mean that this is not yet a reality. For species where stem cell lines are not available,
cloning by SCNT provides another route to producing transgenic animals (Wilmut et al., 1997).
Although the efficiency of producing live transgenic animals by cloning is low, and potentially
prohibitive to laboratories which don’t have appropriate resources, both SCNT and targeted
stem cells have an advantage over embryo microinjection as the donor cells and modification
can be characterised prior to their use.
Although new reagents and techniques such as viral vectors and transposons (Terwilliger
et al., 1989, Sorge and Hughes, 1982, Berkner, 1988, Dupuy et al., 2002), Cre-lox recombin-
ation (Hamilton and Abremski, 1984), GFP and other marker genes (Chalfie et al., 1994) and
miRNAs to induce gene knockdown (Fire et al., 1998) have helped to refine the process of ge-
netic modification, making changes to endogenous genes and making subtle changes to DNA
(i.e. mutating single nucleotides) is still a complex and inefficient process.
1.2. Genome editors
Genome editors are a recently developed technology which allow genetic modifications to be
carried out with unprecedented accuracy and efficiency. Each genome editor has two main
components; a customisable DNA-binding molecule, which is usually a protein or RNA mo-
lecule, and an endonuclease which relies on the DNA-binding molecule for its cleavage spe-
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cificity (i.e. it has no target sequence requirements of its own). When introduced into a cell,
genome editors induce double-strand breaks (DSBs) in the DNA. These breaks, in turn, stimu-
late the cell’s DNA damage response and eventual repair of the DNA. Repair of DSBs in DNA
tends to occur through one of two main mechanisms; non-homologous end joining (NHEJ) or
homology-directed repair (HDR). From the perspective of using genome editors, NHEJ is the
pathway exploited when the researcher wishes to knock out or disrupt a gene, as NHEJ’s error-
prone propensity makes it likely that inactivating mutations will be introduced into the DNA.
When a more precise modification is required, a donor DNA template containing the required
alteration can be introduced into the cell along with the genome editors and incorporated into
the genome by HDR. In addition, both NHEJ and HDR can be used to mediate the deletion of
DNA fragments. The DNA damage response and DNA repair by NHEJ or HDR are described
in Section 1.2.1 below.
Genome editors are particularly useful in cases of gene targeting, where use of an endo-
nuclease to introduce DSBs at the target site can increase the efficiency of targeting by 2 to
3 orders of magnitude (Rouet et al., 1994). More specifically, genome editors can increase
the frequency of gene targeting from 1 in 1x106-1x107 without an editor to 10% of the total
cell population when an editor is used (Park and Telugu, 2013). This leap in efficiency also
makes the production of cells where both alleles have been targeted more likely and, unlike
other methods of genetic modification, there is no requirement to include marker genes, such
as those encoding antibiotic resistance or fluorescent proteins.
1.2.1. DNA repair
1.2.1.1. DNA damage response
An outline of the DNA damage response is given below. For a detailed review, see Ciccia and
Elledge (2010).
DNA damage, including DSBs caused by genome editors, is detected by DNA damage re-
sponse proteins known collectively as phosphoinositol-3-kinase-like protein kinases or PIKKs.
The individual PIKKs are the kinases DNA-PK (a protein complex of DNA-PKcs and Ku),
ATM and ATR. It is known that ATM responds to DSBs where the broken ends are perman-
ently blocked (i.e. they do not end with a 5´ phosphate or 3´ hydroxyl group), which accounts
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for around 10-20% of the total DSBs experienced by a cell (Alvarez-Quilon et al., 2014).
However, it is presently unclear which, if any, of the known PIKKs signal the presence of the
remaining 80-90% of DSBs and by what mechanism this signalling occurs.
Once the presence of DNA damage is detected, ATM and DNA-PK are activated by the
MRE11 complex, which consists of the nuclease MRE11, the DNA-binding protein RAD50
and the adaptor protein NBS1. The MRE11 complex is recruited to the site of the DSB (Lisby
et al., 2004, Lee and Paull, 2005, 2004, Bakkenist and Kastan, 2003) and, in turn, recruits
histone H2AX by phosphorylation (Furuta et al., 2003, Rogakou et al., 1998), which itself
recruits more DNA repair factors (Celeste et al., 2002). ATM also prevents transcription from
occurring near the site of the DSB (Shanbhag et al., 2010) and induces chromatin relaxation
across the whole genome, preventing further DNA damage (Ziv et al., 2006). Activated ATM
and ATR phosphorylate mediator proteins, such as CHK1 and CHK2. This has the effect
of slowing or halting cell cycle progression and amplifies the DNA damage signal (Chehab
et al., 2000, Liu et al., 2000, Matsuoka et al., 2000). This results in the activation of the
ubiquitin-protein ligase BRCA1 (Cortez et al., 1999), which is involved in the regulation of
the S-phase and G2-M checkpoints, as well as the stabilisation and activation of p53 by ATM
and the helicase CHD4 (Kastan et al., 1992, Polo et al., 2010), which act at the G1-S cell
cycle checkpoint. As well as cell cycle arrest, p53 can also initiate apoptosis or senescence in
response to DNA damage.
Once cell cycle arrest has occurred, the cell then repairs the DNA by either NHEJ or HDR,
described below.
1.2.1.2. Non-homologous end joining (NHEJ)
Two distinct NHEJ pathways have been identified; classical NHEJ (cNHEJ), the more studied
of the two, and alternative NHEJ (aNHEJ). Both pathways are error-prone and are likely to
introduce mutations into a repaired DNA site. They are generally exploited in genome editing
techniques when an inactivating mutation is required, but the exact nature of the mutation is
not important.
Classical NHEJ was first described in the 1980s following studies in eukaryotic cells (Wilson
et al., 1982, Roth et al., 1989, 1985, Roth and Wilson, 1986) and is the major DNA repair
pathway in eukaryotes, although it has a tendency to leave small indels in the repaired DNA.
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cNHEJ is initiated when the Ku heterodimer, consisting of the proteins Ku70 and Ku80/Ku86,
forms a ring around free DNA ends resulting from a DSB (Mari et al., 2006). Ku binds to
the DNA sugar backbone, allowing it to bind DNA in a sequence-independent manner (Walker
et al., 2001). The Ku heterodimer protects the DNA ends from further damage and provides
a scaffold for other factors involved in cNHEJ, such as the scaffold protein XRCC4 (Mari
et al., 2006) and DNA-PKcs (Uematsu et al., 2007). XRCC4 enters the nucleus and recruits
DNA ligase IV to form the XRCC4-Ligase IV complex, which stimulates the ligase’s activity
(Grawunder et al., 1997).
DNA-PKcs stimulates synapsis of the broken DNA ends and recruits enzymes involved in
end processing and ligation (DeFazio et al., 2002). Broken DNA ends which still have a 5’
phosphate group and a 3’ hydroxyl group can be directly ligated to each other at this point
and the break repaired. DNA ends which have undergone greater levels of damage are first
processed by enzymes such as Artemis, which opens DNA hairpins (Ma et al., 2002), the Ku
heterodimer, which removes abasic nucleotides from the DNA (Strande et al., 2012) and PNKP,
a phosphatase which adds and removes phosphate groups so that the DNA ends can be ligated
together (Chappell et al., 2002). Several DNA polymerases are used to fill any gaps in the
DNA strands at the site of a DSB, as reviewed in detail by Moon et al. (2007). This polymerase
activity is mediated by the Ku-XRCC4-Ligase IV-XLF complex and PAXX, a scaffold protein
related to XRCC4 (Akopiants et al., 2009, Ochi et al., 2015). DNA ends are finally ligated
together by the XRCC4-Ligase IV complex (Grawunder et al., 1997, Ahnesorg et al., 2006),
an action promoted by the DNA-binding protein XLF (Riballo et al., 2009). The XRCC4-
Ligase IV complex can ligate across gaps (Gu et al., 2007) and can ligate each DNA strand
individually (Ma et al., 2004). This allows one of the DNA strands to be repaired and protected
if the other strand is not able to be ligated. The NHEJ complex then dissociates from the DNA
via an unknown mechanism, although protein ubiquitination is thought to play a role (Davis
and Chen, 2013).
Alternative NHEJ is considered to be more error-prone than cNHEJ and can cause larger
mutations. It was first observed in cells which lacked crucial cNHEJ proteins, such as Ku80,
(Liang and Jasin, 1996), XRCC4 (Kabotyanski et al., 1998), Ku70 (Boulton and Jackson, 1996)
and Rag2 (Corneo et al., 2007). aNHEJ uses areas of microhomology to direct repair (Boulton
and Jackson, 1996, Kabotyanski et al., 1998, Guirouilh-Barbat et al., 2007) and can often cause
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chromosomal translocations due to unstable DNA ends (Simsek and Jasin, 2010, Zhu et al.,
2002). The exact mechanism of aNHEJ has yet to be fully elucidated and it is possible that
there may be multiple aNHEJ pathways (Simsek et al., 2011). However, there is evidence
that RAD52, CtIP, the MRE11 complex and DNA ligase III may all have roles to play in this
process (Boulton and Jackson, 1996, Zhang and Jasin, 2011, Lee-Theilen et al., 2011, Deriano
et al., 2009, Xie et al., 2009, Simsek and Jasin, 2010). Although it was discovered in cNHEJ-
incompetent cells, aNHEJ is also active in WT cells and accounts for about 10% of total NHEJ
activity within a cell (Corneo et al., 2007).
1.2.1.3. Homology-directed repair (HDR)
Homology-directed repair is thought to only be active in the S and G2 phases of the cell cycle
and, indeed, NHEJ is suppressed by Cdk1 at the G2 phase and by BRCA1 at S phase to allow
HDR to occur (Zhang et al., 2009, Davis et al., 2015). Histone modifications and the position
of the DSB within the nucleus also play a role in determining whether DNA will be repaired
by NHEJ or HDR (Pai et al., 2014, Lemaitre et al., 2014). This could have implications on the
success of genome editing, particularly in embryos, as if a cell is not in the correct cell cycle
phase, HDR is far less likely to occur. Synchronising cell cycles and transfection of a donor
template during a more HDR-permissive phase of the cell cycle has been shown to increase
donor integration rates (Rivera-Torres et al., 2014).
DNA is prepared for HDR by the loading of the MRE11 complex onto the free DNA ends and
subsequent activation of ATM (Lee and Paull, 2004). RAD50 is recruited to the MRE11 com-
plex and may help to keep the DNA ends close to each other by forming a bridge between them
(de Jager et al., 2001). ATM regulates resection of DNA, where small deletions are made at the
5’ ends of DNA breaks. This causes Ku complexes to dissociate from the DNA and pushes cells
to be more committed to HDR than NHEJ (Zhang et al., 2009). RPA complexes then bind to
single-stranded 3’ ends (Coverley et al., 1991, 1992), allowing assembly of RAD51 filaments
by SUMOylation of RAD51 monomers (Golub et al., 1998, Shima et al., 2013), mediated by
BRCA1 and BRCA2 (Esashi et al., 2005). RAD51 filaments are known to stimulate strand
invasion into an homologous sequence or, in the case of genome editing, the externally sup-
plied template containing the desired mutation. In prokaryotes, RecA (the RAD51 homolog)
filaments also mediate the search for a homologous sequence in the genome, prior to strand
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invasion (Lesterlin et al., 2014). Once it is paired with a homologous sequence, the invading
strand is repaired by extension by polymerases and annealing to the other end of the break,
which is regulated by the helicase RTEL (Barber et al., 2008). This leads to D-loop formation,
which causes capture of the second end and Holliday junction formation (shown in the con-
text of introducing an exogenous template in Figure 1.1). The removal of Holliday junctions
and restoration of linear DNA molecules can result in either non-crossover and a perfect re-
pair, or crossover, where the aligned chromatids swap portions of their DNA. Non-crossover is
achieved by either dissolution by the mammalian BLM/TOP3a helicase-topoisomerase com-
plex (Ira et al., 2003) or synthesis-dependent strand annealing (Nassif et al., 1994). Crossover
events are caused by resolution of the junction by resolvases (endonucleases) like GEN1 (Ip
et al., 2008), or those associated with the SLX4 complex (Munoz et al., 2009, Svendsen et al.,
2009, Fekairi et al., 2009). For a detailed review of resolvases see West (2009). In the case of
DSBs induced by genome editors, they are likely to be resolved by the gene conversion mech-
anism (see Svendsen and Harper (2010) for detailed description), as both ends of the DSB are
present.
1.2.2. Meganucleases
Meganucleases are endonucleases which recognise and cleave DNA at specific sequences. Un-
like restriction enzymes, which usually recognise a site of 3-8bp in length, meganuclease re-
cognition sites can range in length from 12 to 44bp, but can tolerate some mismatches. This
high specificity means that a meganuclease will only cut at a few loci within a genome; a
favourable characteristic for a genome editor.
Meganucleases are represented in nature by homing endonucleases, an example being I-SceI,
found in yeast mitochondria. These are mobile genetic elements which were first identified in
yeast (Jacquier and Dujon, 1985) and are generally found within introns or inteins and are
noted for their ability to home in on sequences which aren’t already colonised by a homing
endonuclease. There are four major families of homing endonuclease, named after amino
acid motifs shared between the family members: LAGLIDADG or LHEs, which are the most
studied homing endonuclease family, H-N-H, His-Cys box, and GIY-YIG (Stoddard, 2005).
Homing endonucleases can induce DSBs in mammalian cells and, when used in conjunction
with an exogenous template, can stimulate gene targeting via homologous recombination at
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Figure 1.1.: Diagram showing repair of a DSB using an exogenous DNA template (orange) and
Holliday junction formation.
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a far greater efficiency than seen when the targeting vector alone is introduced (Rouet et al.,
1994, Choulika et al., 1995). However, it is highly unlikely that a candidate gene for editing
will contain a natural homing endonuclease recognition site. Therefore, the ability to change
the recognition sequence of a homing endonuclease or to produce artificial meganucleases with
relative ease is imperative to their use as genome editors.
The specificity of a meganuclease can be changed in a number of ways. If the meganuclease
originates from a Group II intron, the specificity of the enzyme can be altered by substituting
the intron RNA sequence which the endonuclease is associated with. This can be used to edit
endogenous gene sequences by supplying the desired sequence as the intronic RNA (Guo et al.,
1997, 2000). Changing the sequence specificity of a homing endonuclease originating from a
Group I intron is more complex and requires the physical structure of the protein to be altered,
such as the DNA-binding abbabba folds in LHEs (Arnould et al., 2006, Smith et al., 2006,
Silva et al., 2006). This can be done by domain swapping (Steuer et al., 2004) or domain
fusion (Chevalier et al., 2002, Epinat et al., 2003), which exploits the natural DNA sequence
specificity of other endonucleases, or by making point mutations within the enzyme (Seligman
et al., 2002, Sussman et al., 2004). The majority of homing endonucleases which have been
characterised so far have been isolated from Group I introns. The process of designing a custom
meganuclease is made easier if the crystal structure of the natural endonuclease in complex with
its DNA target is known (Flick et al., 1998, Jurica et al., 1998, Van Roey et al., 2001, Moure
et al., 2003, Landthaler et al., 2006), but still necessitates the use of computational modelling
if a specific DNA sequence is to be targeted (Ashworth et al., 2010), making the process of
designing a custom meganuclease complex.
Despite this, meganucleases targeting endogenous DNA sequences have been produced (Smith
et al., 2006, Grizot et al., 2009) and have also been used to correct deleterious alleles, such as
those involved in SCID and Duchenne muscular dystrophy, with an efficiency of up to 6%
(Arnould et al., 2007, Chapdelaine et al., 2010). They can also be used to create transgenic
mammals capable of transmitting the transgene through the germline (Menoret et al., 2013,
Wang et al., 2014c). It is also possible to engineer meganucleases with nickase activity (Niu
et al., 2008, McConnell Smith et al., 2009), where only one DNA strand is cut. This reduces
the chances of an NHEJ event occurring at the target site, while still providing favourable
conditions for integration of exogenous DNA by HDR.
9
1.2.3. Zinc finger nucleases
Zinc finger domains were first described during characterisation of the transcription factor IIIA
in Xenopus as repeats of about 30 amino acids in length which could bind zinc ions (Brown
et al., 1985, Miller et al., 1985). The high frequency of cysteine and histidine residues within
these repeats later led to these particular zinc finger domains being placed in the Cys2-His2
class of zinc fingers. Zinc finger domains which fall within this class consist of an a-helix and
an anti-parallel b-sheet which, between them, bind a zinc ion (Pavletich and Pabo, 1991). DNA
recognition is mediated by the a-helix, which binds in the major groove of the target DNA, and
residues at the N-terminal end of the domain, which bind nucleotides on the same strand as
those bound by the a-helix (Pavletich and Pabo, 1991). Each zinc finger domain binds to three
consecutive nucleotides and different zinc finger domains recognise and bind to different DNA
triplets (Huang et al., 1996).
This difference in binding specificities exhibited by different zinc finger domains is the basis
on which a customisable zinc finger nuclease (ZFN) can be constructed from selected zinc
fingers domains (typically three to four) attached to the FokI cleavage domain (Kim et al.,
1996) (see Section 1.2.3.1). Due to FokI’s need to function as a dimer, pairs of nucleases need
to be produced which are designed to line up the two FokI domains at the same cleavage site
(see Figure 1.2). Importantly, fusion of the FokI domain does not affect the DNA specificity of
the zinc finger domains (Smith et al., 1999).
ZFNs can be used in gene targeting experiments to increase targeting efficiencies (Bibikova
et al., 2001), resulting in efficiencies of 3-5% targeting in human cells (Porteus and Baltimore,
2003). They can also be used to stably correct endogenous genes in both immortalised cell
lines and primary cells at a high efficiency, including a substantial population of cells with bi-
allelic corrections (Urnov et al., 2005). The fact that ZFNs can be used in a variety of contexts,
including in different species (Bibikova et al., 2003, Geurts et al., 2009, Watanabe et al., 2010,
Hauschild et al., 2011, Young et al., 2011), as well as facilitating the formation of large inser-
tions and deletions (Moehle et al., 2007, Lee et al., 2010), demonstrates the flexibility of the
system. However, it is not currently possible to target any given DNA sequence as not all DNA
triplets are recognised by a zinc finger domain. In addition to this, DNA binding by arrays
of zinc finger domains is affected by context-dependent effects (i.e. positioning two particular
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zinc finger domains next to each other can influence the strength of DNA binding) (Cathomen
and Joung, 2008). These drawbacks mean there is scope for a more universal genome editor
system to be developed.
1.2.3.1. FokI
FokI is a Type IIs restriction enzyme originally isolated from Flavobacterium okeanokoites (Li
et al., 1992). Type IIs enzymes do not cleave DNA within the recognition site, but rather a pre-
cise distance away from the recognition site. Wildtype FokI consists of two subunits; a 41-kDa
domain which recognises the target DNA sequence of 5’GGATG-3’ (Hiroyuki and Susumu,
1981) and a 25-kDA domain which has endonuclease activity (Li et al., 1992). When two FokI
molecules dimerise, the target DNA is cleaved nine bases downstream of the recognition site
(equivalent to one turn in the DNA helix) (Hiroyuki and Susumu, 1981, Bitinaite et al., 1998)
and FokI can cleave both methylated and unmethylated DNA (Li et al., 1992). In the absence
of a target DNA sequence, the endonuclease domain is sequestered by the recognition domain,
preventing off-target cleavage (Vanamee et al., 2001).
FokI has been used previously to create a chimeric restriction enzyme, by fusion of its en-
donuclease domain to the Drosophila Ubx homeobox domain. This changed the target DNA se-
quence of the enzyme to the sequence recognised by the Ubx domain (Kim and Chandrasegaran,
1994). To improve the cutting efficiency of enzymes using the FokI endonuclease domain, a
linker is used to separate the endonuclease domain from the DNA recognition domain (Smith
et al., 2000). In the case of ZFNs, the spacer is usually 18 amino acids long (Bibikova et al.,
2001).
Chimeric enzymes containing the FokI endonuclease domain need to dimerise in order to
function, as the FokI domain cannot function as a monomer (Bitinaite et al., 1998, Smith et al.,
2000). In order for dimerisation to occur, the target DNA sequences must be present, as FokI
only has a weak dimerisation interaction on its own (Vanamee et al., 2001). Enzyme dimers
must also have a tail to tail conformation, in order for the two FokI domains to be brought
together (Bitinaite et al., 1998).
Since its initial use as an enzymatic domain in genome editors, the endonuclease domain of
FokI has been altered with a number of point mutations to increase the cutting efficiency and
specificity of the editors. The mutations S418P and K441E (also known as the ’Sharkey’ muta-
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Figure 1.2.: Structure and function of zinc-finger nucleases. (a) Each zinc finger domain con-
tain an a-helix and two b-strands with a zinc ion held between the a-helix and one
of the b-strands. (b) Zinc finger nucleases consist of a series of zinc-finger do-
mains connected to the FokI endonuclease by a spacer. Each zinc finger domain
recognises a triplet of nucleotides, as shown in inset box (c), with the two domains
recognising the triplets ’ACG’ and ’GTT’ respectively. (d) Zinc finger nucleases
function as dimers, leading to the creation of a double strand break in the DNA.
Image adapted from Gaj et al. (2013)
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tions) confer an up to 15-fold increase in activity compared to wildtype FokI (Guo et al., 2010),
while the production of obligate heterodimeric domains has helped to increase the specificity.
These heterodimeric mutations are located within a hydrophobic pocket of FokI and are de-
signed so that heterodimers contain oppositely charged amino acids within the pocket. the
attraction between the amino acids in the heterodimers increase the likelihood of the heterodi-
meric complex forming, while also repelling any dimers with the same amino acids (Miller
et al., 2007, Szczepek et al., 2007, Doyon et al., 2011). The most commonly used heterodi-
mers have the point mutations Q486E, I499L and N496D (also known as ELD) and I538K,
E490K, and H537R (also known as KKR) and their use can reduce cytotoxicity effects seen
when genome editors are introduced into a cell or embryo (Young et al., 2011).
1.2.4. TALENs
Transcription activator-like effector nucleases (TALENs) are derived from the transcription
activator-like effectors (TALEs) expressed by bacteria in the Xanthomonas genus, which are
plant pathogens (Bonas et al., 1989). TALEs, such as AvrBs3, are secreted factors which enter
the plant cell (Van den Ackerveken et al., 1996) and interact with the host genes via the TALE’s
DNA recognition domain. Activation of endogenous genes by TALEs can have the effect of
either inducing changes in the cell which benefit the pathogen, such as hypertrophy of the cell
to enhance the spread of the bacteria (Kay et al., 2007), or alternatively inducing a resistance
response in the plant (Bonas et al., 1989).
The DNA recognition domain of TALEs is comprised of an array of TALE repeats, each
of which is about 34 amino acids in length. The repeats have an almost identical amino acid
sequence to each other, with the exception of the residues at positions 12 and 13 within each
repeat. These two amino acids are known as the repeat variable diresidue and are found within
a loop which connects the two a-helices in each TALE repeat (Boch and Bonas, 2010). The
combination of RVDs within a TALE determine its DNA specificity (Bonas et al., 1989, Her-
bers et al., 1992), with each RVD recognising a single nucleotide in the target DNA (Boch
et al., 2009, Moscou and Bogdanove, 2009).
TALENs are constructed from arrays of TALE repeats (usually around 18 RVDs in length)
connected to a FokI cleavage domain via a spacer (Li et al., 2011, Christian et al., 2010). In
comparison to ZFNs, TALENs’ simple 1:1 nucleotide:RVD code and relative lack of context-
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Figure 1.3.: Structure and function of TALENs. (a) Each TALE DNA-targeting domain con-
tains 34 or 20 amino acids, making up a full-length or truncated repeat, respect-
ively. The amino acids are arranged in tandem repeats, with polymorphic residues
at position 12 and 13 forming the RVD (shown by the purple ‘XX’ in (a) and (b)).
(b) The RVD is positioned within the TALE domain at the point of contact with
the DNA strand. (c) Each TALEN contains 13-28 of these domains attached to
a 3’ FokI nuclease by a small spacer. The inset box (d) shows the 1:1 binding
relationship between each subunit and a nucleotide on the targeted DNA strand.
(e) FokI can generally only function as a dimer so two TALENs must bind to a
stretch of DNA to induce a double-strand break between the two binding sites,
however monomeric TALENs are becoming available (Kleinstiver et al., 2014). (f)
Structure of the PthXo1 TALE bound to DNA reproduced from Mak et al. (2012).
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dependent effects offer greater flexibility meaning that any DNA sequence within a genome
can be targeted while sharing a similar mutagenic frequency to ZFNs (Bogdanove and Voytas,
2011). TALENs which use the FokI cleavage domain must been constructed and used as dimers
in the same way as ZFNs (see Figure 1.3). This reduces the potential for off-target effects by
providing greater specificity.
The ease of producing TALENs as compared to ZFNs allows them to have a wider range
of applications, including the ability to create TALEN arrays which span an entire genome
(Kim et al., 2013a) or TALENs which can edit miRNAs (Kim et al., 2013c, Takada et al.,
2013). TALENs can also be inserted into an organism’s genome as DNA under the control
of an inducible promoter to create conditional knockouts (Cheng et al., 2013) and, like ZFNs,
have been shown to function efficiently in a wide range of species (Carlson et al., 2012, Sung
et al., 2013, Liu et al., 2013, Tan et al., 2013, Park et al., 2014).
1.2.5. CRISPRs
The CRISPR/Cas9 system represents a different form of genome editor compared to TALENs
and ZFNs. Instead of a series of DNA-recognising protein domains physically attached to an
endonuclease, CRISPR/Cas9 editors are made up of two separate molecules; a short guide
RNA (sgRNA) molecule, which provides the sequence specificity and a Cas9 endonuclease.
The Cas9 enzyme and sgRNA complex together to form the active editor.
CRISPRs, or clustered regularly interspaced short palindromic repeats, were first identi-
fied as a series of palindromic repetitive sequences within the genomes of bacteria (Ishino
et al., 1987, Nakata et al., 1989). These repeats were alternated with ’spacer sequences’ which
showed no repetition or, indeed, any homology to the rest of the genome. Further analysis
determined that the spacer sequences were extrachromosomal elements derived from invading
pathogens, such as bacteriophages and plasmids (Bolotin et al., 2005, Barrangou et al., 2007,
Garneau et al., 2010). This led to the identification of the CRISPR system as a heritable form
of adaptive immune system which is present in both bacteria and archaea (Bhaya et al., 2011,
Richter et al., 2012), where the spacer sequences are transcribed and processed into small CR-
ISPR RNAs (crRNAs) by CRISPR associated (Cas) proteins, RNaseIII and trans-activating
crRNAs (tracrRNAs) to invoke cleavage of invading pathogenic DNA (Brouns et al., 2008,
Deltcheva et al., 2011). tracrRNAs also bind mature crRNAs via Watson-Crick base-pairing, a
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Figure 1.4.: Diagram of Cas9:sgRNA:target DNA complex. Target DNA containing the PAM
sequence is shown in green. Orange stars indicate where the double strand break
is induced in the DNA, upstream of the PAM.
structure required for successful cleavage by Cas9. The stem-loop structures in tracrRNAs also
help to stabilise the final Cas:crRNA:tracrRNA:DNA complex (Nishimasu et al., 2014, Jinek
et al., 2012).
To date, three types of CRISPR system have been identified (Makarova et al., 2011). The
Type I and Type III systems make use of large multiprotein complexes known as Cascade
complexes to process crRNAs and cleave foreign DNA, making them unwieldy for use as a
genome editor at this time. However, the Type II system, such as the one found in Streptococcus
pyogenes, relies on a single enzyme, Cas9, to carry out both crRNA maturation and DNA
cleavage (Jinek et al., 2012) and is easily programmed to target a desired DNA sequence (Jinek
et al., 2012). The system is simplified by the use of a chimeric short guide RNA (sgRNA),
where the 3’ end of a crRNA is fused to the 5’ end of a tracrRNA. A target DNA sequence is
specified by a 20bp sequence located in the crRNA portion of the sgRNA (Jinek et al., 2012)
(see Figure 1.4).
Studies of the crystal structure of the Cas9 enzyme have shown the presence of two main
lobes; one involved in target recognition and one with nuclease activity. The target recog-
nition lobe contains a positively charged groove where the negatively charged sgRNA:target
DNA complex is held, while the nuclease lobe cleaves target DNA through its RuvC and HNH
domains. Each nuclease domain is capable of cutting a single DNA strand; the DNA strand
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complementary to the sgRNA is cleaved by the HNH domain while the non-complementary
strand is cut by the RuvC domain. The nuclease lobe also recognises the protospacer adjacent
motif (PAM) on the non-target strand of DNA. Different CRISPR systems recognise different
PAMs (Hou et al., 2013); in the case of Cas9 from the Type II system of S. pyogenes, the PAM
sequence is NGG (Jinek et al., 2012). Recognition of a sequence complementary to the sgRNA
must occur before the HNH domain can cleave the DNA (Jinek et al., 2012, Nishimasu et al.,
2014). Once a suitable sequence has been identified, cleavage occurs 3bp upstream from the
PAM (Jinek et al., 2012).
CRISPR/Cas9 has already been shown to be capable of the same range of editing events as
ZFNs and TALENs, such as large deletions (Fujii et al., 2013, Han et al., 2014), gene correc-
tions (Yin et al., 2014) and producing edited cells and animals (Jiang et al., 2013, Cho et al.,
2013, Yang et al., 2013, Tan et al., 2013, Niu et al., 2014). However, one of the greatest
advantages of the CRISPR/Cas9 system is that multiple sgRNAs for different targets can be
introduced into a cell at the same time, a technique known as multiplex editing (Li et al., 2013,
Cong et al., 2013). To this end, vectors have been developed to easily express multiple sgRNAs
at the same time (Tsai et al., 2014, Guilinger et al., 2014). Multiplex editing allows researchers
to use the system in genome-wide screens for either loss- or gain-of function studies (Koike-
Yusa et al., 2014, Shalem et al., 2014, Wang et al., 2014b, Konermann et al., 2014, Gilbert
et al., 2014), or to study multigenic diseases such as cancer (Platt et al., 2014, Xue et al., 2014).
Multiple sgRNAs can also be used to induce large chromosomal deletions as, unlike ZFNs and
TALENs which generate overhangs at the cut site (Kim et al., 2013b), the CRISPR/Cas9 sys-
tem creates blunt ends and can leave a clean deletion between the two cleavage sites, without
any NHEJ artefacts (Jinek et al., 2012). This can be used in adult animals to induce carcino-
genic chromosomal rearrangements, creating more accurate cancer models (Blasco et al., 2014,
Maddalo et al., 2014).
Unlike dimeric ZFNs and TALENs, the simplicity of the monomeric CRISPR/Cas9 system
has raised concerns about its fidelity and, more specifically, the frequency of off-target effects
it induces. Articles published shortly after the establishment of the CRISPR/Cas9 system as a
genome editing tool have shown notable off-target effects. These studies have either tended to
look at the effects of mismatches on cleavage of one particular target, such as GFP (Fu et al.,
2013), or have targeted a gene with very high sequence similarity to others in the genome (e.g.
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CCR5 and CCR2) (Cradick et al., 2013) and have shown that mismatches at the 5’ end of the
sgRNA are better tolerated by the Cas9 system than those at the 3’ end near the PAM (Fu et al.,
2013). Indeed, it may be that, in cases where a target is known to share an unusually high
degree of sequence homology with another site in the genome, the increased fidelity of ZFNs
and TALENs would be better suited to targeting these loci.
However, other research has produced a more global picture of off-target effects by using
both analysis of predicted off-target sites and whole-genome sequencing (Cencic et al., 2014,
Veres et al., 2014, Smith et al., 2014, Yang et al., 2014, Suzuki et al., 2014). These works
have found a much lower level of off-target cleavage than was originally predicted by the
initial experiments described above. By studying the effects of genome editors on endogenous
loci, rather than using an exogenous construct, the context in which these editing events were
studied could be considered to be more relevant to the intended uses of genome editors (e.g. for
producing modified endogenous alleles in cells and embryos). In addition, experiments on the
original CRISPR/Cas system in bacteria have shown the system’s low tolerance for mismatches
(Barrangou et al., 2007). Available assays for determining the rate of on- and off-target effects
induced by genome editors have been recently reviewed by Hendel et al. (2015).
Several methods exist where the frequency of potential off-target effects can be reduced.
Modifying the design of the sgRNA by truncating the 3’ end of the sgRNA or adding two target-
independent guanine residues to the 5’ end of the sgRNA can significantly reduce the number of
off-target editing events, but can also impact on on-target editing efficiencies (Pattanayak et al.,
2013, Cho et al., 2014). Introducing truncations at the 5’ end of the sgRNA, in effect reducing
the length of the sgRNA:target DNA interface from 20bp to 17bp, increases the specificity of
sgRNAs without compromising the on-target activity (Fu et al., 2014).
FokI-Cas9 fusions have been produced to form dimerisation-dependent nickases (Tsai et al.,
2014, Guilinger et al., 2014). Unlike monomeric Cas9 nickases, which can still potentially have
off-target effects, the dimeric nickases require two PAM sites in close proximity to each other
in order to function. This added level of specificity has been shown in recent assays to reduce
the number of off-target cleavage events seen in comparison to the monomeric CRISPR/Cas9
system (Wang et al., 2015), particularly when used in conjunction with 5’-truncated sgRNAs
(Fu et al., 2014). Given that an NGG PAM sequence occurs on average once every 8bp in
the human genome (Cong et al., 2013) means that the FokI/Cas9 nickases retain much of the
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flexibility which makes the CRISPR/Cas9 system so attractive.
1.3. Applications of genetically modified livestock
Despite the relative lack of technologies available to create genetically modified large animals
in comparison to rodents, genetically modified livestock species, such as pigs, cattle, chickens
and sheep can be very valuable in a variety of settings.
The physiological similarities between livestock species and human make large animals a
prime candidate for producing disease models which closely mimic disease progression in
humans. So far, pigs have been primarily used for this and models of hereditary diseases
such as cystic fibrosis and Huntington’s (Rogers et al., 2008b,a, Yang et al., 2010) as well as
noncommunicable diseases such as diabetes and atherosclerosis (Wolf et al., 2014, Wei et al.,
2012) have already been produced. Genome editors, particularly the multiplex editing afforded
by use of the CRISPR/Cas9 system, could allow large animal models of multigenic diseases
such as cancer and heart disease to now be produced (see Khaled and Liu (2014) for a review of
current mouse models of cancer). In a similar vein, large animals have the potential to be used
as bioreactors to produce therapeutic molecules used in the treatment of diseases including
diabetes, melanoma and a1-antitrypsin deficiency (Pohajdak et al., 2004, Lillico et al., 2007,
Wright et al., 1991, Carver et al., 1992) as well as being modified to produce organs suitable
for xenotransplantations (Ekser et al., 2012, Klymiuk et al., 2010).
Given their inherent value in agriculture, there is demand to produce modified livestock with
greater productivity, an area where animal biotechnology has so far lagged behind that of plant
biotechnology. The most prominent example of this is the AquAdvantage salmon (Devlin et al.,
1994), which is currently undergoing FDA assessment to become the first genetically modified
animal to be approved for human consumption. If approved, the AquAdvantage salmon could
be the first of many animals modified to be more productive, including the phytase-expressing
Enviropig, which digests phosphates with greater efficiency than wildtype pigs (Golovan et al.,
2001) and transgenic cattle which produce high casein levels in their milk, improving the qual-
ity (Brophy et al., 2003). Another key way to improve productivity among livestock animals
is to reduce losses from diseases such as bird flu, mastitis and prion diseases by inserting dis-
ease resistance mechanisms into the genome (Lyall et al., 2011, Wall et al., 2005, Richt et al.,
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2007) and as the underlying mechanisms behind key livestock diseases are examined in greater
details, more options for producing disease- resistant livestock will become available.
This project sought to evaluate the use of genome editors to efficiently produce genetically
modified animals for a range of applications; increased productivity, increased disease resist-
ance and chimeric animals for tissue production.
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2. Materials and Methods
All chemicals were purchased from Sigma-Aldrich unless otherwise stated.
2.1. Molecular biology
2.1.1. Bacterial media and antibiotics
Spectinomycin was sourced from AppliChem and 10mg/ml stocks made in water. Ampicillin
was purchased from Sigma-Aldrich and used to make a 50mg/ml stock in water. Bacteria
were grown either in LB medium or on agar plates (made by the Central Services Unit in the
Roslin Institute), containing the appropriate antibiotic where applicable. All spectinomycin-
containing media and plates had a final concentration of 50mg/ml and all ampicillin-containing
media and plates were made to a final concentration of 100mg/ml. Plates were made by pouring
antibiotic-containing LB agar onto 90mm single vent petri dishes.
Where selection for b-galactosidase was required, plates were prepared by first warming at
37°C for at least 30 minutes, then spreading 16ml of 50mg/ml X-gal and 40ml of 0.1M IPTG
onto each plate.
2.1.2. DNA quantification using the Nanodrop spectrophotometer
DNA was routinely quantified using the Nanodrop spectrophotometer (Nanodrop) and ND-
1000 software. Samples are analysed by pipetting 2ml aliquots onto the sensor, lowering the
arm to touch the sample and taking a spectral measurement. To begin quantification, deionised
water was used to calibrate the Nanodrop, followed a ’blank’ sample of 2ml of the solvent
which the DNA was suspended in (e.g. deionised water or elution buffer). A 2ml aliquot of
the DNA-containing sample was then loaded onto the machine and the concentration of DNA
given in ng/ml as well as the 260/280 ratio and the absorption spectrum of the sample. If
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multiple samples were to be quantified, the sensor was cleaned with deionised water and a
lint-free cloth between samples.
2.1.3. Analysis of RNA using the Agilent Bioanalyser
All TALEN and CRISPR RNA was analysed on RNA 6000 Nano chips (Agilent) with the
Agilent 2100 Bioanalyser prior to use. Before setting up the chip, all reagents in the RNA 6000
Nano kit were left at room temperature for 30 minutes to equilibrate. 1ml of dye concentrate
was added to a 65ml aliquot of filtered gel matrix and vortexed until the dye was evenly mixed
into the gel. The gel-dye mix was then centrifuged at 13,000g for 10 minutes. 9ml of the gel-
dye mix was pipetted into the chip (see Figure 2.1) and the chip primed on the Priming Station.
After priming, 9ml of gel-dye mix was added to each of the remaining wells marked ’G’.
5ml of RNA 6000 Marker was added to the ladder well and each sample well to be used in the
assay. Any unused sample wells were filled with 6ml of marker. 2ml aliquots of all the samples
to be analysed and a 1ml aliquot of RNA 6000 ladder were incubated at 70°C for 2 minutes
to remove any secondary structure which could affect analysis. After denaturation, 1ml of the
ladder and all samples were added to the appropriate wells and the chip vortexed on the IKA
vortex mixer at 2400 rpm for 1 minute. All chips were vortexed and assayed on the Bioanalyser
within 5 minutes of the samples being added to the chip.
The two cleaning chips were filled with 350ml of RNase-Zap and nuclease-free water. Before
an assay was started, the electrodes were decontaminated by placing the RNase-Zap chip in the
machine for 1 minute, followed by the nuclease-free water chip for 10 seconds. The RNA Nano
chip was then placed into the machine and the data analysed using the 2100 Expert software.
Assay results were checked to determine the integrity of the RNA and its concentration. These
Figure 2.1.: Image of an Agilent RNA 6000 Nano chip
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results are presented in Appendix A4.
2.1.4. Transformation protocol
Unless otherwise stated, Subcloning Efficiency DH5a competent cells (Life Technologies)
were used in transformations.
Competent cells were stored at -80°C and thawed on ice prior to use. For each transform-
ation, 50ml of cells were aliquoted into a microcentrifuge tube and 2ml (1-10ng) of DNA was
added. After adding the DNA, the pipette tip was moved through the thawed cells to distribute
the DNA evenly. Reactions were incubated on ice for 30 minutes, then heat-shocked at 42°C
for 30 seconds, then returned to ice for a further 2 minutes. 950ml of LB media was added to
each transformation before incubation with shaking at 37°C for 1 hour. 50ml of each transform-
ation was plated onto an agar plate containing the appropriate antibiotic and incubated at 37°C
overnight.
2.1.5. Qiagen Miniprep protocol
Small-scale preparation of plasmids was carried out using the QIAprep Plasmid Spin kit (Qia-
gen) and the standard kit protocol, as described below;
3ml of overnight bacterial culture was spun at 3000g for 5 minutes and the supernatant re-
moved. Cell pellets were resuspended in 250ml of Buffer P1 containing RNase A and LyseBlue
reagent. 250ml of Buffer P2 was added to begin cell lysis and each tube was inverted 4-6 times
until the solution was uniformly blue. After 5 minutes incubation, 350ml of Buffer N3 was
added to neutralise the lysis reaction and the tubes inverted until no blue colour remained. The
tubes were then spun at 13,000rpm in a microcentrifuge for 10 minutes to pellet the precipitated
cell debris. To bind the plasmid DNA from the supernatant, the supernatant was spun through
a filter cartridge at 13,000rpm for 1 minute and the flow-through discarded. The bound DNA
on the filter was washed with 750ml Buffer PE and again spun at 13,000rpm for 1 minute then
spun again to remove any remaining wash buffer. To elute the DNA, 50ml of Buffer EB was
pipetted onto the filter and incubated at room temperature for 1 minute, before a final spin at
13,000rpm for 1 minute. DNA concentration was quantified using a Nanodrop.
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2.1.6. Qiagen Endotoxin-free (EndoFree) Maxiprep protocol
Large-scale production of endotoxin-free plasmid was produced using the Qiagen EndoFree
Plasmid Maxi kit. Competent cells were transformed with the plasmid of interest as in Section
2.1.4 and plated out. After overnight incubation at 37°C, one colony was picked and incubated
in 3ml of LB media containing the appropriate antibiotic at 37°C in a shaking incubator for 6-8
hours. Overnight cultures were then set up with 100ml of antibiotic-containing LB media, to
which the day culture was added and incubated overnight at 37°C.
Overnight cultures were spun at 6000g for 15 minutes at 4°C and the supernatant removed.
To each cell pellet, 10ml of Buffer P1 containing RNase A and LyseBlue was added and the
pellets resuspended by pipetting. The lysis reaction was started by the addition of 10ml of
Buffer P2 and was incubated for 5 minutes before the reaction was stopped with 10ml of chilled
Buffer P3. The solution was filtered into the QIAfilter cartridge through a layer of Miracloth
(Merck Millipore) and was incubated at room temperature for 10 minutes. The lysate was then
filtered through the QIAfilter cartridge into a 50ml Falcon tube. To remove endotoxins from
the lysate, 2.5ml of Buffer ER was added to each sample and the tubes incubated on ice for 30
minutes. This step prevents endotoxins binding to the resin in the columns in the subsequent
steps. During incubation, a QIAGEN-tip 500 column was equilibrated by applying 10ml of
Buffer QBT and allowing it to flow through the column. After endotoxin removal, the lysate
containing the plasmid of interest was poured into the column and allowed to flow through.
The column was then washed twice with 30ml of Buffer QC before elution of the DNA in
15ml of Buffer QN into an endotoxin-free tube. 10.5ml of isopropanol was added to the tube
to precipitate the DNA and the tube spun at 15,000g for 30 minutes at 4°C to pellet the DNA.
The pellet was then washed in 5ml of endotoxin-free 70% ethanol and spun at 15,000g at 4°C
for 10 minutes. The ethanol was removed and the pellet air dried in a microbiological safety
cabinet for 5 minutes to allow any remaining ethanol to evaporate. The DNA pellet was then
resuspended in 200ml of Buffer TE in the cabinet and incubated overnight at 4°C to allow the
DNA to fully resuspend. Concentration of DNA was then quantified using a Nanodrop.
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2.1.7. PCR
All PCRs were carried out using DreamTaq 2x mix (Thermo Scientific). A 10ml PCR is made
up using 5ml of DreamTaq mix, 2.6ml of water and 0.2ml of both the forward and reverse
primers. 2ml of template DNA was added to the 8ml of master mix before the PCR was run
on a TProfessional thermocycler (Biometra). Unless otherwise stated, programs followed a
standard design, as shown below. Annealing temperatures of PCR primers are given in Ap-
pendix A.1.
95°C 2 minutes x1
95°C 30 seconds
x30Annealing temperature 30 seconds
72°C 1 minute
72°C 10 minutes x1
If required, PCR reactions were cleaned up using either the illustra GFX PCR DNA and
Gel Band Purification Kit (GE Healthcare) or the ChargeSwitch kit (Life Technologies). Brief
descriptions of the protocol for both kits are given below.
illustra GFX kit 500ml of Capture buffer type 3 was added to a 50ml PCR reaction and mixed
thoroughly by pipetting. The colour of the mixture was then checked to ensure that it
had not turned pink or red, which would indicate that the pH of the mixture would be too
high for efficient isolation of the PCR product.
Mixtures were loaded onto a GFX MicroSpin column in a collection tube and centri-
fuged at 16000g for 30 seconds. The flowthrough was discarded and the column washed
with 500ml of Wash buffer type 1 and centrifuged at 16000g for 30 seconds. Again, the
flowthrough was discarded and the purified PCR product eluted in 20ml of Elution buffer
type 6 by incubation for one minute and centrifugation at 16000g for one minute.
ChargeSwitch kit The ChargeSwitch magnetic beads were vortexed to fully resuspend the
beads in the buffer. 50ml PCR reactions were mixed with 50ml of Purification Buffer by
pipetting and 10ml of magnetic beads added and mixed by gentle pipetting until the beads
were uniformly spread through the solution.
Solutions were incubated for one minute then placed into the MagnaRack station for one
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minute until the beads formed a tight pellet against the wall of the tube. The supernatant
was removed to leave the beads in the tube and the beads washed by resuspension in
150ml of Wash Buffer and placed in the MagnaRack station for one minute until a pellet
had formed. Used wash buffer was removed without disturbing the pellet of beads and
the beads washed once more.
Purified PCR product was eluted by mixing the beads in 25ml of Elution Buffer and
incubating for one minute. The mixtures were then placed in the MagnaRack station for
one minute or until the majority of the beads had been removed from the buffer. Buffer
containing PCR products was carefully removed from the tube and stored at -20°C.
2.1.8. Gel electrophoresis
Gel electrophoresis was used to assess the products of PCR or restriction digests. Tris-acetate-
EDTA (TAE) buffer was used for all electrophoresis. Agarose gels were made using UltraPure
agarose (Life Technologies). Unless stated, gels were run using the GeneRuler 1kb DNA ladder
(Thermo Scientific) as a size marker in the left hand lane.
2.1.9. DNA sequencing
Routine DNA sequencing of PCR products was carried out by Edinburgh Genomics, who car-
ried out both the Big Dye sequencing reactions (Life Technologies) and the subsequent clean-
up and capillary analysis using an ABI3730 DNA Analyser (Applied Biosystems). 3-10ng of
cleaned-up PCR product (see Section 2.1.7) was sent to Edinburgh Genomics in 5ml of deion-
ised water with 1ml of sequencing primer at a concentration of 3.2ng/ml. Sequencing data from
Edinburgh Genomics was returned as .ftv files and initially analysed using FinchTV (Geospiza
Inc), with subsequent work carried out using the Lasergene software package (DNASTAR) as
necessary.
On occasion, it was necessary to clone PCR products prior to sequencing (e.g to confirm the
nature of an editing event). PCR products were cloned using the CloneJET PCR Cloning Kit
(Thermo Scientific) using the sticky-end cloning protocol. Firstly, a blunting reaction was set
up containing 10ml of 2x Reaction Buffer, 1ml of PCR product and 1ml of the DNA Blunting
Enzyme. The total reaction volume was made up to 18ml with nuclease-free water. The reaction
mixture was vortexed and briefly centrifuged before incubation at 70°C for 5 minutes. After
26
incubation, the reaction was chilled on ice. To ligate the blunted PCR products into a plasmid
vector, 1ml of the pJET1.2/blunt Cloning Vector (at 50ng/ml) and 1ml of T4 DNA Ligase were
added to the completed blunting reaction. Again, the reaction was vortexed and centrifuged
before incubation at room temperature for 5 minutes.
Ligation products were then directly used for bacterial transformation (see Section 2.1.4) or
stored at -20°C until needed. Transformed colonies were picked for overnight cultures and the
plasmids purified using the Miniprep protocol detailed in Section 2.1.5. 200-500ng of plasmid
with 1ml of sequencing primer (at 3.2ng/ml) in a total volume of 6ml was sent to Edinburgh
Genomics for sequencing as described above.
2.2. TALEN construction
2.2.1. TALEN design
TALENs were designed using the ZiFit designer software (http://zifit.partners.org/
ZiFiT/). Briefly, a segment of DNA sequence of 300-400bp in length which surrounded the
intended TALEN target was entered into the software. Where appropriate, the target site was
indicated by the use of square brackets surrounding the nucleotide(s) of interest. Following
analysis of the DNA sequence by the software, three TALEN pairs were selected based on
proximity to the target site and were assembled.
2.2.2. Assembly of TALEN plasmids
TALEN plasmids were constructed using the GoldyTALEN scaffold (Bedell et al., 2012) and
the Golden Gate cloning protocol (Cermak et al., 2011), which is described below.
The first round of cloning constructed arrays of up 10 consecutive RVDs in pFUS vectors.
Different pFUS vectors are required to build TALENs of different lengths. For TALENs of up
to 21 RVDs, the plasmid pFUS_A is used for RVDs 1 - 10, while the pFUS_B vectors are used
for RVDs 11 - n-1 (Table 2.1). pFUS_B plasmids are numbered 1-10, indicating the number of
RVDs which can be cloned into them (e.g. pFUS_B7 can hold 7 RVDs). This does not include
the last RVD in the sequence, which is added in the second round of cloning.
For TALENs more than 21 RVDs in length, the plasmid pFUSA30A is used for RVDs 1-10
and the plasmid pFUSA30B for RVDs 11-20. The remaining RVDs (21 onwards) are inserted
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Vector name Purpose
pFUS_A Vector for RVDs 1-10 of a TALEN up to 21
RVDs long
pFUSA30A Vector for RVDs 1-10 of a TALEN over 21
RVDs long
pFUSA30B Vector for RVDs 11-20 of a TALEN over 21
RVDs long
pFUS_B(1-10) Vector for RVDs 11-(n-1) of a TALEN up to
21 RVDs long
pRCIScript-GoldyTALEN Vector for full-length TALENs
pCAG-T7-TALEN(Sangamo)-FokI-ELD Vector for full-length TALENs
pCAG-T7-TALEN(Sangamo)-FokI-KKR Vector for full-length TALENs
Table 2.1.: Table showing all plasmid vectors used in TALEN construction
into the appropriate pFUS_B vector as above. Plasmid maps are shown in Appendix A.3. All
destination vectors for full-length TALENs carry the Sharkey mutations described in Section
1.2.3, where the ELD and KKR heterodimeric mutations are also explained.
The following protocol is written assuming the construction of a TALEN which is 18 RVDs
long, the length of the majority of the TALENs produced for this project.
To begin TALEN assembly, 150ng of each RVD (at a concentration of 150ng/ml) required
was added to a PCR tube along with 150ng of the appropriate destination vector (i.e. pFUS_A
or pFUS_B). To each reaction, 10U of BsaI restriction enzyme, 40U of T4 DNA ligase and 2ml
of 10x T4 DNA ligase buffer (all NEB) were added and the total reaction volume was made up
to 20ml with water. The example below shows the reagents used in a reaction to create a stretch














10x DNA ligase buffer 2ml
BsaI 1ml
T4 DNA ligase 1ml
Water 5ml
The reactions were placed in a PCR machine and the following cycle was run. This cycle
allows simultaneous digestion of individual RVD plasmids and ligation of digested plasmids




50°C 5 minutes 1x
80°C 5 minutes 1x
After digestion/ligation, 1ml of 10mM ATP and 1ml of PlasmidSafe nuclease (Cambio) was
added to each reaction. The reactions were incubated at 37°C to remove any unligated linear
DNA molecules. The reactions were then transformed into competent cells using the protocol
described in section 2.1.4, increasing the amount of DNA added to each transformation to 5ml.
Agar plates containing spectinomycin were prepared for b-galactosidase selection as described
in Section 2.1.1. Before plating, cells were spun at 13,000 rpm in a microcentrifuge for 3
minutes and the majority of the supernatant poured off. The cell pellet was resuspended in the
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Figure 2.2.: Gel image showing correctly digested pFUS_A and pFUS_B7 vectors with RVD
inserts. Lanes labelled ’B’ contain pFUS_B7 constructs, while those labelled ’A’
contain pFUS_A inserts
remaining supernatant (~200ml) and 50ml plated out followed by incubation at 37°C overnight.
Up to four colonies from each plate were picked and overnight cultures were set up in 3ml of
LB media containing 50ng/ml spectinomycin. Cultures were incubated at 37°C with shaking
overnight. Plasmids of the RVD subsets were purified from the cultures as described in Section
2.1.5.
To test that the purified plasmids had inserts of the correct length, DNA was digested with
XbaI (Promega) and AflII (NEB). This combination of restriction enzymes excises the RVD
insert from the destination vector. Each digestion contained 5ml of DNA (at approximately 150-
300ng/ml), 10U of XbaI, 20U of AflII, 1ml of 10x Buffer 4 (NEB) and 2ml water. Reactions were
incubated at 37°C for one hour, then the products assessed by gel electrophoresis. Reactions
were run out on a 1.5% agarose gel at 10V/cm for 60 minutes. Correctly assembled pFUS_A
subsets produced a band of 1048bp, while pFUS_B7 subsets showed a band of 740bp (Figure
2.2).
To assemble the full-length TALEN, correctly assembled pFUS plasmids were diluted to
150ng/ml. 1ml of each subset was pipetted into a PCR tube and 1ml of the final RVD (at
150ng/ml) was added. To this, 75ng of the final destination vector (either pRCI-Script, pCAG-
T7-FokI-ELD or pCAG-T7-FokI-KKR), 10U of Esp3I (Thermo Scientific), 40U of T4 DNA
ligase and 2ml of 10x DNA ligase buffer were added and the final reaction volume increased
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37°C 15 minutes 1x
80°C 5 minutes 1x
The reactions were transformed into competent cells and plated onto ampicillin plates with
X-gal and IPTG. Plates were incubated at 37°C overnight and three colonies from each plate
were picked to set up overnight cultures. Cultures were incubated in LB with ampicillin
overnight with shaking at 37°C and the plasmid purified from cells using the Qiagen mini-
prep kit.
Purified full-length TALENs were subjected to two separate digests; a digest with StuI and
AatII (NEB) to check that the TALEN insert was of the correct length, giving bands of 360bp,
1750bp, 2000bp and 3575bp for an 18RVD TALEN (Figure 2.3) and a digest with BspEI
(NEB), which cuts in HD repeats only, giving bands in 100bp increments, depending on the
RVD sequence (Figure 2.4). This BspEI digest gave an initial indication whether the RVD se-
quence was correct, although all TALENs were subsequently checked by sequencing (Eurofins
MWG) to verify that the RVD sequence was correct. In the case of TALENs greater than 18
RVDs in length, the pFUS subsets, rather than the full-length TALEN, were sent for sequen-
cing in order to get adequate overlap between the forward and reverse sequences. Correctly
assembled TALEN plasmids were then expanded using the EndoFree Maxiprep protocol de-
tailed in Section 2.1.6.
2.2.3. TALEN RNA synthesis
Restriction digests to linearise TALEN plasmids prior to RNA synthesis were set up using 5mg
of TALEN plasmid, 0.5ml of 10U/ml of SacI and 10ml of 10x buffer A (Roche). Nuclease-free
water (Ambion) was added to each digestion reaction to a total volume of 100ml. Reactions
were then incubated at 37°C for 2 hours before being terminated by the addition of 5ml of 0.5M
EDTA at pH 8.0, 10ml of 3M sodium acetate at pH 5.2 and 200ml of 100% ethanol. Linearised
DNA was precipitated by incubating at -20°C for 15 minutes then centrifuging at 16,000g for
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Figure 2.3.: Gel image showing correctly assembled TALENs after StuI/AatII digest. Sizes of
bands in the GeneRuler 1kb DNA ladder are given on the left side of the image,
while the expected band sizes resulting from StuI/AatII digest are shown on the
right
15 minutes at 4°C. The supernatant was removed and the DNA pellet resuspended in 10ml
of nuclease-free water. Once the pellet was fully resuspended, the DNA concentration was
checked on the Nanodrop before use in the transcription reaction.
mMessage mMachine kits (Ambion) were used to set up in vitro transcription reactions. For
TALENs assembled into the RCIScript vector, the T3 kit was used, while the T7 kit was used
for all other TALEN vectors. 1mg of linearised DNA was added to 10ml 2x NTP/CAP mixture
and 2ml of 10x Reaction Buffer. 2ml of Enzyme Mix was then added to the reaction and the total
reaction volume made up to 20ml with nuclease-free water. Reactions were incubated at 37°C
for 2 hours before treatment with 1ml of TURBO DNase for 15 minutes at 37°C. Reactions
were stopped by the addition of 15ml of Ammonium Acetate Stop Solution (5M ammonium
acetate and 100mM EDTA) and 115ml nuclease-free water.
TALEN RNA was purified by phenol/chloroform extraction. To each reaction, 150ml of
phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma-Aldrich) was added, then 150ml of chlo-
roform. The aqueous phase was pipetted into a new nuclease-free microcentrifuge tube and the
RNA precipitated with 150ml isopropanol. Precipitation was carried out at -20°C for 15 minutes
and the RNA pelleted by centrifugation at 16,000g for 15 minutes at 4°C. RNA was resuspen-
ded in 20ml of nuclease-free water and analysed on the Agilent Bioanalyser as described in
Section 2.1.3.
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TALEN 1 RVD sequence
X HD X X HD X HD X HD HD X X X HD X HD HD HD
300 bp 200 bp 400 bp 100 bp
200 bp 100 bp 200 bp
TALEN 2 RVD sequence
X HD HD X HD X X X X X X X HD X X HD X HD
100 bp 800 bp
200 bp 300 bp
Figure 2.4.: Gel image showing BspEI digest of triplicates of two different TALENs. Tables
showing the position of HD repeats within each TALEN sequence (other RVDs are
shown by ’X’). The predicted band sizes are shown below each sequence. Note that




sgRNAs for use in the CRISPR/Cas system were designed using Zifit. As with the design
of TALENs, a 300-400bp DNA segment surrounding the intended target site was entered
into the design tool and a list of candidate sgRNA target sequences was returned. Candid-
ate target sequences were first selected based on their proximity to the intended target site
and then screened for potential off-target effects using the BLAST nucleotide search (http:
//blast.ncbi.nlm.nih.gov). Prior to searching for potential off-target hits, each sgRNA
target sequence had ’NGG’ added to the 3’ end, replicating the PAM sequence necessary for
cleavage. Four sgRNAs were designed for each locus targeted.
2.3.2. RNA from gBlocks
To produce sgRNAs for embryo injections, total sgRNA sequences, including the specific
gene targeting sequence were ordered as gBlocks (Integrated DNA Technologies), as the pSp-
Cas9(BB) vector was not immediately available. gBlocks were designed containing an in-
dividual sgRNA expressed from a U6 promotor. Primers were also ordered to amplify the
sgRNA sequence from the gBlock and add a T7 promoter at the 5’ end. PCR was carried out
using these primers and the gBlock as a template. Purified PCR products from these reactions
was then used as a template for sgRNA production using the MEGAshortscript T7 kit (Life
Technologies). Transcription reactions were assembled at room temperature as follows;
Reagent Volume (ml)
T7 10x Reaction Buffer 2
T7 ATP Solution (75 mM) 2
T7 CTP Solution (75 mM) 2
T7 GTP Solution (75 mM) 2
T7 UTP Solution (75 mM) 2
Template DNA (maximum of 150nM) <8
T7 enzyme mix 2
Nuclease-free water Up to 20ml total reaction volume
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Figure 2.5.: Template for designing synthesised oligos for cloning of sgRNAs into the pSp-
Cas9(BB) vector. Blue nucleotides show where the specific sgRNA sequence
should be placed, while red nucleotides show the sticky ends added to facilitate
ligation of the oligos into the BbsI restriction site in the plasmid.
Reactions were mixed gently and incubated at 37°C for 3-4 hours. After incubation, 1ml of
TURBO DNase was added to each reaction and incubated at 37°C for 15 minutes to remove
the DNA template. sgRNA was then recovered by phenol:chloroform extraction and ethanol
precipitation as described in 2.2.3, resuspended in nuclease-free water and analysed on the
Agilent Bioanalyser as described in Section 2.1.3.
2.3.3. Linker plasmid ligations
sgRNAs were cloned into the pSpCas9(BB) vector (see Appendix A.3) according to the pro-
tocol detailed in Ran et al. (2013). The pSpCas9(BB) plasmid contains a U6 promotor, which
drives expression of the cloned sgRNA, the Cas9 protein and GFP. Briefly, forward and re-
verse linker oligos containing the 20bp targeting sequence for the sgRNAs and short overhangs
matching the BbsI restriction site in pSpCas9(BB) were designed as shown in Figure 2.5 and
sourced from Invitrogen.
Synthesised oligos were resuspended in deionised water to a final concentration of 100mM
and the following reaction mix prepared for phosphorylation and annealing of the oligos. Re-
actions were carried out in a PCR machine at 37°C for 30 minutes followed by 95°C for 5









Phosphorylated and annealed oligos were diluted 1:200 in deionised water and cloned into











Digestion/ligation reactions were incubated at 37°C for 5 minutes, followed by 21°C for 5
minutes. These two steps were repeated for a total of six cycles before completed reactions
were transformed into competent cells as described in Section 2.1.4, plated onto ampicillin-
containing LB plates and incubated at 37°C overnight. Individual colonies were picked and
added to 3ml of ampicillin-containing LB medium and incubated at 37°C overnight with shak-
ing. Plasmid DNA was purified from overnight cultures using the Qiagen Miniprep kit as
detailed in Section 2.1.5. Purified DNA was stored at -20°C.
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2.4. Transfection of cells with designer nucleases
Bovine embryonic fibroblasts (BEFs), ovine embryonic fibroblasts (OEFs) and an immortal-
ised porcine kidney cell line (PK15) were used for validation of designer nucleases. All cells
were cultured at 37°C and 5% CO2 in high glucose DMEM containing GlutaMax and so-
dium pyruvate (Life Technologies, 31966-021) with 10% FCS (Sigma-Aldrich) and penicil-
lin/streptomycin (Life Technologies). Cells were passaged by removing the medium with an
aspirator and removing any remaining serum by washing in PBS. Cells were then bathed in
TrypLE Express (Life Technologies) and incubated at 37°C until cells had dissociated from the
plastic. Medium was added to each flask to quench the trypsin and the dissociated cells col-
lected into a 15ml Falcon tube. Cells were centrifuged at 500g for 3 minutes and the resulting
pellet split between new flasks or plates as appropriate.
Cells were transfected using the Neon electroporation system (Life Technologies) with 100ml
reaction tips. To assemble the reactions, cells were trypsinised, pelleted and resuspended in
PBS prior to further centrifugation. Cells were resuspended in PBS and a 10ml aliquot of the
cells was taken to determine cell concentration using a haemocytometer. The total number of
cells needed for all reactions were then aliquoted into a new tube and pelleted, meaning that
the cells had now been washed twice in PBS.
To avoid the formation of bubbles within the pipette tip, which would disrupt the electropor-
ation, a 150ml mixture of cells and nuclease was prepared for each transfection and 100ml of
this taken for electroporation. For each reaction, 900,000 cells were resuspended in 150ml of
Buffer R and 1.5mg of designer nuclease added to each aliquot of cells. The electroporation
station was assembled according to the system protocol and 3ml of Buffer E2 was added to the
Neon Tube in the Pipette Station. 100ml of each reaction, containing 600,000 cells and 1mg of
designer nuclease, was taken up in the Neon pipette tip and electroporated using the following
conditions;
Cell type Voltage Duration Number of pulses
BEF and OEF 1800V 20ms 1
PK15 1400V 20ms 2
Each Neon tip was used for up to three electroporations before disposal. Figure 2.6 shows
that three transfections of a GFP plasmid into OEFs carried out using the same Neon tip show
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Figure 2.6.: Brightfield and GFP images of OEFs transfected with a GFP plasmid using the
same Neon tip
similar transfection efficiencies. Following information in Tan et al. (2013), different incub-
ation conditions were used depending on the form of nuclease transfected. Transfected cells
were incubated for three days after electroporation according to the type of nucleic acid trans-
fected, shown in the table below.
Nucleic acid Incubation conditions
RNA only 30°C for three days
DNA only 37°C overnight, then 30°C for two days
RNA designer nuclease + GFP plasmid 30°C for two days, then 37°C overnight
DNA designer nuclease + GFP plasmid 37°C for three days
After three days, cells were harvested and pelleted by centrifugation at 200g for 5 minutes
and removing the remaining medium. Genomic DNA was extracted using the DNeasy Blood
and Tissue Kit (Qiagen). Cell pellets were resuspended in 200ml of PBS before the addition
of 20ml of Proteinase K. 200ml of Buffer AL and 200ml of 100% ethanol were added to each
sample and the resulting solution pipetted into a spin column. Columns were centrifuged at
16,000g for 1 minute to bind DNA to the column. The columns were then washed with 500ml
of Buffers AW1 and AW2 and the DNA was eluted in 200ml of Buffer AE. DNA concentration
was measured on the Nanodrop and designer nuclease activity assayed using either CelI or T7
endonuclease.
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2.5. Analysis of genome editor activity using the Cel1 or T7
endonuclease assay
For both methods of analysis, the stretch of DNA targeted by the nuclease of interest was amp-
lified by PCR. After PCR, the DNA underwent a denature/anneal step to allow the formation of
heteroduplex DNA molecules. This was carried out in a PCR machine by heating the samples
to 95°C for 10 minutes, then decreasing the temperature to 85°C at a rate of -2°C/sec. Reac-
tions were held at 85°C for 1 minute and the temperature decreased by a further 10°C at a rate
of -0.3°C/sec before pausing for 1 minute. This rate of decrease, with 1 minute holds at every
10°C was continued until the reactions reached 25°C.
For analysis using CelI, annealed PCR samples were run on a 1.5% agarose gel with the
GeneRuler ladder to estimate DNA yield. 200-400ng of PCR product in a volume of 8-40ml
was used in CelI digests with the SURVEYOR mutation detection kit (Transgenomic). The
CelI enzyme in the kit cleaves DNA at points of mismatch in heteroduplexes. To each digest,
1/10th of the volume of MgCl was added, along with 1ml of Enhancer and 1ml of Nuclease.
Digests were incubated at 42°C for an hour then run out on a 2% gel. Because the position of
the nuclease cleavage site relative to the PCR product is known in each instance, the result of a
successful CelI digestion can be predicted. In each case the presence of a full-length WT band
and cleavage products were assessed.
For analysis using T7 endonuclease, PCR reactions were cleaned using the ChargeSwitch
kit detailed in Section 2.1.9 before being run out on a 1.5% gel to quantify DNA in each
reaction. A maximum of 200ng of PCR product was resuspended in 1x Buffer 3 (NEB) to a
maximum volume of 19ml. 1ml of T7 endonuclease (NEB) was added to each 19ml solution and
the reactions incubated at 37°C for 15 minutes. After incubation, reactions were immediately
run on a 2% gel and the presence of cleavage products assayed.
For both the CelI and T7 assays, a positive control from the CelI assay kit was used. This
positive control consists of two pre-made PCR reaction mixes containing a known template.
The two templates differ from each other at one SNP, where one template has C and the other
has a G. Both templates were amplified in individual 50ml PCR reactions. Upon completion of
the PCR, 25ml was taken from each reaction and mixed together in a new tube before under-
going the denature-anneal process and the remaining steps of the assay with the other samples.
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Because of the differing G/C SNP between the two templates, the denature-anneal process cre-
ates heteroduplexes which are recognised and cleaved by the CelI enzyme or T7 endonuclease,
providing a positive control for the assay.
2.6. Embryo injection of designer nucleases
Preparation and transfer of embryos, as well as all animal husbandry was carried out by the
staff at the Large Animal Unit. Embryo microinjections were carried out by Mr David Davies.
2.6.1. Preparation and microinjection of porcine embryos
The following media were prepared in advance of harvest and microinjection of porcine em-
bryos.
NCSU-23 HEPES The following components were dissolved in 80ml of sterile water to pro-














0.025g of calcium chloride was then dissolved separately in 5ml of sterile water before being
added to the stock solution. The resulting solution was then checked to ensure that the pH was
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7.4 and the osmolarity fell between 260-280 mOsmol before being stored at 4ºC for up to two
weeks.














0.0499g of calcium chloride was dissolved into a separate 5ml aliquot of sterile water before
being added to the stock solution. Water was added to bring the final volume of the solution to
190ml. The pH of the solution should be 7.4 and the osmolarity should be between 260-280
mOsmol. The solution can be stored at 4ºC for up to two weeks.
Embryo Culture Medium 0.002g of cysteine and 0.08g of bovine serum albumin were ad-
ded to 20ml of NCSU base medium
Porcine embryos for microinjection were collected for females which had undergone superovu-
lation and insemination. Embryo donors were injected with PMSG six days before the embryo
harvest surgery was scheduled and with hCG two days prior to surgery to induce superovula-
tion. Following the hCG injection, the animals were monitored to see whether they went into
heat and, if so, how frequently. This informs as to which animals will be used as embryo donors
and which will be used as embryo recipients if recipients are required. The day before embryo
harvest surgery, donor embryos were inseminated three times (semen sourced from Deerpark
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Pedigree Pigs) and were scanned on the day of surgery to determine whether ovulation had oc-
curred and whether any animals had cystic ovaries, which can affect the quality of the embryos
harvested. Animals which had ovulated and without cystic ovaries were selected for surgery.
During surgery, the uterus of each pig was checked for the number of ovulation points present
and a catheter was then inserted into the uterine horn and the cuff inflated. A bull-nosed needle
was inserted into the oviduct and 30mls of NCSU23 HEPES was flushed through the oviduct
using a syringe before being collected into a sterile tube. The NCSU23 HEPES used for flush-
ing was then poured into a 90mm Petri dish and any embryos recovered, counted and incubated
at 38.5ºC until microinjection.
Genome editors can be delivered into the embryos of many species, such as mice, rats and
rabbits, by injection into either the pronucleus or the cytoplasm. Various groups have compared
the merits of pronuclear injection against cytoplasmic injection as well as injecting genome
editors in different molecular forms (see Horii et al. (2014) as an example). However, it is
currently not possible to effectively visualise the pronucleus of ovine and porcine embryos for
microinjection. For this reason, all embryo injections carried out in the course of this project
were cytoplasmic. All porcine embryos received 2-5pl injections of genome editor RNA into
the cytoplasm. The concentrations of genome editors are given in the relevant Results chapter.
Injected embryos were cultured in Embryo Culture Medium until blastocyst stage (i.e. 6-7
days).
2.6.2. Preparation of ovine embryos
The following media were used in the preparation of sheep embryos for injection;
Oocyte Wash 4ml of 10x stock of Medium199 was added to 34.5ml of deionised water along
with 0.016g of sodium bicarbonate, 0.1192g of HEPES (H-6147) and 0.025g of heparin.
On the day of oocyte collection, 435ml of oestrus sheep serum (sourced from the blood
of ewes in oestrus) was added to the solution and the pH adjusted to 7.4. The osmolarity
was adjusted to fall between 265-290mOsM and the solution was filter sterilised.
Maturation Medium 1ml of 10x stock of Medium199 was added to 8.8ml of deionised wa-
ter along with 0.021g of sodium bicarbonate and 100ml of 200mM L-Glutamine. The pH
was adjusted to 7.6 using either 0.1% hydrochloric acid or 0.1% sodium hydroxide and
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the solution’s osmolarity adjusted to 292mOsM using deionised water. This stock solu-
tion is made fresh each week. On the day of oocyte collection, 2.5ml of oestrus sheep
serum, 5ml of 10mg/ml follicle stimulating hormone, 50ml of 1mg/ml lutenising hormone
are added to the stock solution prior to filter sterilisation. 5ml of 1mg/ml estradiol is then
added.
Stock Solution A The following reagents were mixed together; 3.145g of sodium chlor-
ide, 0.267g of potassium chloride, 0.081g of monopotassium phosphate, 0.091g of mag-
nesium sulphate heptahydrate, 0.03g of Penicillin G and 0.3ml of sodium lactate. 49.7ml
of deionised water was added to this mixture to give a final volume of 50ml. The solu-
tion was then filter sterilised and stored at 4°C. This solution can be stored for up to three
months.
Stock Solution B 0.21g of sodium bicarbonate was dissolved in 10ml of deionised water.
A small amount of phenol red was then added until the solution took on a slight pink
colour. The solution was then filter sterilised and stored at 4°C. This solution is made
fresh every week.
Stock Solution C 0.051g of sodium pyruvate was added to 10ml of deionised water before
filter sterilisation and storage at 4°C. This solution can be stored for up to two weeks.
Stock Solution D 0.262g of calcium chloride dihydrate was added to 10ml of deionised
water before filter sterilisation and storage at 4°C. This solution can be stored for up to
three months.
Fertilisation Medium 1ml of Stock Solution A, 1ml of Stock Solution B, 70ml of Stock
Solution C and 100ml of Stock Solution D were added to 7.6ml of deionised water. 200ml
of oestrus sheep serum was added and the osmolarity of the solution checked to ensure
that it was between 265 -285 mOsM. The pH was then adjusted using 0.1M sodium
hydroxide until it was between 7.7 and 7.8 before filter sterilisation and storage at 4°C.
This solution was made fresh each week.
SOFaaBSA 2ml of Stock Solution A, 2ml of Stock Solution B, 140ml of Stock Solution C
and 200ml of Stock Solution D were added to 15ml of deionised water. 400ml of BME
amino acids, 200ml MEM, 0.006g of glutamine and 0.08g of BSA were then added to
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the solution. The solution were checked to ensure that the pH fell between 7.3 and 7.5
and that the osmolarity fell between 265 -285 mOsM. This solution is made fresh each
week.
Ovaries were collected from a abattoir in Bridge of Allan and transported to the lab in Thermos
flasks containing PBS warmed to 38.5°C. Prior to collection, all media required for harvest and
IVM of the oocytes were placed into an incubator or hot box to warm.
Upon delivery of the collected ovaries to the lab, the temperature of the flasks was checked to
ensure that the interior had remained above 26°C. A drop in temperature below this could affect
the viability of the oocytes. The ovaries were then rinsed in warm PBS and oocytes aspirated
from the follicles using a 10ml syringe with an 18-gauge needle. Every 2-3mls of follicular
fluid was added to a tube containing 5-6mls of warmed oocyte wash medium and kept in a water
bath until all oocytes had been collected. Oocytes were recovered for the wash medium by
emptying the contents of the tube into a Petri dish and removing viable oocytes. Only oocytes
with layers of cumulus cells were selected for IVM. Selected oocytes were then subjected to
three washes in oocyte wash medium, followed by one wash in maturation medium. 40-50
oocytes were placed into each well of a 4-well plate containing 800ml maturation medium in
each well. The plate had been equilibrated in a 5% CO2 incubator for at least 1 hour prior to
use. Oocytes were incubated overnight at 38.5°C and 5% CO2.
The day after collection, IVF was carried out on the matured oocytes in preparation for
injection. As on the day of collection, all media required for IVF was pre-warmed before use.
At approximately 22 hours after IVM was begun, the oocytes were washed in oocyte wash
medium to remove the cumulus cells and then washed twice in fertilisation medium. Groups
of ~40 oocytes were placed into 450ml of fertilisation medium in each well of a 4-well plate
and incubated at 38.5°C while the sperm was prepared.
2 hours before IVF was planned, a sperm pellet stored in liquid nitrogen was thawed by
agitation in a glass tube in a water bath warmed to 37°C. The semen was then layered at the
bottom of a test tube containing 1ml of fertilisation medium and incubated for 2 hours at 38.5°C
and 5% CO2. 25ml of the semen was reserved and pipetted onto a glass slide to check motility
of the sample. After 2 hours incubation, 100ml of sperm from the top third of the test tube was
removed and 10ml used to perform a cell count. 1x106 sperm cells were added to each well of
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matured oocytes and the plate placed back into the incubator for 24 hours before injection.
2.6.3. Injection and transfer of ovine embryos
Prior to injection, embryos were washed in SOFaaBSA to remove any sperm and cumulus
cells and sorted to ensure that only live, fertilised embryos were used for injection. As with
the porcine embryos, each embryo was injected with a 2-5pl injection of RNA encoding the
nuclease in question. All injections were cytoplasmic. RNA concentrations are given in the
relevant Results chapter. After injection, embryos were cultured in vitro for 6-7 days until they
reached blastocyst stage.
Crossbred or Scottish Blackface ewes were used as embryo recipients. All recipients were
checked for a body condition of 2.5 or higher and for good health in the udder and teeth. To
induce oestrus, progesterone sponges (Chronogest, MSD Animal Health) were inserted into
the ewes and were left in the animal for between 11 – 15 days before removal. Ewes normally
entered oestrus 36 – 48 hours after removal of the sponge. This was timed so that recipients at
6 days post oestrus were available to receive injected blastocysts at day 6 of development.
Recipient ewes were anaesthetised and prepared for surgery by scrubbing the surgery site
with an iodine based solution (Pevidine). A mid line incision was made and the uterus exposed.
The number and location (i.e. left or right ovary) of corpus lutea were recorded. Transfers were
not carried out if no corpus lutea were found. A blunt needle was used to make a hole in the
uterine horn on the same side as the ovary showing corpus lutea and a Drummond pipette
containing 2-4 blastocysts was inserted into the hole made by the blunt needle. The incision
was then closed and the recipient allowed to recover. Pregnancies were identified by ultrasound
scanning at about 28 days post IVF.
2.6.4. In vitro analysis of embryos
Injected embryos were cultured for 1 week post injection for in vitro analysis. All embryos
which had either reached blastocyst stage or had cleaved following injection were collected
in 3ml of PBS in individual PCR tubes. Total DNA from each embryo was amplified using
the Repli-G Mini kit (Qiagen). Fresh D2 buffer was made from 5ml of 1M DTT and 55ml of
Buffer DLB for each batch of amplifications. 3.5ml of Buffer D2 was added to each PCR tube
containing an embryo and tubes incubated on ice for 10 minutes to denature the DNA. 3.5ml
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of Stop Solution was then added to each tube to halt the denaturation and 40ml of master mix
containing DNA Polymerase, Reaction Buffer and nuclease-free water added to each reaction.
Reactions were incubated at 30°C for 16 hours followed by an incubation at 65°C for 3 minutes
to inactivate the polymerase. The resulting DNA was diluted 1:20 before being used in PCR-
based assays. Embryos were analysed for evidence of editing by either a CelI assay (see Section
2.5) or by direct sequencing of PCR products (see Section 2.1.9).
2.6.5. Identification of edited animals
Animals born from embryos injected with designer nucleases were earclipped soon after birth
as part of standard husbandry practises. DNA from the earclip tissue was extracted using the
DNeasy Blood and Tissue Kit and the region of interest amplified as described in Section 2.5.
PCR reactions were then purified and sent for sequencing as detailed in Section 2.1.9. The
resulting sequence chromatograms were analysed for evidence of multiple traces at the target
site, the presence of which would indicate that the animal had been edited.
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Stem cells are primarily characterised by their abilities to self-renew and to differentiate into
cells from a range of different lineages. One of the earliest identified stem cells was the haema-
topoietic stem cell (HSC), which was demonstrated to be capable of repopulating the haema-
topoietic system of an irradiated host (Till and McCulloch, 1961). HSCs were subsequently
found to be one of a number of different adult stem cells, which control the replenishment of
cells within a specific organ or tissue. In terms of their ability to differentiate into different
cell types, adult stem cells are designated as multipotent, as they generally contribute to a re-
stricted number of related cell types (e.g. HSCs form all cell lineages in the blood but are not
considered to make a significant contribution to other tissues).
By contrast, embryonic stem cells (ESCs) are known for their pluripotency as they readily
contribute to cell types in all three of the germ layers and, when injected into a recipient em-
bryo, can form a chimeric animal (Gardner, 1968, Bradley et al., 1984) (chimerism is discussed
in greater detail in Section 3.1.2). ESCs were first established from mouse blastocyst explants
(Evans and Kaufman, 1981, Martin, 1981) and, thus far, have only been successfully isol-
ated from mouse, rat, monkey and human embryos (Buehr et al., 2008, Thomson et al., 1995,
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1998). This is mostly due to the fact that ESCs from different species require different culture
conditions in order to maintain the delicate balance of transcription factors which sustain the
pluripotency of the cells (Wang et al., 2012b), requiring the investment of significant amounts
of time and resources to elucidate the specific conditions suited to expanding ESCs from a par-
ticular species. This severely restricts the application of this powerful technology (discussed
in Section 1.1) in larger livestock species, such as pigs and sheep, where such methods are not
currently optimised.
A potential solution to this restriction was developed in the form of induced pluripotent
stem cells (iPSCs). By ectopically expressing a number of genes associated with pluripotency
in terminally differentiated cells, such as skin fibroblasts, pluripotent cells could be isolated.
These cells demonstrated the ability to form teratomas and to contribute to embryos, in the same
manner as ESCs (Takahashi and Yamanaka, 2006, Okita et al., 2007). This technique has the
potential to allow stem cells to be created for any species, greatly facilitating the production of
transgenic animals from species which do not currently have established ESC lines. However,
no ’gold standard’ iPSC lines have yet been established for any large animal species, largely
due to ongoing technical issues with the iPSC method such as the epigenetic ’memory’ that
iPSCs retain of their original cell type (Barrero and Izpisua Belmonte, 2011, Ohi et al., 2011)
and the lack of defined culture conditions as mentioned above.
3.1.2. Chimerism
A chimera is an organism where some cells have a different genotype from others and is gener-
ally produced by the injection of donor cells into a recipient animal. The resulting animal will
have some cells derived from the recipient, while others will have originated from the injec-
ted donor cells. Chimeras can be created using adult animals or embryos. The most common
examples of adult chimeras are haematopoietic chimeras, where HSCs are transplanted into an
irradiated recipient to reconstitute the haematopoietic niche (Till and McCulloch, 1961). An-
imals which are chimeric in other organs, such as the liver, can also be produced (Mallet et al.,
2002, Wang et al., 2002, Azuma et al., 2007).
Embryonic chimeras can be produced either by injection of pluripotent ESCs or by embryo
aggregation. The first rodent chimeras were produced by embryo aggregation (Tarkowski,
1961, Mayer and Fritz, 1974) and were among the first described examples of differing coat
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colour in a chimeric animal, where a single animal exhibited both agouti and black fur. Embryo
aggregation has also been used to create chimeras in species which do not have naive ESC lines
available (Gardner and Munro, 1974, Tucker et al., 1974, Brem et al., 1984, Tachibana et al.,
2012). However, this method makes the creation of transgenic animals very complex as a fully
transgenic donor embryo must first be produced, making the use of ESCs a more attractive
option.
The ability of an ESC to contribute to a chimera is dependent on whether the cell is in
a ’naive’ or ’primed’ state (Nichols and Smith, 2009). Primed stem cells represent a later
developmental stage than naive cells and are distinguished by their reliance on Erk signalling
and their inability to contribute to chimeras. This is exemplified by mouse ESCs, which are
naive, while mouse epiblast stem cells are primed (Tesar et al., 2007). Although the first human
and primate ESC lines isolated were in a primed state, the addition of specific factors to the
culture conditions has permitted the subsequent derivation of naive human ESCs (Gafni et al.,
2013), raising the possibility that naive ESCs from large animal species may eventually be
developed.
3.1.2.1. Interspecific chimerism
Interspecific chimeras are produced by using a donor source of cells from a different species
to the recipient. As with intraspecific chimeras (i.e. those where both donor and recipient cells
are from the same species), interspecific chimeras can be created at the adult and embryonic
stages of development. The first published example of an adult interspecific chimera was the
transplantation and subsequent growth of human tumour material in immunodeficient mice
(Rygaard and Povlsen, 1969). Immunodeficient mice, such as the SCID mouse model can be
used to create humanised models of development or disease by transplantation of human cells
such as HSCs (McCune et al., 1988, Eyrich et al., 2011), hepatocytes (Mercer et al., 2001) or
neurons (Han et al., 2013, Wang et al., 2013c). Transplantation of multiple donor cell types can
also produce mice which are chimeric in multiple organs (Wilson et al., 2014). The extensive
use of the SCID mouse to produce humanised models, the current deficiencies of the model
and future developments have been reviewed by Pearson et al. (2008).
One of the oldest examples of embryonic interspecific chimeras are quail-chick chimeras.
These have been used as a method to track cell migration during embryonic development by
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transplantation of tissue from one species into the embryo of the other (e.g. transplantation
of quail somites into a chick embryo) (Le Douarin, 1973, Le Douarin et al., 1975). Staining
the DNA using the Feulgen-Rossenbeck method allows cells from the quail to be easily dis-
tinguished from those of the chicken, due to differences in their chromatin structure during
interphase. This allows cells originating from the transplant to be tracked as they disperse
through the embryo. Chimeras constructed by transplantation of the quail neural crest into
chick embryos are viable and neurons from the transplanted quail tissue interact with those
from the chick (Kinutani and Le Douarin, 1985). However, these animals develop neurological
problems after two months of age, due to immune rejection of the graft. Quail-duck chimeras
have also been used in studies of embryonic development (Yamashita and Sohal, 1987).
At around the same time as the creation of quail-chick chimeras, mammalian interspecific
chimeras were produced from different mouse species, such as Mus musculus and Mus caroli,
or from rat and mouse cells and embryos. These chimeras were first reported during investig-
ations into early mammalian development and therefore were not taken to term (Gardner and
Johnson, 1973, Stern, 1973, Rossant, 1976). However, subsequent efforts only produced vi-
able chimeric animals when different mouse species were used as the donor and host (Rossant
and Frels, 1980). This suggests that the evolutionary distance between host and donor species
places a restriction on the ability of interspecific chimeras to form, with closely related species
more likely to form viable chimeras then those less related to each other.
In larger animals, viable sheep-goat chimeras have been produced by two methods; ICM
transfer, where a donor ICM is inserted into a host blastocyst, and blastomere aggregation,
where dissociated cells from 4-cell or 8-cell stage embryos are combined (Fehilly et al., 1984).
The success of chimera formation was observed to be dependent on the extra-embryonic tis-
sues, such as the trophectoderm and chorionic epithelium, being derived from cells of the
same species as the recipient female. Transfer of the ICM from a goat blastocyst to a sheep
blastocyst, for example, resulted in the live births of lambs, kids and sheep-goat chimeras
from sheep recipients. This need for compatibility between the recipient female and the extra-
embryonic tissue could explain the restrictions on the evolutionary distance between donor and
recipient seen in the mammalian chimeras described above. Using cells such as blastomeres
which can contribute to extra-embryonic tissues could cause rejection of the chimeric embryo
by the recipient female if the extra-embryonic tissues derive from the donor species. This is
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reinforced by the accidental creation of viable rat-mouse chimeras using ESCs, which do not
contribute to the extra-embryonic tissues (Brenin et al., 1997).
As with forming intraspecies chimeras, the success of generating interspecific chimeras also
appears to be dependent on the ’primed-ness’ of the donor cells in addition to the evolutionary
distance between the donor and host species. Attempts to form interspecific chimeras from
primed monkey ESCs and mouse embryos failed to produce viable animals and found that al-
though monkey ESCs could become incorporated into the inner cell mass of mouse blastocysts,
they do not interact with the mouse host cells or proliferate within the embryo. Other attempts
using embryo aggregation and tetraploid complementation either did not create viable embryos
or produced embryos which failed to implant in vivo (Simerly et al., 2011). This is most likely
due to the fact that monkey ESCs are thought to be more primed than those of rodents and
are incapable of contributing to chimeras. Chimeric monkeys have thus far only been created
as the result of aggregating multiple embryos at the totipotent 4-cell stage (Tachibana et al.,
2012). The effect of primed stem cells in chimera formation can also be seen in studies where
human ESCs are injected into mouse or chick embryos in studies of early development (Muotri
et al., 2005, James et al., 2006, Goldstein et al., 2002). Although all three studies saw evidence
of differentiation of the injected human ESCs, Goldstein et al. (2002) and James et al. (2006)
observed that the human ESCs tended to remain as a single mass within the embryo and did
not disperse through the organism. Muotri et al. (2005) found that their injected ESCs could
migrate through the brain of the resulting animals however only 0.1% of all neurons studied
were of human origin.
3.1.2.2. Blastocyst complementation
Blastocyst complementation was first reported in 1993 by Chen et al. (1993). They used mice
which were deficient for the Rag-2 gene, which is involved in V(D)J recombination during
antibody production in B and T lymphocyte maturation (Oettinger et al., 1990). As a result
of this, Rag2-/- mice do not have mature T or B cells, but are otherwise healthy and fertile.
The lack of mature lymphocytes means that the animals can be considered to have a vacant
developmental niche which would have been occupied by B and T cells. By injecting Rag2-/-
embryos with WT mouse ESCs, the researchers were able to create mice with mature, func-
tional B and T lymphocytes derived from the injected donor cells. This technique of injecting
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cells to fill an empty developmental niche created by mutation or deletion of a gene has been
named blastocyst complementation.
Since this original paper, various studies have adapted this technique to correct disease phen-
otypes (Mueller et al., 2005, Stillwell et al., 2009, Jansson and Larsson, 2010) and to rescue
embryonic-lethal phenotypes (Fraidenraich et al., 2004).
3.1.2.3. Blastocyst complementation in interspecific chimeras
One of the most powerful demonstrations of the potential of blastocyst complementation
was demonstrated by Kobayashi et al. (2010). In this study, the concept of filling an empty
developmental niche with donor stem cells was used with recipient Pdx1-/-mice, which do
not form a pancreas during embryogenesis and therefore die as neonates. The authors firstly
demonstrated that the pancreas niche can be filled by injected mouse ESCs and iPSCs, giving
rise to healthy, viable animals with a functional pancreas. They then went on to describe the
production of mouse/rat interspecific chimeras through injection of WT rat ES and iPS cells
into WT mouse blastocysts and vice versa.
Donor rat cells in these mouse-rat chimeras were shown by GFP expression to contribute to
the developing embryo, but not to the placenta. Although the number of live-born chimeras
and the average degree of donor cell contribution were considerably lower than those generally
seen in intraspecific chimeras, some chimeras did grow to adulthood, with a total development
rate of ~20%. These techniques of blastocyst complementation and interspecific chimeras
were finally combined by injecting Pdx1-/-mouse blastocysts with rat iPSCs. 24% of embryos
injected using this protocol resulted in live-born animals. Analysis of the chimeric pancreata
showed that the organs secreted pancreatic hormones and were capable of maintaining blood
glucose homeostasis in a diabetes model. This is the first recorded production of an entire organ
in an animal using blastocyst complementation and has exciting implications for the future of
organ transplantation, as the ability to produce species-specific organs for transplants would
overcome many of the immunological and physiological difficulties seen in xenotransplantation
currently (see Ibrahim et al. (2006) and Yang and Sykes (2007) for reviews).
This work has now been transferred into large animal models, with the creation of donor-
cell-derived pancreata in pigs (Matsunari et al., 2013). In this case, pancreas development in
a line of transgenic pigs was ablated by the overexpression of Hes1 from the Pdx1 promoter,
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leaving the pigs with only vestigial pancreata. To rescue pancreas formation in these embryos,
blastomeres from donor pig embryos were injected into morula-stage embryos. The donor
embryos were engineered to express orange fluorescent protein, allowing donor-derived cells
to be easily identified. Chimeric piglets resulting from these injections were viable, unlike
the Hes1 transgenic animals, and were able to control their blood sugar levels. Analysis of
a chimera 12 months after birth showed that the pancreas was present and fluoresced orange,
indicating that it was formed from the injected donor cells. However, donor-derived orange
cells were detected throughout the animal, including in the brain and gonads, areas where the
presence of human cells would present an ethical issue. As such, the method still requires
significant refinement before human donor cells can be used to produce organs. The progress
of this work in large animals is also hampered by the lack of availability of pluripotent stem
cells from large animal species, specifically those capable of contributing to chimeras. There
are also significant ethical considerations to be taken into account, as described in Section
3.4.4.
Attempts to replicate this success in kidney formation have also run into difficulties (Usui
et al., 2012). Work in Sall1-/-mice, which die shortly after birth and have malformed or absent
kidneys, shows that injected WT mouse ESCs and iPSCs can fill this vacant niche and ful-
fil the developmental pathways initiated by Sall1. However, of the eight complemented mice
pups produced, none survived to adulthood. Injection of rat pluripotent cells has also com-
pletely failed to rescue the Sall1-/-phenotype, suggesting that some developmental niches are
not amenable to being filled by foreign cells, particularly those from a different species. This
could potentially restrict not only the types of organs which could be produced by this pro-
cedure, but also which donor and recipient species can be used. There are also further issues
in using blastocyst complementation to produce organs for human transplant, as any tissues in
the organ which do not originate from the empty niche (e.g. blood vessels, neurons and fibro-
blasts in the pancreas which are not affected by knockout of Pdx1), could still trigger immune
rejection of the organ in the eventual transplant recipient.
Blastocyst complementation has also been used to produce ESC-derived thymi in rat-mouse
chimeras (Isotani et al., 2011). For these experiments, nu/nu mice, which do not have a thymus
and therefore do not produce T lymphocytes, were used as recipient blastocysts. Unlike the
Pdx1-/- mice used in the work by Kobayashi et al. (2010), the nude mouse phenotype is not
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lethal. Injection of the nu/nu mice blastocysts with GFP rat ESCs resulted in chimeric animals
which had thymi derived from the GFP-expressing rat ESCs and had populations of CD4- and
CD8-positive cells in the blood. However, the donor-derived thymi were noticeably smaller in
size than would be expected for a mouse thymus and the CD4- and CD8-positive cells were
of mouse origin, rather than the donor rat ESCs. When the chimeric thymus was transplanted
under the renal capsule of a nu/nu rat, CD4- and CD8-positive cell populations were seen in
the blood eight weeks after transplantation. This suggests that the injected rat ESCs did not
themselves directly contribute to the T cell population, but, by reconstituting the thymus, were
able to stimulate the maturation of T lymphocytes from the recipient nu/nu mouse and rat cells
3.1.2.4. Blastocyst complementation in the haematopoietic niche
In this project, a two-pronged strategy was used to work towards the development of a chi-
meric large animal capable of producing human-derived tissues suitable for transplantation,
bypassing the technical issues associated with trying to produce a complex, multicellular tis-
sue in vitro. Blood was selected as the target tissue as, firstly, there is currently no robust in
vitro differentiation protocol to produce HSCs from stem cells, although individual lineages
can be produced (see Olsen et al. (2006) for review) and, secondly, a range of vacant develop-
mental niches within the haematopoietic system can be produced by different gene knockouts,
allowing either whole blood or specific cell populations to be donor-derived. It was decided to
focus on Runx1-/- animals, which are incapable of undergoing definitive haematopoiesis dur-
ing embryogenesis, and therefore do not produce any blood, and Rag1-/- animals, which do not
produce B or T lymphocytes. In the first set of experiments, blastocyst complementation was
carried out using Runx1-/- or Rag1-/- mice to produce a mouse/rat interspecific chimera with
blood derived from the donor rat ESCs (see Figure 3.1). In parallel, genome editors were used
in an attempt to create Runx1-/- and Rag1-/-large animal models for use in future blastocyst
complementation experiments.
3.1.3. Runx1
Runx1 (also known as AML1, Cbfa2 or Pebp2aB) is a transcription factor which is expressed in
HSCs and is essential for the initiation of definitive haematopoiesis in the developing embryo
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Figure 3.1.: Diagram showing the hypothesised outcome of performing blastocyst comple-
mentation experiments using Runx1-/- or Rag1-/- mouse embryos. By injecting
GFP-positive rat ESCs, which are capable of forming cells within the haematopoi-
etic lineage, into mouse embryos with a vacant haematopoietic niche, viable chi-
meric animals with blood cells derived from the rat ESCs should result. In the case
of Runx1-/- embryos, all haematopoietic cells should be GFP-positive and, there-
fore, rat-derived while in the case of Rag1-/- embryos, the B and T lymphocytes
populations should be of rat origin.
(Wang et al., 1996). It was first identified as part of the fusion transcription factor Runx1:ETO,
which was implicated in the development of acute myeloid leukaemia (AML) (Miyoshi et al.,
1991, Erickson et al., 1992). The role of Runx1 in the progression of AML is outside of the
scope of this project, but has been recently reviewed by Hatlen et al. (2012).
3.1.3.1. Runx family members
Runx1 is a member of the Runx gene family, the other members of which are Runx2, required
for skeletal development (Komori et al., 1997), and Runx3, which is involved in neural devel-
opment (Levanon et al., 2002). All members of this gene family share a 128 amino-acid long
DNA-binding domain with a b-barrel structure (Levanon et al., 2001, Bravo et al., 2001). This
domain is homologous to the runt protein in Drosophila (Meyers et al., 1993, Ogawa et al.,
1993, Kurokawa et al., 1996) and binds in a sequence-specific manner (Meyers et al., 1993).
The function of runt in Drosophila has been reviewed by Canon and Banerjee (2000). The runt
homology domain of the Runx proteins also binds the ubiquitously expressed Cbfb protein to
form the heterodimeric transcription factor Cbf. Although Cbfb does not bind to DNA itself, it
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enhances the DNA binding properties of the Runx proteins (Ogawa et al., 1993). In the case of
Runx1, this is achieved by relieving the DNA binding inhibition caused by Runx1’s negative
regulatory region, which lies 3’ of the Runt domain (Kanno et al., 1998) and by protecting
Runx1 from ubiquitinisation and subsequent degradation (Huang et al., 2001).
Despite their key roles in the development of very different tissues, expression of the Runx
proteins is not restricted to cells of a specific lineage, such as blood, as Runx1 is also expressed
in neurons and bone (see Section 3.1.3.3 for more details), while Runx3 is expressed in haema-
topoietic cells (Cai et al., 2011, Wang et al., 2013a). The extent of Runx protein co-expression
requires additional regulation to ensure that cell development proceeds towards the correct lin-
eage. To this end, both the bone and neuron development processes are negatively regulated in
Runx1-expressing HSCs (Tanaka et al., 2012).
3.1.3.2. Gene and protein structure of Runx1
The Runx1 gene spans 260kb and contains two promoter regions, known as P1 and P2, and
12 exons. P1 is the distal promoter located upstream of the first exon, while P2, the prox-
imal promoter, initiates transcription at exon 3 (Miyoshi et al., 1995, Ghozi et al., 1996). Use
of the promoters varies between different stages of haematopoietic development and between
different haematopoietic cell populations (Bee et al., 2009, Sroczynska et al., 2009). mRNA
transcripts produced from P2 are translated via an IRES rather than by cap-dependent transla-
tion, which is used for transcripts from P1 (Pozner et al., 2000). Homozygous deletion of the
Runx1 IRES is embryonic lethal. IRES-knockout mouse embryos die from circulation failure
at stage E14.5, a later stage of development than Runx1-knockout embryos (as discussed in
Section 3.1.3.6), and show reduced numbers of HSCs and increased HSC apoptosis (Nagama-
chi et al., 2010).
Six of the Runx1 exons are common to all members of the Runx gene family. Exons 2, 3 and
4 form the runt homology domain, which binds a TGTGG consensus site (Wilson et al., 2010)
and exons 5 and 6 encode the negative regulatory region, which inhibits DNA binding, and the
transactivation domain (Levanon et al., 2001, Huang et al., 2012). Twelve alternatively spliced
Runx1 mRNA species have been identified (Levanon et al., 2001) and three of these isoforms
have been recognised as performing the majority of the functions of Runx1. These isoforms
are Runx1a, Runx1b, both of which are transcribed from the P2 promoter, and Runx1c, which
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is transcribed from P1 (Miyoshi et al., 1995). It should be noted that the Runx1a isoform is
only found in humans and other primates (Komeno et al., 2014). The 5’UTRs of these three
isoforms combine with the IRES to provide a level of translational regulation for Runx1 as
5’UTRs originating from the P1 promoter initiate translation more readily than those from the
P2 promoter. The IRES also exhibits different levels of activity in different cell types (Pozner
et al., 2000).
3.1.3.3. Expression and function of Runx1 in non-haematopoietic tissues
As mentioned previously, Runx1 expression and function is not restricted to cells of the haema-
topoietic lineage. Like Runx2, Runx1 also plays a role in bone development. Use of conditional-
knockout animals has shown that loss of Runx1 expression after the onset of definitive haema-
topoiesis affects development of the sternum and may also impact on palette development
(Liakhovitskaia et al., 2010). Mice which carry a combination of a Runx1-null allele and a
Runx1-hypomorphic allele, and therefore have very limited Runx1 expression levels, show im-
paired skeletal growth in the time between birth and weaning, pointing to a role for Runx1 in
chondrocyte differentiation (Soung et al., 2012).
Runx1 is also expressed in denervated skeletal muscle, where helps to prevent autophagy
and muscle wasting after damage to the muscle (Zhu et al., 1994, Wang et al., 2005), and in
certain neural populations (Stifani et al., 2008). It is required to stimulate the expression of
nociceptive receptors in neurons and conditional knockout mutants show a delayed response to
noxious heat and cold stimuli (Chen et al., 2006).
3.1.3.4. Expression and function of Runx1 in haematopoietic stem cells
Runx1 expression is essential for the successful initiation of definitive haematopoiesis in the
developing embryo (Wang et al., 1996, Okuda et al., 1996). Definitive haematopoiesis be-
gins on the ventral surface of the embryonic dorsal aorta (Mueller et al., 1994, Medvinsky and
Dzierzak, 1996, North et al., 2002, Eilken et al., 2009) and establishes the long-term haema-
topoietic system of an organism, as opposed to primitive haematopoiesis, which occurs in the
extraembryonic tissues and provides only limited, short-term support for the embryo. In mouse
embryos, definitive haematopoiesis begins at E10 (Medvinsky and Dzierzak, 1996). Runx1 is
required for the survival of cells undergoing endothelial to haematopoietic transition (EHT) in
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the dorsal aorta (North et al., 1999, Kissa and Herbomel, 2010, Boisset et al., 2010, Liakhovit-
skaia et al., 2014). Cells which undergo EHT derive from a subset of cells in the dorsal aorta
endothelium known as haemogenic endothelial cells, which are located in discrete intra-aortic
clusters (North et al., 2002, Taoudi et al., 2008, Lancrin et al., 2009). These cells are typified
by their expression of Runx1, which is induced by signalling through Notch and the FGF path-
ways from the surrounding endothelial cells via Hes1, which interacts with the transactivation
domain of Runx1 (Nakagawa et al., 2006, Butler et al., 2010, Clements et al., 2011, Guiu et al.,
2013, Lee et al., 2014). It is thought that expression of Runx1 in these cells in increased by
exposure of the cells to fluid sheer stress caused by the initiation of blood circulation in the
embryo (Adamo et al., 2009). Although haemogenic endothelial cells express Runx1, it is not
necessary for their specification (Sakai et al., 2009, Liakhovitskaia et al., 2014), but is key for
the process of EHT.
EHT begins when cells in the ventral endothelium of the dorsal aorta undergo a series of
contractions, causing individual endothelial cells lining the vessel to bud off into the circulation
and simultaneously take on a haematopoietic phenotype (Kissa and Herbomel, 2010, Boisset
et al., 2010). These cells, which express both Runx1b and Runx1c (Challen and Goodell, 2010),
go on to become definitive HSCs and populate the haematopoietic niche. Runx1 facilitates this
transition by upregulating genes involved in cell migration and adhesion, such as those involved
in integrin signalling (Lie-A-Ling et al., 2014). Lack of Runx1 makes these budding events
much rarer and any cells which are released from the dorsal aorta apoptose upon leaving the
endothelial layer (Kissa and Herbomel, 2010, Boisset et al., 2010). However, once these HSC
progenitors have successfully formed, Runx1 expression is again no longer essential (Chen
et al., 2009b). The HSC progenitors then migrate firstly to the foetal liver and subsequently to
the bone marrow.
This transition of cells from a endothelial phenotype to a haematopoietic one is caused by
transcriptional activity controlled by Runx1, which upregulates expression of haematopoietic
genes such as CD41 and CD34 (Levantini et al., 2011, Sroczynska et al., 2009, Tanaka et al.,
2012) and downregulates endothelial gene transcription (Sakai et al., 2009, Tanaka et al., 2012).
This is partly executed by targeting of Runx1 to the transcriptional repressors GFI1 and GFI1b
(Lancrin et al., 2012).
Once a HSC has formed, Runx1 takes on a more regulatory role in HSC maintenance, by
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slowing proliferation and decreasing apoptosis (Cai et al., 2011), and haematopoietic cell dif-
ferentiation. This requires Runx1 to co-operate with many other transcription factors to reg-
ulate gene expression including SCL, LYL1, LMO2, FLI-1, ERG and GATA2. Transcrip-
tion can be initiated by a complex containing all or a subset of these factors (Wilson et al.,
2010) and many genes controlled by Runx1, including Runx1 itself, are also controlled by the
SCL/Gata2/Fli1 triad (Tanaka et al., 2012). Indeed, expression of Runx1 in haemogenic en-
dothelial cells is dependent on binding of the triad to the Runx1 +23 enhancer (Nottingham
et al., 2007).
Runx1 helps to regulate HSC differentiation and expansion by regulating the expression of
genes such as HMGA2 (Lam et al., 2014), PU.1 and c-MYC. The repression of c-MYC expres-
sion by Runx1 may indicate the cell’s progressive loss of potency as it differentiates into a HSC
and subsequently into specialised cell types (Jacobs et al., 2013). Runx1 also induces global
changes in gene expression through epigenetic changes, such as histone acetylation, to initiate
haematopoietic development pathways (Lichtinger et al., 2012). This occurs via interactions
with epigenetic regulators such as Pcgf1, which ubiquitinates histone H2A and negatively regu-
lates haematopoietic progenitor self-renewal (Ross et al., 2012), and the chromatin remodeling
SWI/SNF complex (Bakshi et al., 2010). Runx1 expression is regulated by FGF signalling,
which switches to a negative regulatory role after the initiation of Runx1 expression (Pouget
et al., 2014) and through a rheostat mechanism with Smad6, which targets Runx1 for proteo-
somal degradation, thereby regulating the Runx1 dosage in cells (Knezevic et al., 2011).
3.1.3.5. Expression and function of Runx1 in differentiated haematopoietic
cells
Runx1 is also active in the development of specialised haematopoietic cell types and it has been
suggested that different Runx1 isoforms could determine the differentiation pathways followed
by an individual HSC (Komeno et al., 2014). Runx1 stimulates megakaryocyte differentiation
from bipotential megakaryocyte/erythrocyte precursors (Tijssen et al., 2011) by repressing the
expression of genes such as MYH10 (Antony-Debre et al., 2012) and other genes associated
with erythroid development (van Riel et al., 2012). Runx1 is also needed for B-lymphocyte
progenitor survival and progression of B cell development (Niebuhr et al., 2013), maintaining
T-lymphocyte and platelet populations by regulation of PU.1 (Huang et al., 2008) and in con-
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trolling the expression of T-cell receptors (TCRs) (Cieslak et al., 2014) and co-receptors, such
as CD4 (Taniuchi et al., 2002).
3.1.3.6. Runx1-knockout phenotype
The importance of Runx1 in the establishment of definitive haematopoiesis was first identified
by the creation of the Runx1-knockout mouse (Wang et al., 1996, Okuda et al., 1996). Ho-
mozygous disruption of the Runx1 gene causes embryos to die between stages E11.5 and 12.5
due to a lack of definitive haematopoiesis. At stage E10.5, when definitive haematopoiesis
normally begins, Runx1-/- embryos show signs of necrosis in the CNS. At the point of embryo
death at E11.5-12.5, Runx1-/- embryos exhibit extensive haemorrhaging, which is mostly as-
sociated with the CNS and considered secondary to the actual cause of death, and a pale liver,
indicative of a block in foetal liver haematopoiesis (Wang et al., 1996, Okuda et al., 1996).
Interestingly, this phenotype is recapitulated both in Cbfb-/- embryos, demonstrating that both
parts of the CBF dimer are required for definitive haematopoiesis (Sasaki et al., 1996), and
in embryos where Runx1 is only selectively deleted in cells expressing the endothelial marker
Tek (Li et al., 2006). Conversely, restoration of Runx1 expression in only Tek-expressing cells
is capable of partially rescuing the Runx1-/-phenotype (Liakhovitskaia et al., 2009). Runx1-/-
embryos also show a loss of expression of key haematopoietic genes which lie downstream of
Runx1 in the development pathway, such as PU.1, M-CSF and c-Myb (Okada et al., 1998).
By contrast, Runx1+/- embryos are viable, although the embryos undergo definitive haema-
topoiesis earlier and produce fewer haematopoietic progenitors than their wildtype counterparts
(Cai et al., 2000). This viability of Runx1+/- is likely to be at least partially due to the ability
of other factors such as Runx3 and Gata2 to compensate for a decreased Runx1 dosage (Staber
et al., 2014), exemplified by the fact that Runx1+/-:Gata2+/- mice are not viable (Wilson et al.,
2010).
The creation of conditional deletion mutants in Runx1 has allowed the function of Runx1
in adult animals to be studied in greater detail (Samokhvalov et al., 2006). Loss of Runx1 in
adult animals does not cause any severe phenotypic effects but is rather characterised by al-
terations in different haematopoietic populations, including a large drop in platelet numbers,
decreased lymphocyte numbers and an increase in myeloid cells (Growney et al., 2005). This
can be linked to the decreased expression of genes such as Cebpa, as lowered Cebpa levels
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cause an increased number of progenitors to enter monopoeisis and a decrease in those enter-
ing granulopoiesis (Guo et al., 2012) and, as such, reflects the role of Runx1 in specialised
haematopoietic lineages (see Section 3.1.3.5), rather than in HSCs.
Deletion of Runx1 in adult animals also increases the number of quiescent HSCs (Ichikawa
et al., 2008), indicating that Runx1 is a negative regulator of quiescence. This regulation of
quiescence can be linked to the regulation of Runx1 expression over the course of the cell
cycle. Runx1 expression increases as cells progress from G1 to S phase, while cells in G1
arrest have lower expression levels of Runx1. This suggests a role for Runx1 in driving cell
cycle progression (Bernardin-Fried et al., 2004, Peterson et al., 2005).
3.1.4. Rag1
Rag1 is a protein which, along with Rag2, forms the Rag recombinase complex, found in the
immune systems of jawed vertebrates (Leu and Schatz, 1995, Kapitonov and Jurka, 2005).
The Rag recombinase stimulates V(D)J recombination of antigen receptor loci, such as those
encoding immunoglobulins and T-cell receptors, in developing B- and T-lymphocytes (Schatz
et al., 1989, Mombaerts et al., 1992). Animals which are deficient for either Rag1 or Rag2 do
not produce mature B- or T-lymphocytes, but are otherwise healthy (Mombaerts et al., 1992).
3.1.4.1. Structure of Rag1
The Rag1 gene consists of two exons, where the large second exon encodes the majority of
the Rag1 protein (Mombaerts et al., 1992). Transcription and translation of Rag1 produces a
protein 1040 amino acids in length. Early experiments which analysed the activity of truncated
Rag1 mutants identified a ’core’ region spanning amino acids 384-1010 which, on its own, has
the same level of recombination activity as the full-length protein (Sadofsky et al., 1993, Silver
et al., 1993). This core region contains a nonamer-binding domain, which binds the nonamer of
RSS sites via a GGRPR motif and also plays a role in the synapsis of two RSS sites (Yin et al.,
2009). A DDE motif required for DNA cleavage is also found in the core region (Fugmann
et al., 2000b).
It is believed that the Rag proteins and RSS sites evolved from an ancient transposon system,
as the RSSs bare some homology to the terminal inverted repeats seen in transposons, while
the Rag1 and Rag2 proteins share 35-38% identity with the Transib transposase. Despite this
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Figure 3.2.: Diagram showing the main stages of V(D)J recombination between two coding
sequences as mediated by the Rag recombinase. Note that recombination can be
initiated by Rag1 binding to either the 12 RSS or the 23RSS. Figure adapted from
Schatz and Ji (2011).
relatively low degree of homology, all residues known to be essential for V(D)J recombination
are conserved between Transib and the Rag proteins (Kapitonov and Jurka, 2005, Fugmann
et al., 2000b).
3.1.4.2. The Rag recombinase in V(D)J recombination
Although Rag1 is capable of directing V(D)J recombination on its own, complexing with Rag2
vastly increases the recombination efficiency (Oettinger et al., 1990). Figure 3.2 shows the
stages of V(D)J recombination.
Rag1 and Rag2 are expressed in B- and T-lymphocyte precursors (Schatz et al., 1989). This
limited expression reduces the risk of the Rag recombinase inducing DSBs in the DNA of other
cell lineages. Further to this, Rag2 expression levels vary throughout the cell cycle, with the
highest levels seen during the G0 and G1 phases, before degradation of Rag2 occurs at the
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G1/S boundary (Lin and Desiderio, 1994). This additional level of expression control ensures
that the Rag recombinase is not active during DNA replication. The nuclear position of antigen
receptor loci forms another control mechanism and prevents the recombination and expression
of T-cell receptor loci in B-lymphocytes and vice versa (Kosak et al., 2002).
V(D)J recombination requires the presence of RSSs in the genome. RSSs have a conserved
heptamer sequence of CACAGTG, separated by a spacer of either 12bp or 23bp from a con-
served nonamer sequence of ACAAAAACC. While the nonamer sequence is essential for
V(D)J recombination, the heptamer is not, although it does enhance the binding of Rag pro-
teins to the RSS (Difilippantonio et al., 1996). The difference in the spacer sequence length
allows RSSs to be designated as a 12RSS or a 23RSS. Recombination at these loci follows the
12/23 rule, as recombination can only occur between a 12RSS and a 23RSS and not between
two RSSs with the same spacer length (Hesse et al., 1989). The 12/23 rule is in part enforced
by the Rag recombinase as the Rag1/Rag2 complex make recombination between two 23RSSs
energetically unfavourable, while Hmgb1, another protein recruited to RSSs by Rag1, prevents
recombination between two 12RSSs (Swanson, 2002).
In addition to the 12/23 rule, V(D)J recombination proceeds in a defined order, with D to
J recombination occurring before V to DJ. This is only applicable to heavy chains of antigen
receptor loci, as light chains only undergo V to J recombination. It is believed that this precise
order is controlled by DNA-binding proteins such as c-Fos, which enhance the binding of
Rag1 to the appropriate RSS sites (Wang et al., 2008). There is also epigenetic regulation of
V(D)J recombination (Stanhope-Baker et al., 1996), where histone acetylation and chromatin
remodeling by the SWI/SNF complex increase V(D)J recombination at certain sites (Kwon
et al., 2000). The histone modification H3K4me3 also encourages V(D)J recombination via
interactions with the PHD finger of Rag2 (West et al., 2005). This allows hairpin formation at
the coding ends, which would otherwise be blocked by the C-terminal domains of Rag1 and
Rag2, to occur (Grundy et al., 2010). Although Rag2 recognises H3K4me3 sites throughout
the genome, specificity to antigen receptor loci is provided by the binding of Rag1 to the RSS
(Matthews et al., 2007, Ji et al., 2010). A more detailed review of how V(D)J recombination is
regulated by chromatin structure is provided by Subrahmanyam and Sen (2010).
At the onset of V(D)J recombination, Rag1 binds to a nonamer sequence at an RSS. This
binding can be mediated by transcription factors such as Runx1 and Pax5 (Cieslak et al., 2014,
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Zhang et al., 2006). Rag1 then recruits Rag2 and Hmgb1 to the RSS (Difilippantonio et al.,
1996, Little et al., 2013). While Rag1 and Rag2 together are sufficient to induce DSBs in short
stretches of DNA in vitro, the DNA-bending protein Hmgb1 is required for successful DNA
cleavage in vivo (Stanhope-Baker et al., 1996). Hmgb1 is important for mediating DNA bend-
ing at the 23RSS to bring the nonamer and heptamer sequences together in the Rag recombinase
complex (Ciubotaru et al., 2013, 2014).
This recruitment of proteins to an RSS results in multiple Rag proteins binding to a single
RSS, in the form of a Rag1 dimer and a Rag2 monomer (Swanson, 2002). Upon formation of
the paired complex (see Figure 3.2), ’recombination centres’ are formed, where many Rag1,
Rag2, Hmgb1 and potentially other proteins participate in V(D)J recombination (Ji et al., 2010,
Schatz and Ji, 2011). Rag1 induces a single strand nick at an RSS between the end of the
coding sequence and the first nucleotide of the heptamer (Fugmann et al., 2000a). The freed
3’ hydroxyl group then invades the uncut strand via transesterification, causing a DSB and
forming a hairpin at the coding end and a blunt ended signal end (McBlane et al., 1995).
The newly formed hairpins at the coding ends of the break are stabilised by protein kinases
such as ATM and resolved by NHEJ repair (see Section 1.2.1) (Bredemeyer et al., 2006, Corneo
et al., 2007, Deriano et al., 2009), with the hairpins being cleaved by the DNA-PK:Artemis
complex (Ma et al., 2002). While the coding ends undergo DNA repair, Rag1 and Rag2 form
a post-cleavage complex with Hmgb1 and DNA-PK on the signal joint, possibly to prevent
reintegration of the excised DNA (Agrawal and Schatz, 1997). The imprecise nature of NHEJ
repair further increases antigen receptor diversity by introducing mutations into the coding
sequences (Fugmann et al., 2000a).
Although Rag1 and Rag2 are primarily known for their role in producing antigen receptors in
acquired immunity, there is evidence that they also play a role in maintaining cell populations
in the innate immune system. The expression of both Rag1 and Rag2 in NK cells increases the
cells’ genomic stability, allowing cells to exist in a steady state rather than entering apoptosis
and creates heterogeneous NK cell populations (Karo et al., 2014). It is possible that further
study of other cell populations may uncover a wider range of roles for Rag1 and Rag2.
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3.2. Additional Methods
3.2.1. Culture of stem cells
KMO-/- and GFP-Cre mouse ES cells were provided ready for injection by Mr Damian Mole
and Dr Peter Hohenstein respectively. Kynurenine 3-monooxygenase (KMO) is an enzyme
involved in tryptophan metabolism, however, these cells were used for injections as it was a
proven mouse ESC line which would contribute black coat colour to recipients with white fur.
By the same token, the GFP-Cre line was also used because it had been previously shown
to contribute to chimeras and expressed GFP, which would have simplified identification of
chimeras.
DAK31 WT and GFP rat ESCs and OF1 feeders were provided by Dr Tom Burdon. The WT
cells have been previously proven to contribute to chimeric offspring (Blair et al., 2012). The
GFP line was produced by transfecting WT DAK31 rat ES cells with a pCAGGS-EGFP-IRES-
PURO construct and selecting stably transfected, puromycin resistant clones. Transfections
and selection of clones was carried out by Dr Stephen Meek.
Prior to irradiation, OF1 feeders were grown in GMEM (Sigma-Aldrich) supplemented with
10% FCS (Sigma-Aldrich), 2mM GlutaMAX (Life Technologies), 1mM sodium pyruvate (Life
Technologies), 1:100 dilution of NEAA (Life Technologies) and a 1:500 dilution of 50mM
b-mercaptoethanol (Life Technologies). OF1 medium was filter sterilised before use and OF1
cells were grown in gelatinised flasks and passaged using TryPLE Express (Life Technologies).
Feeder cells were irradiated with 5 Gy and either directly used for rat ESC culture or frozen in
freezing medium (50% FCS, 40% GMEM and 10% DMSO) and stored at -80ºC until required.
3x104 irradiated cells were seeded in each gelatinised well of a 24 well plate for ESC culture.
DAK31 ESCs were cultured in N2B27 media supplemented with LIF and inhibitors. N2B27
media was prepared by combining 100ml of DMEM/F12 with 100ml of Neurobasal media
(Life Technologies) and adding 1ml of 100x N2 supplement, 2ml of 50x B27 minus vitamin
A supplement and 2ml GlutaMAX (Life Technologies). N2B27 medium was filter sterilised
before use. PD0325901 and CHIR99021 inhibitors were purchased from Hilary McLauchlan
at the University of Dundee. 1mM aliquots of both inhibitors were made by dilution in N2B27
medium. 10µl of 1mM PD0325901, 30µl of 1mM CHIR99021 and 10µl of rat ESGRO® LIF
(Millipore) were added to 10ml of N2B27 medium to make 2i+LIF medium. 2i+LIF medium
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Figure 3.3.: Gel image showing examples of Runx genotyping results. Heterozygotes are in-
dicated by an asterisk.
was stored at 4°C and protected from light.
All cell lines, including feeder cells, used in these experiments were IMPACT-tested by
IDEXX Bioresearch before being used for embryo microinjections. No contaminating patho-
gens were detected in any cells.
3.2.2. Animals and embryo injections
SD rats were provided by Dr Matthew Sharp at the BRR mouse facility at the Royal Infirmary
of Edinburgh.
Runx1tm1Spe/J males were sourced from The Jackson Laboratory and mated with WT C57/Bl6
females to establish a Runx1 colony. Individuals were earclipped at weaning as part of stand-
ard animal husbandry practises. DNA was extracted from the ear clips using the Fast Tissue-
to-PCR kit described in Appendix 3.2.3 and genotyped by PCR using the Runx1 common,
wildtype and mutant primers listed in Section A.1. Figure 3.3 shows an example of genotyping
results. WT animals produced a single band of 400bp, while heterozygotes have an additional
band at 700bp.
Rag1-/- mice were provided from an established colony managed by Dr James Richards.
Because the Rag1-/- phenotype is not embryonic lethal, the colony was maintained by mating
Rag1-/- animals, ensuring that all offspring would also be Rag1-/-. This was validated by flow
cytometry, which confirmed that no B or T lymphocytes were present in the blood of the mice
(carried out by Dr James Richards).
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Female mice of 6-8 weeks of age were selected as embryo donors. Donors were superovu-
lated, mated and the embryos harvested following the schedule below.
Day 1 Donors injected with 5IU of PMSG
Day 2
Day 3
a.m. - Donors injected with 5IU of hCG
p.m. Set up overnight matings
Day 4
Cull donors and harvest 1-cell embryos
Culture to 8-cell stage (Day 6)
Day 5
Day 6
Cull donors and harvest 8-cell embryos
Inject 8-cell embryos
Day 7
Cull donors and harvest blastocysts
Inject blastocysts
Transfer embryos into recipients
Donors were culled by cervical dislocation and embryos injected at different times depending
on the stage of embryo required. Micromanipulation and injection of embryos was carried out
by Dr William Ritchie.
To harvest 1-cell and 8-cell embryos, the oviducts were dissected out and placed in a 60mm
dish with M2 medium (Millipore) and opened by gently tearing the bursa with forceps. Em-
bryos were collected and cultured in microdrops of gassed KSOM medium (Millipore) under
mineral oil (Sigma-Aldrich) at 37°C and 5% CO2 until injection and transfer. Blastocysts were
harvested by removing the uterus and flushing each uterine horn with 0.2ml M2 medium before
culture in KSOM microdrops.
Injection of ESCs into embryos was carried out using a microinjection rig equipped with
the XYClone laser system. A hole was made in the zona pelucida with the laser and embryos
were injected with either 2-3 or 5-7 ESCs, in order to find the optimum number for chimerism.
Embryos were then cultured in fresh KSOM microdrops until uterine transfer into recipients.
F1 recipients were set up by mating with vasectomised males 2 days before transfers were
scheduled. In the case of Rag1-/- embryos, recipients and any offspring were housed in isolators
to protect the offspring from infection.
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Figure 3.4.: Rex1 PCR on a premixed mouse/rat DNA ’gradient’. The table above the gel
shows the ratio of mouse:rat DNA present in each lane.
3.2.3. PCR analysis of animals
Animals resulting from embryo injection of ESCs were culled and tissue samples flash-frozen
on dry ice. The Fast Tissue-to-PCR kit (Fermentas) was used to extract DNA from tissues.
2-5mg of tissue was added to a microcentrifuge tube containing 100ml of Tissue Lysis Solution
and 10ml of Proteinase K and incubated at room temperature for 10 minutes. Samples were then
incubated at 95ºC for 3 minutes before the addition of 100ml of Neutralisation Solution. 4ml of
solution from each sample were used in 20ml PCR reactions. Primers against the gene Rex1
were used to distinguish between mouse and rat DNA. The presence of mouse DNA produces
a band of 301bp, while a band of 379bp indicates the presence of rat DNA. Figure 3.4 shows
the results of carrying out the PCR on a range of samples containing known amounts of mouse
and rat DNA.
3.3. Results
3.3.1. Embryo injections to create rat-mouse chimeras
Table 3.1 shows all embryo injections undertaken for the blastocyst complementation experi-
ments.
WT rat and mouse embryos were used to determine whether the production of interspecific
chimeras could be established, in addition to the Runx1-/- and Rag1-/- mouse embryos described



























































































































































































































































































































































































































































































































Figure 3.5.: Images of C57/Bl6 control and Runx1-/- mouse embryos injected with DAK31
GFP cells. All embryos shown are at blastocyst stage.
previous work has shown that injecting ESCs into 8-cell stage embryos can result in enhanced
contribution from the injected donor cell and, in some cases, an animal completely derived
from the donor cells (Poueymirou et al., 2007). Despite numerous rounds of injections and
attempts to improve the outcome of these experiments (detailed below), live births were only
achieved in injections of rat 8-cell embryos with mouse ESCs and injections of Rag1-/- murine
blastocysts with rat ESCs. Animals resulting from these injections were culled and analysed
by PCR screening for chimerism, as presented in Sections 3.3.2 and 3.3.3.
After injection of WT rat ESCs into WT mouse blastocysts had failed to produce any live
births, DAK31 GFP ESCs were injected into WT and Runx1-/- mouse embryos in order to
track the injected cells and make any chimeras easier to detect. Some injected embryos were
not transferred but were imaged to determine whether there was any focal localisation of the
injected cells within the embryo (Figure 3.5). In all the embryos, a GFP signal from the injec-
ted cells could be seen as one group associated with the ICM, suggesting that the cells were
localising to the appropriate part of the embryo. However, because no births resulted from this
set of injections, the decision was made to use the non-GFP rat ESC line for future injections
as, although it was derived from a proven ESC line, the GFP line itself had not yet been proven
to contribute to live offspring.
Four recipients of Runx1-/- mouse embryos injected with DAK31 ESCs were culled at mid-
gestation to determine the reason behind the lack of live births. Only one implantation site was
70
Figure 3.6.: Images of dissected uteri from recipients containing injected Runx1-/-embryos
culled at mid-gestation. One implantation site was seen in the uterus from Re-
cipient 4 (indicated by arrowhead).
found from all four dissected uteri (Figure 3.6). This strongly suggests that the embryos in this
set of injections were being reabsorbed early in gestation. As a result of this, future injections
were carried out using blastocysts rather than 8-cell embryos. This was in an effort to reduce
the length of time the embryos spent in culture prior to transfer, as the culture conditions were
thought to be potentially affecting embryonic development. It was also decided to switch from
Runx1-/- host embryos to Rag1-/-, to ascertain whether a different source of embryos could
solve the problem. In addition, the non-lethal Rag1-/- phenotype should allow for a greater
number of live pups to be born. Live births were achieved from injection of Rag1-/- blastocysts
with DAK31 WT ESCs and the offspring were analysed (see Section 3.3.3).
The final set of injections, where Rag1-/- embryos were injected with GFP-Cre-ERT2 mouse
ESCs, produced no live offspring. Recipients were dissected one week after the litters were
due in order to determine the fate of the embryos. Dissection revealed that 3 of the 4 recipients
had been pregnant and each animal contained between 2-4 implantation sites. This strongly
suggests that all three recipients had given birth to offspring, which were cannibalised soon
after birth. It is likely that the cannibalism was triggered by either all the pups being born dead
or dying or by the recipient’s rejection of the litter due to an external stressor (Weber et al.,
2013). Although litter loss is considered a rare phenomenon in mice, rates can vary widely
and it can occur in up to 50% of litters (Weber et al., 2013). That being said, the loss of three
litters is highly unusual and, combined with the relatively low number of implantation sites
found (a total of 8 from 54 transferred blastocysts), suggests that there were problems with the
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development of the embryos, causing the majority to be reabsorbed.
3.3.2. Analysis of SD rat/mouse chimeras
Of the 21 animals resulting from injection of SD rat embryos (white fur) with C57/Bl6 mouse
ESCs (black fur), one was visually chimeric as it had both white and black fur, indicating
contribution from the injected ESCs. All other animals had white coats. The visually chimeric
animal died 17 days after birth. Post-mortem examination showed that the animal’s kidneys and
heart were both enlarged which, combined which other observations, indicate that the animal
died from a circulatory disorder. Tissue samples were collected as part of the post-mortem
examination and analysed for the presence of mouse DNA by PCR (Figure 3.7). Mouse DNA
was clearly detected in the kidney and muscle, confirming that the animal was a rat/mouse
chimera. Although the black skin colouring on the chimera was derived from the injected
mouse ESCs, no mouse DNA was detected in the PCR assay, despite the fact that at least
some of the cells in the sample must have originated from the donor mouse ESCs. This result
has likely been affected by a combination of the DNA extraction kit used, which does not
completely lyse the tissue sample and therefore only extracts DNA from the edges of the sample
which have been lysed in the incubation time, and the somewhat low sensitivity of the PCR
assay, as discussed below.
The remaining animals from these injections were culled at weaning and tissue samples
taken for analysis (Figure 3.8). No mouse DNA could be detected by PCR in any of the tissues
sampled, suggesting that they were not chimeric. However, Figure 3.4 shows that the PCR
screen is only capable of detecting a minimum of 2.5% mouse DNA in rat DNA. Although
Figure 3.7 shows that this level of sensitivity is adequate to demonstrate tissue chimerism in an
overtly chimeric animal, it is likely that a chimera where 1% or less of the total cells are derived
from the donor cells will not be picked up by the screen. Therefore, in this and similar assays
presented in this chapter, the possibility that extremely low-level chimeras were produced but
not detected cannot be discounted.
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Figure 3.7.: PCR analysis of rat/mouse chimera. Mouse DNA contributed by the injected ES
cells can be seen in samples taken from the kidney and muscle
Figure 3.8.: PCR screen for chimerism in remaining animals resulting from injection of mouse
ES cells into rat embryos. Numbers with the same colour indicate members of the
same litter.
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Figure 3.9.: PCR analysis of Rag1-/- mouse embryos injected with rat ESCs. Animals are
grouped according to the number of cells injected.
3.3.3. Analysis of animals resulting from injection of rat ESCs into
Rag1-/- embryos
Two separate sets of injections involving Rag1-/- embryos produced live-born animals. As the
recipient Rag1-/- mouse strain had black fur and the donor DAK31 ESCs would produce agouti
fur, identification of chimeric animals may not have been visually apparent. Therefore, as in the
previous section, all animals were culled at weaning and tissue samples taken for PCR analysis.
The results can be seen in Figures 3.9 and 3.10. No evidence of rat DNA was detected in any
of the tissues or animals analysed, despite the use of a proven ESC line. The mouse/rat positive
control used in each PCR assay also indicates that the assay should be capable of detecting any
significant amounts of rat DNA present in the samples and suggests that the animals are either
not chimeric or only possess a very low level (<5%) of chimerism.
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Figure 3.10.: PCR analysis of Rag1-/- mouse embryos injected with rat ESCs. In this set of
injections, all embryos were injected with 5-7 cells in an attempt to produce some
chimeras.
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3.3.4. Runx1 TALENs in large animals
In parallel to the blastocyst complementation experiments, genome editors were designed to
reproduce the Runx1-/- and Rag1-/- genotypes in large animals. This would create suitable
recipient embryos for future blastocyst complementation work.
Three pairs of TALENs targeted to exon 2 of the porcine Runx1 gene were designed (Figure
3.11), with the aim of creating non-functional Runx1 alleles in the pig. Exon 2 was selected
as it is equivalent to exon 3 in the human Runx1 gene, which is the first exon common to both
Runx1b and Runx1c transcripts (note that, as previously mentioned, the Runx1a isoform is only
expressed in primates). Once constructed and checked by sequencing, as detailed in Section
2.2, each pair of plasmids encoding Runx1 TALENs was co-transfected into PK15 cells with
a GFP plasmid to indicate transfection efficiency. DNA from transfected cells was collected
three days after transfection and used in a T7 endonuclease assay to check for signs of TALEN
activity (Figure 3.12 (a) and (b)). No evidence of TALEN activity was found. To ensure that the
Runx1 target locus in PK15 cells was the same as the porcine genome sequence used to design
the TALENs and PCR primers, the PCR product amplified by the Runx1 primers was sent
for sequencing. Alignment of the sequenced PCR product with the porcine Runx1 sequence
showed complete consensus between the two, indicating that the the DNA sequences to which
the TALENs were designed were present in PK15 cells (Figure 3.12 (c)).
Figure 3.11.: Positions of TALEN binding sites in exon 2 of the porcine Runx1 locus. Primers
used for analysis are shown by green boxes.
76
Figure 3.12.: Transfection of PK15 cells with TALENs targeted against Runx1. (a) Brightfield
and GFP images of PK15 cells transfected with one of the Runx1 TALEN pairs
and a GFP plasmid to show transfection efficiency. (b) Results of T7 assay of
DNA isolated from transfected cells. Note the lack of cleavage products indic-
ating the absence of TALEN activity. (c) Sequence alignment of Runx1 TALEN
target site sequenced from PK15 DNA aligned against the Runx1 sequence from
the porcine genome. The area targeted by the Runx1 TALENs is highlighted in
the green box.
77
3.3.5. Rag TALENs and CRISPR sgRNAs in porcine and ovine cells
In order to develop Rag1-/- pigs and sheep, TALENs were designed against exon 2 of the por-
cine and ovine Rag1 genome sequences, which contains the majority of the coding sequence of
the gene (Figure 3.13 (a) and (b)). sgRNAs for use in the CRISPR/Cas9 system were also de-
signed against the sheep Rag1 locus (Figure 3.13 (c)). Rag1 TALENs were initially constructed
into the pRCIScript vector (performed by Mrs Claire Neil) and subsequently reconstructed into
the Sangamo ELD/KKR vectors once these plasmids became available. Transfection of Rag1
TALEN pairs as mRNA produced from the RCIScript vector into either PK15 or OEF cells
and subsequent CelI assay showed that ovine Rag1 TALEN pair C was active in OEFs (Figure
3.14), albeit with a seemingly low efficiency. In order to visualise the TALEN activity it was
necessary to increase the exposure of the original image to the point where the other bands on
the image were saturated. Therefore, it is not possible to accurately quantify the amount of
editing seen. No TALEN activity was seen in PK15 cells. GFP expression in the transfected
cells indicated that the transfection efficiencies were as expected.
A repeat transfection and CelI assay of OEFs with plasmids encoding the Rag1 TALENs
did not show any evidence of TALEN activity, including from pair C, which had previously
shown editing activity (Figure 3.15 (a)). A number of troubleshooting steps were undertaken
to determine the cause of this loss of activity, as it was a problem common to other genome
editors used in this project. Firstly, DNA from previously transfected cells was analysed using
the T7 endonuclease assay as previous experience with this assay in the lab (and subsequent
published data in Vouillot et al. (2015)) suggested that it was more sensitive to the presence
of heteroduplexes than the CelI enzyme. This step also helped to address whether there were
any problems with the CelI assay reagent, such as a defective enzyme batch. The results of
the T7 assay (Figure 3.15 (b)) show that the T7 endonuclease does appear to be more sensitive
to mismatches than the CelI enzyme as cleavage products were seen on the gel which were
not produced during a CelI assay. Unfortunately, the presence of cleavage products in the ’No
TALEN’ control lane indicated that these cleavage products were not caused by any editing
activity on the part of the TALENs, but rather from the presence of endogenous SNPs in the
OEF genome.
To ensure that transfection of the TALEN plasmids into OEFs was successful and not failing
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Figure 3.13.: Positions of binding sites of genome editors within exon 2 of the porcine and
ovine Rag1 loci. PAMs for sgRNAs are underlined in dark blue. (a) Porcine Rag1
TALENs. (b) Ovine Rag1 TALENs. (c) Ovine Rag1 sgRNAs for CRISPR/Cas9.
Primers used for analysis are shown by green boxes.
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Figure 3.14.: Results of CelI assay on OEFs (left) and PK15 cells (right) transfected with Rag1
TALEN pairs A, B and C. Cleavage of editing products in can be seen in OEFs
transfected with Rag1 TALEN pair C (indicated by arrowheads).
due to operator error, two sets of new transfections were carried out. One set was carried out
by Dr Chris Proudfoot (Figure 3.15 (c)) while the other involved the co-transfection of Rag1
TALENs with a GFP plasmid to assess transfection efficiency (Figure 3.15 (d) and (e)). CelI
assays on DNA from both sets of transfections yielded negative results.
sgRNA oligos were cloned into the pSpCas9(BB) vector and transfected into OEFs (Figure
3.16). Although GFP expression indicated that transfections had been successful, assessment
of the transfected DNA in a CelI assay did not show any evidence of CRISPR/Cas9 editing
activity.
Finally, it was suggested that the endogenous target sites within the PK15 and OEF Rag1
loci may not match the sequences given in the porcine and ovine genomes due to the presence
of SNPs and other point mutations. To investigate whether this was the case, the PCR product
amplified using Rag1 primers in both OEFs and PK15 cells was sent off for sequencing and
aligned back to the original porcine and ovine sequences used to design the TALENs (Figure
3.17). Some SNPs were found in the PK15 Rag1 target site however, the cells were heterozyg-
ous at every SNP position, with one allele being the same nucleotide as the porcine genomic
sequence. No differences which would be predicted to have an adverse effect on TALEN and
sgRNA binding were detected.
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Figure 3.15.: Results of attempts to rectify lack of activity detected using the Rag1 TALENs.
(a) CelI assay of duplicate transfections of Rag1 TALEN in Sangamo ELD/KKR
vectors. No evidence of editing was detected, including in pair C, which had
previously given a positive result in this assay. (b) T7 assay on OEFs transfected
with the Rag1 TALENs. Note that cleavage products are visible in all samples,
included the no TALEN control, indicating that cutting is not due to the presence
of editing events resulting from TALEN activity. (c) T7 assay on transfections
carried out by Dr Chris Proudfoot. In this set of transfections, duplicate transfec-
tions were carried out for each TALEN pair. As in (b), cleavage products are seen
in every lane, including the no TALEN control. (d) Brightfield and GFP images
of PK15 cells transfected with one of the Rag TALEN pairs and a GFP plasmid
to allow sorting for transfected cells. Cells were sorted by GFP expression and
GFP-positive and GFP-negative populations tested for TALEN activity by CelI
assay, the results of which are shown in (e). No evidence of TALEN activity was
seen in any of the sorted populations.
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Figure 3.16.: Validation of Rag1 sgRNAs in OEFs. (a) Brightfield and GFP images of cells
transfected with sgRNAs in the pSpCas9(BB) vector. Images at 100x magnifica-
tion. (b) CelI assay on OEFs transfected with one of the Rag1 sgRNAs and Cas9.
Note the absence of cleavage products.
Figure 3.17.: Sequence alignments of Rag1 TALEN and CRISPR target sites sequenced from
PK15 or OEF DNA aligned against their counterparts in the porcine or ovine
genome. Areas targeted by the Rag1 editors are highlighted in green boxes. SNPs
detected in the PK15 Rag1 sequence are marked with an asterisk.
82
3.3.6. Rag TALENs and CRISPR sgRNAs in porcine and ovine embryos
In parallel to the work in cells, Rag1 TALEN pair C mRNA was injected into ovine and porcine
embryos. These embryos were harvested from donors but were not subsequently required for
their intended microinjection experiments and would otherwise have been disposed of. As
harvesting these embryos takes a significant amount of effort and, in the case of sheep, embryos
are only available during the few months of the breeding season once a year, it was decided
to inject the Rag1 genome editors in these embryos for in vitro analysis rather than have the
embryos go to waste.
The TALEN RNA was injected at a concentration of 2ng/ml. The resulting blastocysts were
assessed in vitro for TALEN activity by CelI assay (Table 3.2). The binding sites recognised
by the TALENs in pair C are conserved between the porcine and ovine Rag1 sequences so
the same TALEN pair can be used in both species. No edited embryos were identified as a
result of TALEN mRNA injection. Some injected ovine embryos were reserved for transfer
into recipient animals to produce live-born animals (Table 3.3). Six lambs were born as a result
of injection of Rag1 TALEN mRNA into embryos. Amplification and sequencing of the Rag1
target site from these lambs only produced a single trace of the wildtype Rag1 sequence on the
resulting chromatograms, indicating an absence of editing. These results contrast starkly with
editing efficiencies previously obtained in the lab, where 18% of in vitro embryos and 21% of
live born piglets resulting from injection of TALEN mRNA were edited (Lillico et al., 2013).
However, the TALENs used in this case, which were targeted against the gene RELA, were
shown to have a higher activity in cells than the Rag1 C TALEN.
To discover whether multiplexing the Rag1 sgRNAs would improve CRISPR/Cas9 activity,
ovine embryos were injected with pairs of the Rag1 sgRNAs. sgRNAs were paired based on
the distance between the two cut sites and whether deletion of that distance would cause a
frameshift mutation. sgRNAs F1 and R2 were injected in one injection mix, while F2 and R1




Rag1 TALEN C (RCIScript)
Sheep 8 0
Pig 22 0
Table 3.2.: Table summarising embryos injected with genome editors targeted against Rag1








Pregnancies Lambs Edited lambs
Rag1 TALEN C
(RCIScript)
114 56 (49%) 22 (19%) 2 3 0
Rag1 TALEN C
(Sangamo)
43 28 (65%) 12 (28%) 2 3 0
Rag1 F1 and R2
CRISPR
31 16 (52%) 2 (6%)
1* 1 0
Rag1 F2 and R1
CRISPR
30 11 (37%) 4 (13%)
Table 3.3.: Table summarising microinjections carried out in ovine embryos with genome ed-
itors designed to target Rag1. Percentage values for cleavage and blastocyst form-
ation are given in relation to the number of embryos injected. * indicates that both
embryos injected with the Rag1 F1 and R2 CRISPRs and embryos injected with
the F2 and R1 CRISPRs had been transferred into the recipient which then became
pregnant.
were used as a pair in a separate mix (Table 3.3). sgRNA-injected embryos were transferred
into recipients and 1 live-born lamb was obtained. DNA from an earclip taken from the lamb
was amplified and sent for sequencing however, no edited alleles were detected.
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3.4. Discussion
Issues connected to the design and use of genome editors in this project are primarily dis-
cussed in detail in Chapter 6. Therefore, this discussion section will focus on the blastocyst
complementation experiments.
3.4.1. Difficulties in producing viable interspecific chimeras and
potential solutions
Although the blastocyst complementation experiments produced a live-born rat/mouse chi-
mera, it died 17 days after birth from a circulatory disorder. Given that the greatest amount
of mouse DNA in the chimera was seen in the kidneys, which were discovered to be enlarged
at post-mortem, it is possible that the animal’s chimerism contributed to its death. However,
Kobayashi et al. (2010) note that the interspecific pancreata generated in their experiments ten-
ded to grow to the size normally found within the host animal, rather than the size that would
normally be associated with the donor cells (i.e. a rat-derived pancreas in a mouse would grow
to a mouse size). In this case of injecting mouse ESCs into a rat blastocyst, it seems highly
unlikely that the fact that the donor cells were from a different species would cause the kidney
enlargement, especially as, if organ size was determined by the donor cells alone, one would
expect the kidneys to be considerably smaller than those in a WT rat. It seems more likely that
the enlarged kidneys were caused by a disorder which was not directly caused by the donor
cells.
The lack of live births from injections using WT and Runx1-/- mouse embryos suggests a
problem with the embryo culture conditions, causing the embryos to be reabsorbed shortly
after transfer into the recipients, as demonstrated by Figure 3.6, where only one implantation
site was seen in recipients culled at mid-gestation. Considering that implantation should occur
at the late blastocyst stage, and therefore shortly after embryo transfer into recipients (Wang
and Dey, 2006), this strongly suggests that the embryos were reabsorbed. Although switching
to Rag1-/- blastocysts and to blastocyst injections produced live-born animals (although no
chimeras), interpretation of this data is compounded by the fact that the Runx1-/- and Rag1-/-
mouse colonies were housed at different sites and, while every effort was made to maintain
consistency between the injection groups, it was not possible to control for every potential
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variable in the reagents and equipment used. This means that there are many factors which
varied between these sets of injections and one or more of them could have contributed to the
lack of live-born animals from the Runx1-/- and WT mouse embryos.
The fact that no chimeras were produced from multiple rounds of injection of Rag1-/- em-
bryos using proven stem cell lines indicates a potential problem with the donor cells, rather than
with the PCR assay, where the positive controls consistently worked. The DAK31 rat ESC line
used for the majority of these injections is well characterised and can produce chimera rates of
~35% when injected into rat embryos (Linda Sutherland, personal communication). However,
the data from Kobayashi et al. (2010) indicate that interspecies chimera generation is signific-
antly less efficient than intraspecies chimera production and that chimera rates can vary greatly
between lines. Interestingly, when rat ESCs were injected into mouse blastocysts, only ~10%
of the animals produced were chimeric as opposed to the ~35% chimera rate seen when a rat
iPSC line was used in mouse embryos. It is possible that the combination of the DAK31 cells
and the Rag1-null embryos results in a poor chimera rate and that, by simply carrying out more
injections or trying a range of different rat ES or iPS cell lines, a viable rat-mouse chimera
would have been obtained.
It would also be of use to see how much the donor cells contribute to embryonic development
after the blastocyst stage. Although analysis of embryos injected with GFP ESCs indicated that
the donor cells were colocalising with the ICM of the blastocysts, it would be informative to
culture the embryos to the egg cylinder stage as described by Bedzhov et al. (2014) to ensure
that the cells are still retained in the embryo and interacting with the host cells and not ejected
from the embryo.
3.4.2. Using partially differentiated cells as donor cells
Another potential alternative for a donor cell source would be to use HSCs or partially dif-
ferentiated pluripotent stem cells. Indeed, partially differentiated mouse ESCs expressing the
markers AA4.1+ and B220- have been shown to be capable of reconstituting the immune sys-
tem of Rag1-/- mice (Potocnik et al., 1997), demonstrating that the vacant lymphoid niche in
these animals can be colonised in intraspecific chimeras. However, there are currently no robust
protocols to induce pluripotent stem cells to differentiate into haematopoietic precursors and
most successful protocols make use of transgenes to influence cellular differentiation (Tashiro
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et al., 2012), something which would ideally be avoided if this method is ever to be used to
produce clinical products.
Primary HSCs therefore present a more attractive source of donor cells, at least for the estab-
lishment of the technique in rodents and large animals, and have already been used to establish
interspecific chimeras. Transplantation of human HSCs into mid-gestation pig embryos res-
ulted in animals which showed a low level of chimerism in the bone marrow 18 months after
birth (Ogle et al., 2009), while injection of human HSCs into the liver of sheep foetuses also
produced low-level chimeras (Abe et al., 2014). The fact that these chimeras can be produced
is a promising indicator that future blastocyst complementation experiments may be a success.
However, it should be noted that chimerism in the sheep, which persisted up to 40 months after
birth, was only observed when donor cells had undergone forced transient expression of HoxB4
prior to injection (Abe et al., 2014) which, as discussed, is not desirable in for the purposes of
producing blood for clinical patients.
Another issue with these chimeras is that any chimerism observed ultimately disappeared
from the animals. It is unclear why the donor human HSCs were eventually lost from the bone
marrow, but it is potentially due to incompatibilities between the donor cells and the recipient
haematopoietic niche, which is either incapable of permanently sustaining the human HSCs
or allows the recipient HSCs to outcompete the donor HSCs. An alternative view could be
that these donor HSCs could also persist for as long as they did because of supporting factors
provided by the host HSCs, a cell population which would not be present in Runx1-/- animals.
The compatibility between donor cells and a vacant recipient niche needs to be understood in
greater detail.
3.4.3. Interspecies compatibility in the haematopoietic niche
The stem cell niche is the physical environment surrounding a stem cell population which
regulates the characteristics of the inhabiting stem cells (Schofield, 1978). HSCs are dependent
on the surrounding niche for their development and even require the support from stromal cells
for growth in vitro (Dexter et al., 1977). It is important to realise that HSCs travel through
a number of niches during development, from the dorsal aorta to the foetal liver and then on
to the bone marrow. In addition, the bone marrow niche itself contains microenvironments
which maintain different states of the HSCs such as quiescence and proliferation. Therefore,
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a donor and recipient species used for blastocyst complementation require compatibility in all
the niche microenvironments. The many different components of the bone marrow niche, from
the different cell types to cytokines and physical factors, have been reviewed extensively (Wang
and Wagers, 2011, Sarrazin and Sieweke, 2011, Mendelson and Frenette, 2014).
The potential for incompatibility between donor HSCs and a recipient niche was investigated
experimentally by Butler et al. (2010), where murine HSCs were cultured on human endothelial
cells which provide numerous factors known to be necessary for HSC maintenance. Only one
factor, sKitL, was found to not be cross-compatible between the two species, suggesting that
there exists a high degree of conservation in HSC niches between species but that some factors
may block niche colonisation. The current rise of systems biology may also help to find pos-
sible incompatibilities between donor cells and recipient niches in that signalling pathways and
transcriptional networks can be compared across multiple niches in the same species (i.e. the
dorsal aorta, the foetal liver and the bone marrow) (Charbord et al., 2014) and across different
species (Boyle et al., 2014, Gerstein et al., 2014).
One solution to this issue of interspecies compatibility would be to produce animals with
humanised stem cell niches. The feasibility of this has been investigated in mice, where artifi-
cial scaffolds and human mesenchymal stem cells were used to create a humanised HSC niche
(Groen et al., 2012) in adult mice. Although this could potentially circumvent any interspecies
incompatibility in the niche, this process requires immunodeficient recipients and also implants
the humanised niche as an addition to the host niche, rather than as a substitution. This results
in the support of human HSCs, making this an interesting technique for HSC expansion, but
the circulating blood cells are mixed with those of the mouse, meaning that whole blood cannot
be produced using these animals.
3.4.4. Restricting donor cell contribution to specific lineages
This work could ultimately lead to the creation of interspecific chimeras using human cells,
meaning that important ethical considerations need to be taken into account, as recently re-
viewed by Shaw et al. (2014). One of the main issues with this area of research is that recipient
animals injected with human cells may be inadvertently endowed with ’human features’ with
the brain, gametes and physical features such as the skin and eyes being of particular concern.
Indeed, Han et al. (2013) demonstrated a significant increase in learning ability in mice en-
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grafted with human neural precursors. These concerns require both the donor cells and the
recipient niche to be carefully chosen. In the case of the Runx1-/- mouse, the fact that Runx1
expression and function is not confined to the haematopoietic niche (as discussed in Section
3.1.3.3) is a potential cause for concern as any injected pluripotent stem cells may rescue defi-
ciencies caused by loss of Runx1 in tissues other than the blood, such as bone and the nervous
system in addition to their random contribution to tissues throughout the embryo.
This could potentially be solved by using donor cells with a more restricted potency, such
as HSCs. However, HSCs have been shown to be capable of contributing to tissues derived
from all three germ layers in the developing embryo (Pessac et al., 2012), including liver tissue
(Lagasse et al., 2000) and skeletal muscle (Ferrari et al., 1998, Gussoni et al., 1999). HSCs
also express cell markers associated with ’stemness’, including Oct4, Sox2 and Klf4; three
of the four factors used to make iPS cells (Takahashi and Yamanaka, 2006), as well as genes
associated with early progenitor cells in each of the three germ layers (Pessac et al., 2011). This
means that injection of HSCs into a recipient embryo does not guarantee that donor contribution
will be limited to the haematopoietic niche as they do not seem to preferentially colonise their
’intended’ niche (Pessac et al., 2012).
An alternative method for limiting donor cell contribution to chimeras has been recently
published by Kobayashi et al. (2014), using the Pdx1-null animals first described in Kobayashi
et al. (2010) (detailed in Section 3.1.2.3). An inducible Mixl1 transgene was inserted into donor
pluripotent stem cells and Mixl1 transiently expressed both prior to and after injection of the
donor cells into a recipient embryo. Mixl1 expression pushes cells to preferentially contribute
to tissues and organs derived from the endoderm rather than any ectodermal or mesodermal
lineages. However, in addition to the pancreas fully consisting of donor-derived cells, as inten-
ded, the researchers also found increased contribution of the donor cells to other organs, such
as the heart. This, coupled with the use of a transgene, demonstrate that there is some way
to go before large animal interspecific chimeras will be able to produce organs and tissues for
transplant into humans.
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4. Using genome editors to produce
myostatin-knockout sheep
4.1. Introduction
4.1.1. Skeletal muscle development and characteristics
Skeletal muscle is derived from specialised stem cells, known as satellite cells. Satellite cells
are located within the skeletal muscle at the boundary between a mature myotube and the
extracellular matrix (Mauro, 1961) and are generally found in a quiescent state, similar to
other tissue-specific stem cells. Satellite cells exit quiescence when there is an active need to
produce more differentiated muscle cells (recently reviewed in detail by Wang et al. (2014d)).
Upon activation, satellite cells differentiate into myoblasts, which subsequently fuse together
to form myotubes. These myotubes are then arranged into bundles called myofibres, which
form the basic unit of a muscle (Gilbert, 2010). This process is shown in Figure 4.1.
Myofibres have been historically classified as fast twitch or slow twitch, depending on their
speed of contraction (Peter et al., 1972). Fast twitch fibres predominantly express MHC Type
II fibres and generally have a larger diameter than slow twitch fibres, which express more
MHC Type I fibres (Pette and Staron, 2000). Fast twitch fibres are more likely to produce
ATP by glycolytic means while slow twitch myofibres, which contain a higher number of
mitochondria than fast twitch fibres, produce ATP by oxidative means. Producing ATP by
glycolysis allows fast twitch fibres to produce ATP more quickly than slow twitch fibres, but at
the cost of increased lactic acid production, meaning that fast twitch fibres fatigue more rapidly
than slow twitch (Levy et al., 2006, Hall and Guyton, 2011).
Muscle development and the balance of fast to slow twitch fibres in myofibres is regulated
by myostatin, amongst other factors.
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Figure 4.1.: Muscle development from satellite cell to myofibre
4.1.2. Myostatin
The role of myostatin as a negative regulator of muscle growth was first identified by the strik-
ing phenotype of the myostatin-null mouse (McPherron et al., 1997), described in detail in
Section 4.1.3. Myostatin is a member of the TGF-b family (McPherron et al., 1997) and is
most closely related to BMP11 (McPherron et al., 1999), which also regulates growth and de-
velopment in a number of tissues and is expressed in a wider range of tissues than myostatin
(Lee and Lee, 2013). Myostatin is highly conserved across species (McPherron et al., 1997,
McPherron and Lee, 1997), which is indicative of its important regulatory role.
Myostatin expression begins during embryogenesis in the myotome compartment of devel-
oping somites from stage E9.5. Expression continues into adulthood, where it is primarily
expressed in skeletal muscle (McPherron et al., 1997), although there is also limited expres-
sion in adipose tissue, where myostatin negatively regulates brown adipocyte differentiation
(McPherron et al., 1997, McPherron and Lee, 2002, Braga et al., 2013).
The myostatin gene contains three exons, which, once transcribed and translated, form an
peptide of 376 amino acids in length. Transcription of myostatin is initiated by the binding
of FoxO1 and Smad transcription factors to the promoter region (Allen and Unterman, 2007).
The full-length peptide is processed into three parts; amino acids 1-23 form the signal peptide
for secretion from skeletal muscle into the circulatory system, amino acids 24-266 form the
propeptide and amino acids 267-376 form the mature protein (McPherron et al., 1997, Lee and
McPherron, 2001). Like other TGF-b family members, the full-length peptide is processed
firstly to remove the signal peptide, then the propeptide is cleaved from the mature protein by
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BMP-1/tolloid metalloproteinases (Wolfman et al., 2003), which allows activation of the ma-
ture myostatin protein. During processing, which occurs in skeletal muscle, mature myostatin
proteins dimerise via disulphide links (McPherron et al., 1997). The propeptide appears to play
a role in ensuring that the mature protein is folded correctly and regulates protein expression
by holding myostatin in a latent, inactive form (Lee and McPherron, 2001, Hill et al., 2002).
Myostatin can be also be inhibited by molecules such as follistatin and follistatin-like proteins
like FLRG (Hill et al., 2002, Cash et al., 2009, 2012), GASP-1 and GASP-2 (Lee and Lee,
2013). These inhibitors are thought to prevent myostatin from binding to its receptors (Lee and
McPherron, 2001).
Latent and activated myostatin protein circulates in the blood (Zimmers et al., 2002) and,
once activated, acts on cells via autocrine signalling (McPherron et al., 1997, Rios et al., 2004).
Myostatin-mediated signalling can occur via the TGF-b or MAPK signalling pathways. TGF-
b signalling is initiated by the binding of myostatin to the activin type II receptor ActRIIB
(Rios et al., 2004) and the subsequent binding and activation of the type I receptors ALK4 and
ALK5. ALK4 and ALK5 activate the signal transducers Smad2 and Smad3 by phosphorylation
(Rebbapragada et al., 2003). This ability of myostatin to activate Smad proteins suggests that it
may have a role in stimulating its own transcription. Myostatin also signals through the MAPK
pathway via p38 and the TAK1-MKK6 cascade (Philip et al., 2005). Myostatin-induced MAPK
signalling is independent from TGF-b signalling.
Myostatin’s regulation of muscle growth occurs through two main mechanisms. Firstly, it
induces satellite cell quiescence via the upregulation of the Cdk inhibitor p21 and decreasing
Cdk2 protein levels, which prevents cells from entering S phase (McCroskery et al., 2003).
It also reduces myoblast proliferation, causing myoblast cells to remain in G1 phase and re-
duces the expression of MyoD and myogenin proteins, which are two key drivers of muscle
development. (Joulia et al., 2003).
In addition to its role in controlling muscle growth, myostatin also regulates the type of my-
ofibres which develop. Although it is expressed throughout skeletal muscle, it is differentially
expressed in myofibres in fast and slow muscles, where it inhibits the development of the MHC
Type II myofibres found in fast-twitch muscles and encourages the expression of slow-twitch
MHC Type I myofibres. Myostatin also regulates muscle growth by inducing satellite cell
quiescence via the upregulation of the Cdk inhibitor p21 and decreasing Cdk2 protein levels,
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preventing cells from entering S phase (McCroskery et al., 2003).
4.1.3. Myostatin-knockout phenotype
The striking phenotype of the myostatin-knockout mouse was first described by McPherron
et al. (1997). Knockout animals were created by replacing exon 3 of the myostatin gene,
which encodes the mature protein, with a neomycin cassette. The resulting knockout animals
had a total body size which was about 30% bigger than that of wildtype animals and indi-
vidual muscles which weighed 2-3 times more than wildtype counterparts (McPherron et al.,
1997), leading to the naming of the phenotype as double muscled. Sections from muscles of
myostatin-null animals showed than this increase in muscle was due to a combination of hyper-
trophy (knockout muscles had a total cell count which was 86% higher than wildtype muscles)
and hyperplasia (myostatin-knockout muscle fibres had a larger diameter than wildtype con-
trols) (McPherron et al., 1997). Double muscled animals have increased absolute muscle power
but reduced endurance (Baligand et al., 2010, Matsakas et al., 2010) and exhibit a 70% reduc-
tion in adipose tissue accumulation despite having similar food intake and metabolic rates to
wildtype animals (McPherron and Lee, 2002).
A second double muscled mouse line has also been characterised. The Compact mouse
arose from a breeding program selecting for high carcass protein content (Varga et al., 1997)
and displays a similar hypermuscular phenotype to the myostatin-null mouse described above.
The Compact phenotype is cause by a 12bp deletion which causes a deletion of four amino
acids and the substitution of a further amino acid in the propeptide. Given the central role of
the propeptide is regulating the mature myostatin protein, it is likely that the double muscling
of the Compact mouse is due to the mutated propeptide either failing to prevent misfolding
of the mature protein or sequestering an increased amount of myostatin protein (Szabo et al.,
1998). Given the nature of the mutation, it is likely that the Compact mouse represents the
effects of a substantial knockdown of the myostatin protein, rather than a complete knockout.
Dominant negative myostatin mutants, where the myostatin signalling pathway has been
experimentally disrupted, also exist. Examples include ActRIIB mutants (Lee and McPherron,
2001) and mutants where the cleavage site between the propeptide and mature protein has
been disrupted (Zhu et al., 2000). However, some of these mutants differ from the myostatin-
null mouse in that they show a phenotype due to hypertrophy only with no contribution from
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hyperplasia (Zhu et al., 2000).
Several mechanisms which cause the double muscle phenotype have been elucidated. The
hypertrophy of the muscles is at least partially due to an increase in satellite cell proliferation,
leading to production of more myoblasts. The proliferation rate of myoblasts themselves is
also increased by the loss of myostatin (McCroskery et al., 2003). An increased number of
myoblasts also contributes to myofibre hyperplasia, as an increased number of myoblasts fuse
together to create a single myofibre. Hyperplasia is also partly driven by an increase in protein
synthesis via upregulation of Akt/mTOR signalling (Rodriguez et al., 2011, Trendelenburg
et al., 2009).
The increased power and fatigability of double muscled animals stems from myostatin’s reg-
ulation of the types of MHC molecules expressed in myofibres. Muscle fibres from knockout
mice are more likely to differentiate into those containing MHC IIB fibres, which confer fast-
twitch properties (Amthor et al., 2007, Girgenrath et al., 2005). This increases muscle power,
but at the expense of fibres containing MHC Type I, or slow-twitch, fibres, which increase
endurance. This switch from MHC Type I to MHC Type II fibres is influenced by downreg-
ulation of MEF2C and upregulation of MyoD caused by loss of myostatin (Hennebry et al.,
2009). Loss of myostatin also causes more myofibres to take on glycolytic characteristics and
lose oxidative properties, including a reduction in mitochondrial numbers and respiration rate
(Amthor et al., 2007, Baan et al., 2013, Mouisel et al., 2014). Producing energy through glyco-
lytic rather than oxidative means has a greatly reduced efficiency, thereby increasing the ATP
cost of contraction (i.e. more ATP is required to generate the same amount of force compared
to a WT myofibre) (Giannesini et al., 2013). However, oxidative activity can be increased
following a regular exercise regimen (Matsakas et al., 2010).
4.1.3.1. The myostatin-knockout phenotype in livestock animals
Based on this description of the double muscled phenotype caused by a loss of myostatin in
mice, it is clear to see why a similar mutation in livestock animals such as cattle and sheep
would have a high agricultural value. Double muscled animals yield more and leaner meat
and, indeed, there are already examples where naturally occurring inactivating mutations in
myostatin have been selected for in certain breeds. The best known example of this is the
Belgian Blue cattle breed, which shows a 20-25% increase in muscle size over other cattle
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breeds (McPherron and Lee, 1997) . The double muscle phenotype of the Belgian Blue is
caused by an 11bp deletion within the third exon of myostatin, which causes a frameshift and
the production of a severely truncated mature protein only twenty amino acids long (McPherron
and Lee, 1997, Grobet et al., 1997). This mutation completely abrogates myostatin’s function,
rendering the animal a true functional knockout.
Double muscling is also seen in Piedmontese cattle and Texel and Norwegian White sheep.
Piedmontese cattle have a G to A transition in the third exon that causes a cysteine to tyrosine
substitution. This is thought to disrupt the structure of the mature protein, leaving it non-
functional as the substituted cysteine is highly conserved, not only across myostatin proteins
from different species, but across all TGF-b family members, suggesting the importance of the
cysteine in the protein (McPherron and Lee, 1997).
Like the Piedmontese, the Texel mutation is a G to A transition in the 3’ UTR of the myostatin
gene, creating an illegitimate target site for the microRNAs mir1 and mir206 (Clop et al.,
2006, Takeda et al., 2010). This results in a RNAi-induced reduction in the levels of myostatin
mRNA to around one-third of the levels seen in wildtype animals via RNAi (Clop et al., 2006).
This increases muscle-related traits and decreases fat-related traits in Texel animals but, un-
like knockout animals, the mutation has no significant effects on total body weight or growth
traits (Johnson et al., 2009, Masri et al., 2011). Norwegian White sheep have the same G to A
transition in the myostatin 3’UTR and some animals also have a 1bp deletion within exon 3.
This deletion produces a truncated mature protein however, as the extent of truncation is sig-
nificantly less than that seen in the Belgian Blue, it is not clear whether the protein retains any
biological activity (Boman et al., 2009). However, lambs which are homozygous for this dele-
tion tend to die shortly after birth and the mutation is being actively bred out of the population
(Boman et al., 2011).
Despite the presence of myostatin knockout mutations in the natural populations of some
livestock breeds, it would be of great use to be able to quickly introduce established or new
myostatin alleles in other breeds. Current double-muscled animals, such as the Texel and
Belgian Blue, are not feasible breeds to be used in many places where livestock farming occurs,
for a variety of reasons. Inappropriate environmental conditions, such as an increased outdoor
temperature, can limit some breeds’ ability to thrive, as they cannot adequately regulate their
body temperature. In addition to this, some areas, such as parts of Sub-Saharan Africa, can have
95
severely restricted access to veterinarians and other animal husbandry resources. This would
be a particular problem considering the reproductive issues associated with Belgian Blue cattle,
meaning that the productivity benefits of the breed would be significantly negated by the loss
of animals during labour. Therefore, the ability to introduce myostatin-knockout mutations
into breeds which are well adapted to their local conditions could be of great benefit to local
farmers.
Recent publications have described attempts to produce sheep and goats using various tools
such as RNAi or genome editors such as ZFNs or CRISPRs (Zhang et al., 2013, Zhong et al.,
2014, Ni et al., 2014), emphasising the value of the double muscled phenotype. This results
chapter presents the use of TALENs and CRISPRs to produce edited myostatin alleles in sheep
via embryo microinjection.
4.2. Additional materials and methods
4.2.1. Muscle staining
Four different leg muscles were sampled; the soleus, the tibialis anterior, the gastrocnemius
and the peroneus longus (see Figure 4.2). A section of muscle was cut away from the central
portion of each muscle and each sample divided for either cryosectioning or wax embedding,
as described below. Images of all stained sections were taken at 200x magnification. Three
images were taken for each muscle from each animal and the cross-sectional area of each fibre
in the images was measured using ImageJ.
4.2.1.1. Muscle cryosections and enzyme staining
Muscle samples to be cryosectioned were embedded in OCT compound (Tissue-Tek) on cork
discs before being snap frozen using Cryospray (VWR international) and placed into liquid
nitrogen. Samples were then recovered from the liquid nitrogen for long-term storage at -
80ºC. 10mm serial sections were cut in a cryostat machine and placed onto poly-L-lysine slides.
Freshly cut sections were allowed to dry at room temperature for one hour prior to staining.
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Figure 4.2.: Image showing the location of the gastrocnemius (G), the peroneus longus (P), the
soleus (S) and the tibialis anterior (TA) within the leg.
4.2.1.2. ATPase staining
The following solutions were prepared in advance of ATPase staining;
Formal-cacodylate sucrose fixative 20g of paraformaldehyde was added to 100ml of
distilled water and dissolved by heating to 60ºC using a magnetic stirrer. Drops of 10%
sodium hydroxide were added until the solution cleared then the following reagents were
added; 62.5g of sucrose, 10.7g of sodium cacodylate, 0.625g of sodium pyrophosphate
and 400ml of distilled water. The pH of the solution was then adjusted to 7.4 and the
fixative stored at 4ºC.
1% ammonium sulphide Just before use, 3ml of 20% ammonium sulphide (Fisher Sci-
entific) was added to 60ml of distilled water.
Glycerin jelly 30g of glycerol jelly was warmed in 50ml of distilled water and 20ml of gly-
cerol until the jelly had fully dissolved. The jelly was then aliquoted and stored at 4ºC.
Individual aliquots were warmed to 37ºC before use.
ATPase incubation medium 1.21g of Tris base (Fisher Scientific) and 0.2g of calcium
chloride were added to 100ml of distilled water and the pH adjusted to 9.5. Just be-
fore use, 40ml of the solution was aliquoted and 60mg of ATP (disodium salt) was added
to the aliquot.
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After drying, fresh cryosections were fixed in formal-cacodylate sucrose fixative at 4ºC for
60-90 minutes. Slides were then washed once in distilled water before being placed in a glass
Coplin jar containing ATPase incubation medium and incubated in a water bath set to 37ºC for
45-60 minutes.
After incubation, the slides were washed twice in a 1% calcium chloride solution (each wash
was three minutes long), then transferred to a 2% cobalt nitrate solution for three minutes.
Slides were then washed twice in distilled water and briefly plunged into 1% ammonium sulph-
ide to develop. Excess ammonium sulphide was then removed by two washes in distilled water
and sections mounted using glycerin jelly and coverslips.
4.2.1.3. NADH staining
The following solutions were prepared in advance of NADH staining;
0.1M phosphate buffer 8.5g of sodium chloride, 1.07g of disodium phosphate and 0.39g
of monosodium phosphate were dissolved in 1 litre of distilled water.
NADH incubation medium A 10mg nitrotetrazolium blue tablet was added to 10ml of
0.1M phosphate buffer (described above) and vortexed until the tablet was fully dis-
solved. The solution was then stored until needed, at which point 8mg of NADH was
added to the solution just before use.
After drying, slides with fresh cryosections were covered in NADH incubation medium and
incubated at 37ºC for 45 minutes. Slides were then washed twice in distilled water and mounted
using glycerin jelly before being covered with a coverslip and left to dry overnight.
4.2.1.4. Wax embedding and HE staining
Muscle samples for wax embedding were fixed in 4% paraformaldehyde overnight. Fixation
was carried out on a rocking platform at 4ºC. The following day, the samples were washed
using the following protocol and stored at 4ºC in the final 70% ethanol wash.
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Wash reagent Wash time Wash temperature
PBS 30 minutes 4ºC
30% ethanol 15 minutes Room temperature
70% ethanol 30 minutes Room temperature
70% ethanol 30 minutes Room temperature
Samples were then placed into labelled histology cages and processed for wax embedding
using the following protocol.
Reagent Incubation time
70% ethanol 2 hours
90% ethanol 2 hours
100% ethanol 2 hours







Samples were subsequently embedded in wax blocks and stored at 4ºC. 10mm sections were
cut on a microtome and placed onto poly-L-lysine slides. Sections were incubated at 50ºC
overnight to melt away excess wax before staining.
H&E staining was carried out using a Leica XL autostainer using the following protocol.






100% ethanol 3 minutes
100% ethanol 2 minutes
95% ethanol 2 minutes
Distilled water 5 minutes
Haematoxylin 3 minutes
Distilled water 3 minutes
Distilled water 3 minutes
Tap water 2 minutes
Distilled water 2 minutes
Eosin 2 minutes
Distilled water 45 seconds
70% ethanol 30 seconds
95% ethanol 30 seconds
95% ethanol 30 seconds
100% ethanol 1 minute
100% ethanol 1 minute






4.3.1. TALEN and CRISPR design and validation
TALENs (designed by Dr Daniel Carlson) and CRISPRs were designed to target exon 3 of
the MSTN gene, which corresponds to the mature protein (see Figure 4.3), and constructed
as detailed previously. MSTN TALENs were originally designed against the bovine MSTN
locus only and were provided as capped mRNA by Recombinetics. This TALEN mRNA was
transfected into OEFs and BEFs using the Neon system and a CelI assay carried out. Evidence
of editing was seen in both cell types, with TALEN activity being higher in the BEFs than the
OEFs (Figure 4.4), as indicated by the greater intensity of the cleavage products. The amount
of exposure in the image means that the amount of editing seen cannot be quantified. An image
at a lower exposure would not have clearly shown the activity of the TALENs in the ovine cells.
The success of this validation meant that the TALEN mRNA could be used further in embryo
injections, detailed in Section 4.3.2.
The MSTN TALENs were subsequently constructed into the ELD/KKR vectors, which al-
lowed TALENs which were specific to either the bovine or ovine MSTN target site to be pro-
duced (performed by Mrs Claire Neil). The completed TALENs were then transfected into
BEFs or OEFs as plasmid DNA along with a GFP plasmid to assay transfection efficiency
(Figure 4.5 (a)). However, unlike the positive results found upon transfection of the MSTN
TALEN mRNA, transfection of the plasmids did not lead to the production of any cleavage
products in a CelI assay (Figure 4.5 (b)).
To eliminate the possibility that the TALENs may have been inadvertently cloned into the
incorrect version of the heterodimeric ELD/KKR vectors so that, for example, both TALENs
had been cloned into an ELD vector, the region of FokI containing the ELD and KKR point
mutations was sequenced for each TALEN along with the empty ELD and KKR plasmids
(Figure 4.6). Aligning the resulting sequences showed that the left and right TALENs were
in their intended destination plasmids, with the left TALENs in the ELD vector and the right
TALEN in the KKR vector.
The MSTN target sites in the bovine and ovine fibroblasts were sequenced to check for
possible mismatches between the target DNA and the TALEN RVDs, although this was thought
unlikely as the TALENs had been previously shown to be active in both cell types. The target
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Figure 4.3.: Positions of (a) TALEN and (b) sgRNA binding sites in exon 3 of the ovine
myostatin locus. The bovine SNP is highlighted in (a) by an asterisk. PAM se-
quences for each of the sgRNAs are underlined in blue.
Figure 4.4.: Gel image showing the results of a CelI assay on OEFs and BEFs transfected with
MSTN TALEN RNA provided by Recombinetics. Cleavage products are indicated
by the arrowhead.
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Figure 4.5.: Validation of bovine and ovine MSTN TALENs in the Sangamo ELD/KKR vec-
tors. TALENs targeted to either the bovine MSTN (bMSTN TALEN) or ovine
MSTN (oMSTN TALEN) loci were transfected into BEFs and OEFs along with
a GFP plasmid to show transfection efficiency. (a) Brightfield and GFP images
of transfected BEFs and OEFs 3 days after transfection. Cells were transfected
with both versions of the MSTN TALENs to determine whether the difference in
efficiency observed in Figure 4.4 was maintained with the new expression vectors.
Images at 100x magnification. (b) Results of CelI assay on transfected cells. No
evidence of TALEN activity was seen in any of the transfected samples.
sites in both the BEFs and OEFs aligned completely with their respective genomic sequence
(Figure 4.7). This, combined with the results of other troubleshooting steps taken for the Rag1
TALENs (see Figure 3.15), left no clear reasons why the TALENs had suddenly lost their
activity.
The MSTN sgRNAs were constructed in the pSpCas9(BB) vector and, as with the MSTN
TALENs, tested by transfection into BEFs and OEFs (Figure 4.8). Although the expression of
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Figure 4.6.: Sequence alignments of the FokI region of the myostatin TALENs which contains
the heterodimer ELD/KKR mutations. The ELD/KKR point mutations are high-
lighted in green boxes
Figure 4.7.: Sequence alignments of myostatin TALEN target sites sequenced from OEF or
BEF DNA aligned against their counterparts in the ovine or bovine genome. Areas
targeted by the myostatin TALENs are highlighted in green boxes
GFP in the cells showed that the plasmid had been successfully transfected, no editing activity
was observed following a CelI assay. To ensure that the transfection protocol was appropri-
ate for use with the CRISPR/Cas9 system, repeat transfections were carried where BEFs and
OEFs were co-transfected with the MSTN F1, F2, R1 and R2 CRISPR/Cas9 plasmids along-
side a separate transfection where BEFs were transfected with a plasmid containing a sgRNA
sequence targeted against Nanos2 (provided by Dr Simon Lillico). This sgRNA had been pre-
viously shown to be capable of editing. The results of a T7 assay carried out on these cells
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is shown in Figure 4.9. Although co-transfection of the MSTN sgRNAs did not result in any
editing activity, cleavage products can be seen in the lane containing DNA isolated from BEFs
transfected with the Nanos2 sgRNA, showing that the transfection protocol is suitable for use
with CRISPR/Cas9 plasmids.
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Figure 4.8.: Validation of MSTN sgRNAs in BEFs and OEFs. (a) Brightfield and GFP images
of OEFs transfected with sgRNAs cloned into the pSpCas9(BB) vector. Images at
100x magnification. (b) Results of CelI assay on transfected OEFs. (c) Brightfield
and GFP images of BEFs transfected with sgRNAs cloned into the pSpCas9(BB)
vector. Images at 100x magnification. (d) Results of CelI assay on transfected
BEFs. Note that there is no evidence of CRISPR activity in either (b) or (d).
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Figure 4.9.: Gel image showing the results of a T7 assay on ovine and bovine fibroblasts trans-
fected with plasmids containing all four MSTN sgRNA sequences (F1, F2, R1
and R2) in addition to bovine fibroblasts transfected with a plasmid containing the
Nanos2 sgRNA sequence. Although no evidence of editing was seen in any of the
cells transfected with the MSTN CRISPRs, cleavage products indicating editing
activity in BEFs transfected with the Nanos2 CRISPR are shown by arrowheads.
4.3.2. Embryo injections
Ovine oocytes were prepared for injection and injected with either MSTN TALEN mRNA or
sgRNAs. These injections are summarised in Table 4.1. MSTN TALEN mRNA was injected
at a concentration of 2ng/ml. Zygotes injected with MSTN CRISPRs were injected with all
four sgRNAs, with each individual sgRNA at a concentration of 10ng/ml, in addition to capped
and polyadenylated Cas9 mRNA (PNA) at a concentration of 100ng/ml. All injections had a
volume of 2-5pl injected into the cytoplasm.
In addition to the embryos transferred into recipients, some embryos injected with the MSTN
sgRNAs were cultured to blastocyst stage and analysed by PCR amplification and subsequent
sequencing of the MSTN locus for the presence of editing events. No edited alleles were
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detected in any of the 28 embryos analysed (data not shown).
DNA from lambs resulting from these injections was sequenced to determine whether any of
the animals were edited. Out of 16 lambs born, two lambs, one injected with MSTN TALENs
and one injected with MSTN sgRNAs, were found to have edited myostatin alleles. The ana-
lysis of these animals is presented in Sections 4.3.3 and 4.3.4.
Construct Embryos injected Cleaved embryos Embryos
transferred








56 28 (50%) 5 (9%) 0 - -
MSTN sgRNAs
(F1, F2, R1, R2)
23 8 (34%) 7 (31%) 0 - -
MSTN sgRNAs
(F1, F2, R1, R2)
and PPT1 sgRNA
40 30 (75%) 15 (38%) 3 4 1
Table 4.1.: Table summarising microinjections carried out in ovine embryos with genome ed-
itors designed to target myostatin. Percentage values for cleavage and blastocyst
formation are given in relation to the number of embryos injected.
4.3.3. Identification and analysis of TALEN-edited lamb
The edited lamb produced by the injection of MSTN TALEN mRNA was found to be a mosaic
with one edited allele (Figure 4.10 (b)), as the second trace on the chromatogram had a lower
signal intensity than the wildtype trace, excluding the possibility that the animal was a hetero-
zygote. It is therefore clear that the editing event took place in a single cell after the zygote had
already undergone cell division. Cloning of PCR products confirmed that a 3bp deletion had
occurred at the locus although, due to the slightly repetitive nature of the sequence immediately
surrounding the cut site, it is unclear exactly which three nucleotides have been deleted (the
possible deletion events are shown in Figure 4.10 (d)). However, the result of each potential
event is the deletion of a single amino acid, arginine 283, from the myostatin protein.
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Figure 4.10.: Identification and analysis of myostatin-edited lamb produced using TALENs.
(a) Image of genome-edited lamb (ID = 3T004). (b) Comparison of sequence
chromatograms from wild-type and edited animals. The red line marks the be-
ginning of the ’shadow’ trace, indicating gene editing. The sequence shown by
the ’shadow’ trace is shown under the chromatograms. The relatively weak signal
from the shadow trace compared to the ’wildtype’ trace indicates that the animal
is a mosaic, rather than a heterozygote. (c) Comparison of wildtype and edited
DNA sequences. The black line indicates the point where the shadow trace ap-
pears on the edited chromatogram and where the two sequences diverge from
each other. The red boxes indicate sequence common to the two alleles and show
the 3bp deletion caused by the editing event. (d) The three possible deletions res-
ulting from gene editing. Note that sequences in (b) and (c) are from sequencing
reactions using the myostatin reverse primer and are the reverse complement of
the sequences shown in (d). Figure (d) adapted from Proudfoot et al. (2014).
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The TALEN-edited lamb was not used in a breeding programme due to the fact that the edited
myostatin allele was not predicted to be severely affected by the loss of arginine 283, in addition
to the animal’s mosaic status, which would mean that few offspring, if any, would inherit the
edited allele. It was therefore decided to cull the animal and perform a more detailed analysis
of the muscle phenotype by measuring the cross-sectional area of muscles fibres. Samples
were taken from four calf muscles; the gastrocnemius, the peroneus, the soleus and the tibialis
anterior. These muscles were selected to represent the range of different muscle properties
found in the leg, in case the edited myostatin protein had differing effects on different muscles
as previous work has found that different muscles within the same animal exhibit hypertrophy
and hyperplasia to different degrees upon knockout of myostatin (Baan et al., 2013). The
tibialis anterior and peroneus predominantly consist of fast-twitch fibres (Baldwin and Tipton,
1972, Ariano et al., 1973, Xu et al., 1998), while the gastrocnemius and soleus contain higher
proportions of slow-twitch fibres (around 50% and 70% respectively) (Edgerton et al., 1975).
Muscle samples were either fixed for wax embedding or frozen in OCT for cryosectioning.
Originally, H&E staining was used to make the boundaries of each myofibre clear for the
quantification of cross-sectional areas. However, wax embedding of the muscle samples caused
significant shrinkage of the fibres to occur, which would have impacted on the results (Figure
4.11). Cryosections of muscle samples stained for either ATPase or NADH activity did not
appear to shrink to the same extent (Figure 4.11) (although some slight shrinkage was observed
in the sections stained for ATPase activity), so were used in place of the H&E sections in the
analysis.
Cross-sectional areas of myofibres were calculated using ImageJ. Each muscle has an n of
between 52 and 127. The data are presented in Figure 4.12. It is clear that the mean cross-
sectional areas of myofibres in the edited animal are amongst the smallest out of the five animals
analysed in total and it is therefore safe to anticipate that the edited myostatin allele in this
animals does not exert a phenotypic effect. Because only one edited animal was available for
analysis, two-tailed t-tests were carried out by comparing each control muscle to the equivalent
edited muscle. Although there are significant differences between some of the muscle samples,
the fact that there is only one edited animal means that the degree of variation seen between the
control animals cannot be adequately accounted for when analysing the single edited animal.
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Figure 4.11.: Comparison of the effects of different staining methods on sections of tibialis
anterior muscle from a control animal. Scale bars represent 100mm. Darker stain-
ing in the ATPase and NADH sections indicate increased ATPase activity and
oxidative activity, respectively. Note that the fibres in the H&E stained section
(left image) have shrunk significantly in comparison to those in the ATPase and
NADH-stained sections (centre and right images), making the H&E sections un-
suitable for analysis of myofibre size.
Figure 4.12.: Graph comparing the mean cross-sectional areas of muscle fibres taken from the
legs of the TALEN-edited sheep and four unedited controls. T-tests were carried
out comparing each control animal to the edited animal in each muscle. * = P
<0.05, ** = P <0.01, *** = P <0.001
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4.3.4. Identification of CRISPR-edited lamb
Sequencing of earclip DNA from the lambs resulting from injections of the MSTN CRISPRs
showed one animal to be heterozygous for an editing event (Figure 4.13 (b)). Subsequent se-
quencing of cloned PCR products (Figure 4.13 (c)) showed that the majority of sequenced PCR
products harboured a 20bp deletion which is situated 16bp downstream of the deletion event
found in Belgian Blue cattle (Figure 4.13 (d)). In addition to this, two sequences also contain
single nucleotide changes at sites upstream or downstream of the 20bp deletion (highlighted in
Figure 4.13 (c)). Given that sequencing of other PCR products using the DreamTaq polymerase
did not show the introduction of SNPs at such a high frequency, it is anticipated that these base
changes are the result of editing events which occurred after cell division in the embryo.
The 20bp deletion event found in this edited animal converts a TGT codon, which codes
for cysteine, to a TGA stop codon. As a result of this immediate truncation of the protein,
this animal is predicted to produce a shorter myostatin protein than that found in the Belgian
Blue (Figure 4.13 (e)). Because this animal is a heterozygote, it is not expected to have a
double muscled phenotype. However, the presence of a non-functional allele should cause an
intermediate muscle phenotype, as discussed in Section 4.4.2. A more detailed analysis of the
muscle fibres will be carried out at a later time to confirm the animal’s phenotype as the current
priority is to breed from this animal.
The restricted breeding season and small offspring numbers of sheep mean that it is often
necessary to inject multiple editors into the same embryo, to maximise the use of limited re-
sources. Because of this, the CRISPR-edited lamb had also been injected with sgRNAs targeted
against PPT1 as part of a separate project in the group (PPT1 sgRNAs were designed and val-
idated by Dr Simon Lillico). Sequencing was carried out to determine whether the PPT1 locus
had also been edited in this animal. Figure 4.14 (a) shows a alignment between the PPT1 locus
amplified from the edited lamb against the PPT1 sequence available in the sheep genome. No
indications of editing are present, despite confirmation of the PPT1 sgRNAs’ activity in vitro
(Dr Simon Lillico, personal communication). The ovine myostatin cDNA sequence was also
checked to ensure that it contained no off-target binding sites for the PPT1 sgRNA. The largest
area of homology detected was a 6bp fragment in exon 2 of myostatin, with no appropriate
PAM sequence present to allow cleavage by Cas9 (Figure 4.14(b)).
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Figure 4.13.: Identification and analysis of myostatin-edited lamb produced using CRISPRs.
(a) Image showing genome-edited sheep on right (yellow mark on back, ID num-
ber is 4T005) (b) Sequencing chromatogram from 4T005 DNA at the MSTN
target site. The green line indicates the beginning of the editing event. as both
traces have an equal signal intensity, the animal was determined to be a hetero-
zygote. (c) Alignment of sequences from PCR clones of 4T005 DNA against the
ovine MSTN sequence. The 20bp deletion event is clearly visible. Other nuc-
leotides which differ from the ovine sequence are highlighted (d) Section of the
ovine MSTN sequence annotated to show the location of the deletion event in
4T005 (green) in relation to the 11bp Belgian Blue deletion (blue). Nucleotides
which, in the presence of the 20bp deletion found in 4T005, form a TGA stop
codon are highlighted in red. (e) Amino acid sequence of the mature myostatin
protein. Amino acids which are absent in both Belgian Blue cattle and in one
allele of 4T005 are coloured in orange. Residues which are present in Belgian
Blue cattle but absent in 4T005 are coloured in red.
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Figure 4.14.: Analysis of potential PPT1 editing in the CRISPR-edited lamb (ID - 4T005).
(a) Sequence alignment of the PPT1 locus in 4T005 against the ovine genomic
sequence. The binding site of the PPT1 sgRNA is shown by a red box and the as-
sociated PAM sequence underlined. SNPs between the two sequences are shown
by asterisks. (b) Section of exon 2 of ovine myostatin showing area of homology
with the PPT1 sgRNA binding site (green box). Based on this area of homology,
the length of the whole sgRNA is shown by the dashed blue box and the site
where the PAM should be is underlined.
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4.3.5. Determining the presence of the Texel G/A SNP in the edited
animals
As both edited lambs resulted from abattoir-derived oocytes, their genotype at other loci of the
myostatin gene is unknown. The abattoir occasionally receives Texel sheep for slaughter, so
there was a possibility that one or both of the edited lambs could carry the Texel SNP described
in Section 4.1.3 and, therefore, could be compound heterozygotes. The location of the Texel
SNP in the 3’UTR has already been determined (Takeda et al., 2010) and DNA from both
animals was sequenced to see if the Texel SNP was present. Figure 4.15 shows the results of
the sequencing. Both animals are homozygous for the wildtype G at the SNP, indicating that
the Texel myostatin mutation is not present.
Figure 4.15.: Chromatograms showing that both myostatin-edited lambs are homozygous for
the ’G’ SNP in the 3’UTR of myostatin and not the Texel ’A’ SNP, which cre-
ates an octomer motif (highlighted in purple box) and, as a result, an illegitimate
miRNA binding site. The SNP is marked on each chromatogram by an asterisk.
4.4. Discussion
This chapter demonstrates how embryo microinjection of genome editors, specifically TALENs
and CRISPRs, can be used to introduce a desired allele into a particular breed or species, as
exemplified here with a non-functional myostatin allele. The speed with which an allele can be
introduced into a population using genome editors as opposed to conventional breeding is ex-
tremely attractive for agricultural purposes. This is especially true for sheep, which only breed
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once a year. For example, it took 30-40 years of breeding the Texel SNP into the Norwegian
White sheep breed before the allele was almost fixed in the population (Boman et al., 2011).
By having the ability to produce multiple animals containing the desired allele in one breeding
season via embryo microinjection, the time an allele takes to reach fixation in a population can
be drastically reduced.
Two edited animals were produced in this project, one from each type of genome editor used.
They are discussed in greater detail below, with the validation of genome editors discussed in
Chapter 6.
4.4.1. Effects of the edited myostatin allele in the TALEN-edited lamb
The TALEN-edited lamb was found to have a 3bp deletion at the myostatin target site. The
low signal intensity of the edited sequence on a chromatogram indicated that the editing event
had occurred after the injected zygote had undergone cell division and that only a proportion
of the cells in the animal actually contained the edited allele. This means that any phenotypic
effect exerted by the edited allele would potentially be reduced due to the predominance of the
wildtype allele.
The deletion led to the loss of a single amino acid, arginine 283, from the mature myostatin
protein. Interestingly, microinjections using the MSTN TALEN mRNA in bovine zygotes and
carried out in parallel to this work obtained strikingly similar editing events in two out of the
three edited cattle obtained in total (Proudfoot et al., 2014). As with the edited lamb, one of
the edited cattle was mosaic, with two edited alleles in addition to a wildtype allele, again
indicating that the TALENs were active after cell division. In addition, one of these edited
alleles also had a deletion of arginine 283. A second edited calf had a myostatin allele where
cysteine 282 was lost from the protein. It seems unlikely that the loss of a single amino acid
from the protein would be capable of exerting a significant phenotypic effect, unless the amino
acid played a key functional or structural role in the protein.
Analysis of the crystal structure of the mature myostatin protein complexed with the inhibitor
follistatin (Cash et al., 2009) shows that arginine 283 is located within a b-strand and may par-
ticipate in hydrogen bonding with aspartic acid 271. It is possible that loss of arginine 283 may
cause a change in the structure of the myostatin protein either through the loss of this hydrogen
bond or by the loss of the arginine residue impacting on the local structure, particularly the di-
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sulphide bridge formed by cysteine 281. This could result in a hypomorphic myostatin allele,
where the protein’s ability to dimerise or to bind inhibitors such as the myostatin propeptide
are altered (Cash et al., 2009, 2012), although this would need to be confirmed by modelling
of the edited protein’s structure and in vitro activity assays. However, the effects of this allele
are unlikely to be as severe as those seen when a myostatin-null allele is present and may not
result in a visible phenotype.
4.4.2. Effects of the edited myostatin allele in the CRISPR-edited lamb
The CRISPR-edited lamb was heterozygous for a 20bp deletion, which is predicted to result in
one allele which produces a severely truncated myostatin protein, in addition to the WT allele.
As the edited protein is predicted to be shorter than that found in Belgian Blue cattle, it is very
likely that this allele is non-functional. Studies of animals heterozygous for a non-functional
myostatin allele have shown these animals exhibit an intermediate phenotype, suggesting that
myostatin has an additive effect. As an example, the muscle weights of heterozygous mice
have been found to fall between those of wildtype and myostatin-null animals (McPherron and
Lee, 2002) and increased muscularity has been observed in larger heterozygous animals, such
as dogs (Mosher et al., 2007).
This intermediate phenotype is also seen in heterozygous livestock animals and can increase
the agricultural value of the animals. Lambs which are heterozygous for the Texel G/A SNP
showed an increased growth rate and improved feed conversion rate in comparison to wildtype
controls (Haynes et al., 2012), while calves heterozygous for inactivating myostatin mutations
had a heavier birth weight and a higher carcass score (i.e. increased muscle content and de-
creased fat content) at slaughter (Allais et al., 2010).
As mentioned previously, the main priority for future work is to use this animal for breeding
in a n effort to expand the edited allele into a population. However, an application has also
been made to the Home Office for approval to take muscle biopsies from this animal under
anaesthesia for subsequent analysis. This should indicate whether the edited lamb does indeed
exhibit the intermediate phenotype found in heterozygotes.
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4.4.3. Inactivating myostatin at different developmental stages
As described in Section 4.1.3, knocking out myostatin during embryonic development results
in increased muscle mass via an increase in both hypertrophy and hyperplasia. Several studies
have investigated the effects of inactivating myostatin in adult animals, through either condi-
tional deletion of myostatin or inhibiting myostatin using antibodies. Although an increase in
muscle mass is seen when myostatin is inactivated in these animals, it is not as great as the
increase seen when myostatin is knocked out during embryonic development. This is due to
the fact that the increase in muscle mass is solely due to an increase in hypertrophy with no
contribution from hyperplasia (Whittemore et al., 2003, Welle et al., 2007), as adult muscles
exhibit a restricted ability to grow by hyperplasia (Levy et al., 2006). Therefore, inactivating
myostatin by embryo microinjection of genome editors can produce greater enhancement of
muscle mass in the resulting animal than any interventions which are taken when the animal
is already mature as it is still possible to increase muscle growth by hyperplasia as well as
hypertrophy.
4.4.4. Economic viability of the myostatin-knockout phenotype in sheep
Despite the clear agricultural value of the double-muscled phenotype in agriculture, knocking
out myostatin in livestock also brings disadvantages, primarily with breeding. Belgian Blue
calves are routinely delivered by Caesarian section as the increased muscularity of both the cow
and calf mean that the calf is unable to travel through the birth canal unassisted (Bellinge et al.,
2005). These birthing difficulties are a significant trade-off against the increased productivity
of double-muscled livestock and may make these animals unsuitable in some circumstances.
Sheep are a particularly good example of this, as they tend to be farmed less intensively and
with less supervision than cattle. This makes the establishment of interventions such as delivery
of lambs by Caesarian section more problematic as sheep tend to be more dispersed across
farmland and need to be brought together. Further to this, sheep breeds such as the Herdwick,
which are left to graze on poor-quality pasture for prolonged periods rather than being actively
fed are likely to show fewer benefits from an myostatin-inactivating mutation as those which
receive feed of a higher quality, which will have a greater growth rate. (Haynes et al., 2012).
These restrictions may be possible to circumnavigate through careful choice of the nature
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of myostatin mutation used and the recipient breed. The Texel myostatin mutation is less
severe than that of the Belgian Blue and, as a result, Texel ewes do not encounter birthing
difficulties. It is possible that introduction of a similar knockdown mutation using genome
editors instead of a knockout could bring the desired productivity advantages without causing
birthing difficulties and is something that should be investigated further. An alternative method
could be to use breeds which are known for giving birth with relative ease, such as the Nelore
cattle (Proudfoot et al., 2014) as the recipients for these mutations, as they may be less affected
by the complications caused by the double-muscled phenotype during labour.
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5. Using genome editors to engineer host
resistance to FMDV proteases
5.1. Introduction
Foot-and-mouth disease (FMD) is a highly contagious disease which primarily affects cloven-
hoofed livestock animals, causing painful vesicles to form around the feet and mouth and lead-
ing to lameness and loss of productivity in the animal. Although the disease has a mortality rate
of ~1%, it has a 100% morbidity rate and causes considerable production losses for farmers
through weight loss or low milk production, particularly as highly productive livestock breeds
are more susceptible to FMD (Parida, 2009, Knight-Jones and Rushton, 2013). The FMD epi-
zootic in the UK in 2001 alone is estimated to have cost $12-20 billion in production losses
and with 75% of the global population living in FMD-enzootic countries, such as those in sub-
Saharan Africa, reducing the spread of FMD could bring significant economic benefits (Parida,
2009, Knight-Jones and Rushton, 2013).
The causative agent of FMD is foot-and-mouth-disease virus (FMDV), an RNA virus and
member of the Picornaviridae family. Seven immunologically distinct FMDV serotypes have
been identified based on the neutralising antigenic sites found on the capsid proteins, with
numerous subtypes within each serotype. These serotypes, O, A, C, SAT 1, SAT 2, SAT 3 and
Asia 1, along with the equine rhinitis A virus, make up the Aphthovirus genus and FMDV is
considered to be the prototype aphthovirus (Fields et al., 2007, Mahy, 2005).
FMDV primarily infects members of the order Arteriodactyla, although more species can
either be infected experimentally or can carry the disease without showing clinical symptoms
(Thomson et al., 2003, Weaver et al., 2013). The virus can be transmitted in a number of direct
and indirect ways, but generally infects a susceptible animal either by inhalation of aerosolised
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virus or through open wounds in the skin. FMDV initially infects epithelial cells which express
integrin receptors (described further in Section 5.1.3), such as those on the soft palette, tonsil
and pharynx (Prato Murphy et al., 1999), before spreading through the body via the lymph
nodes and circulatory system. The main sites of FMDV replication are epithelia in the skin,
mouth, tongue and tonsils (Mahy, 2005, Stenfeldt et al., 2014a).
Although an FMDV infection can generally be cleared by the host in a number of days,
different livestock species show significant differences in their susceptibility to the virus and
their ability to transmit the virus to other animals. Pigs and cattle generally exhibit severe clin-
ical symptoms upon FMDV infection, in contrast to sheep, which only show mild symptoms.
However, pigs require a far greater dose of FMDV than sheep or cattle to become infected but,
once infected, produce significantly more aerosolised virus than either sheep or cattle. Finally,
there is evidence that both sheep and cattle can become carriers of FMDV once the clinical
symptoms have subsided. Sheep are only thought to exist in this carrier state for a number of
weeks but cattle have been found to be FMDV carriers over three years after infection. This
is compounded by the fact that around 50% of infected cattle become FMDV carriers after
infection, forming a significant reservoir for the virus. There is no evidence for a carrier state
in pigs (Alexandersen et al., 2002, Kitching, 2002, Kitching and Alexandersen, 2002, Kitching
and Hughes, 2002, Stenfeldt et al., 2014b).
Vaccines against FMDV have been developed using inactivated virus and form an integral
part of some countries’ FMDV containment measures, despite having a number of drawbacks.
The use of inactivated virus carries a risk that some active viral particles may be present in
the final vaccine, although recent research into the production of empty FMDV capsids could
solve this issue (Porta et al., 2013). In addition, the vaccines can only provide protection against
the specific serotypes and subtypes used to produce the vaccine and can be overcome by high
levels of circulating virus (Kitching, 2002). The vaccines also cause problems for farmers in
FMDV-enzootic areas as it is difficult to distinguish a vaccinated animal from one which has
been infected with FMDV. This can restrict a farmer’s trading opportunities as countries which
are free of FMDV will only import goods from certified disease-free animals. This emphasises
the need for improved FMDV control measures.
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5.1.1. Possible uses of genome editors in FMDV control
The RNA genome of FMDV renders it unsuitable as a genome editing target, as the high
mutation rate of the virus makes it difficult to implement long-term control measures which
rely on the conservation of a particular structure or sequence which has been inserted into the
genome using genome editors. This is particularly true if the inserted sequence reduced the
fitness of the virus, which would be a likely aim of any FMDV control measures targeting the
virus itself.
However, FMDV is known to interact with a number of host proteins at various points in
its life cycle (see Figure 5.1). The most notable examples of these interactions are cleavage
of host proteins by the FMDV proteases, as described in Section 5.1.4. These interactions are
key successful replication of the virus and therefore present a range of attractive alternative
targets for genome editing and FMDV control. If these host proteins could be edited so that
the viral interactions are abolished, this could provide a way to introduce a degree of FMDV
resistance into a livestock population. This chapter describes the selection of potential target
host proteins and the design of genome editors to introduce specific mutations which may
abolish interactions between these proteins and FMDV.
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Figure 5.1.: The life cycle of FMDV. The three host proteins which are the subject of research
in this chapter are shown in bold. (1) FMDV particles enter a cell via integrin
receptors on the cell membrane. (2) Viral particles undergo disassembly in early
endosome, allowing the FMDV gneome to be released into the cytoplasm. (3) A
translation initiation complex forms at the 5’end of the FMDV genome. This com-
plex consists of proteins form the host cell, including eIF4A1 and eIF4G1. (4) The
FMDV genome is translated, allowing the L and 3C proteases to be produced. (5)
The L and 3C proteases cleave host proteins. This can have numerous effects in the
cell, including the shutoff of cellular translation and the innate immune response.
(6) Copies of the FMDV genome are produced by the virus’ 3D polymerase. (7)
New viral particles are assembled and released (8) by cell lysis.
5.1.2. The structure of FMDV
FMDV is a spherical, non-enveloped virus with a diameter of about 30nm (Acharya et al.,
1989). The icosahedral virus capsid is made up of four structural proteins, VP1, VP2, VP3 and
VP4, which encapsulate a positive sense ssRNA genome found on a single molecule (Fields
et al., 2007). The genome is approximately 8.3kb long and contains a single ORF of about
7kb. The protein VPg is covalently linked to the 5’ end of the FMDV genome and is removed
upon cell entry to act as a primer for genome replication (Mahy, 2005). The FMDV genome
attached to VPg is an infectious agent as the presence of this alone in a host cell is sufficient to
trigger viral replication (Belsham and Bostock, 1988).
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Translation of the ORF produces a polyprotein which is processed by viral proteases to
produce the mature viral proteins. In addition to the four structural proteins, the polypeptide
also produces non-structural proteins including the leader (L) and 3C proteases (discussed in
greater detail in Section 5.1.4) and the RNA-dependent RNA polymerase 3D. Translation of
the polyprotein is mediated by a Type II IRES at the 5’ end of the genome (Chamond et al.,
2014) and can be initiated from one of two AUG codons located at the 3’ end of the IRES
(Belsham and Brangwyn, 1990), although only the second AUG after the IRES is absolutely
necessary for genome translation (Cao et al., 1995). The FMDV IRES has extensive secondary
and tertiary structure, which is recognised by the host translation initiation factors (Lozano
et al., 2014).
5.1.3. FMDV replication
As mentioned previously, FMDV enters cells via integrin receptors at the plasma membrane,
which recognise the RGD sequence found on the bG-bH loop of the capsid protein VP1 (Fox
et al., 1989, Leippert et al., 1997). Integrins are heterodimers consisting of one a and one
b subunit and FMDV can be bound by integrins consisting of an av subunit complexed with
a b1, b3, b6 or b8 subunit (Jackson et al., 1997, Neff et al., 1998, Jackson et al., 2000a,b,
2004). The avb6 receptor is the predominant receptor on epithelial cells infected by FMDV
and, as such, is considered the main determinant of virus tropism in vivo (Monaghan et al.,
2005). Different FMDV serotypes exhibit different integrin preferences, which are thought
to be influenced by the amino acids surrounding the RGD binding sequence (Jackson et al.,
1997) and some serotypes have also been found to use heparin sulfate as a receptor (Fry et al.,
1999). As FMDV is capable of binding to integrins from species which are not considered
natural hosts of FMDV, it is unlikely that these molecules determine the host range of the virus
(Jackson et al., 1997). Ruiz-Saenz et al. (2009) provide more details on the receptors used by
FMDV.
Upon binding of integrin receptors, FMDV is internalised into the host cell by clatherin-
dependent endocytosis and localised to early-stage or recycling endosomes (Berryman et al.,
2005). As FMDV is very labile, the low pH environment of the endosome causes disassembly
of the capsid (Carrillo et al., 1984, 1985) and release of the genome into the cytoplasm for
subsequent translation and replication (Belsham and Bostock, 1988). The process by which
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the FMDV genome is released from the endosome is currently unknown and is an area of
active research, particularly at the Pirbright Institute.
Although the FMDV genome is uncapped, it is translated using components of the host cap-
dependent translational machinery, which is subverted by the virus. Initiation of translation
requires the presence of the host factors Met-tRNAi, eIF2, eIF3, eIF4A, eIF4B, eIF4E, eIF4G
and the ribosomal 40S subunit (Pestova et al., 1996a, Pilipenko et al., 2000). The initiation
complex is stabilised by PTB (Kolupaeva et al., 1996) and the ribosomal 60S subunit is re-
cruited to the FMDV genome after this initiation complex has formed. As translation proceeds,
eIF2 becomes dispensable and is potentially degraded (Welnowska et al., 2011, Redondo et al.,
2011) and PTB and eIF3 are cleaved by the FMDV proteases (Rodriguez Pulido et al., 2007). It
is, as yet, not clear whether this degradation of key translation initiation factors is a mechanism
of switching the FMDV RNA from translation to genome replication, thereby ensuring that the
translating ribosomes do not disrupt progression of the 3D polymerase along the genome, or if
degradation of these factors is just part of the ’collateral damage’ incurred by the presence of
the active FMDV proteases in the host cell.
Replication of the RNA genome is carried out by the 3D polymerase using VPg as a primer.
A negative-sense RNA intermediate is first synthesised, from which many copies of the positive-
sense genome can be produced and encapsulated in the newly synthesised capsid proteins. New
virus particles are released upon lysis of the host cell (Fields et al., 2007).
5.1.4. The FMDV proteases and their interactions with host proteins
The two FMDV proteases, L and 3C, are responsible for the majority of processing of the
FMDV polyprotein and for the subversion or destruction of host proteins and pathways, as re-
viewed by Chase and Semler (2012). Preventing protease cleavage of host proteins and main-
taining host functions, including immune responses to the presence of the virus, presents an
attractive mechanism for reducing FMDV replication in the host cell.
Both proteases are described below, with their targets discussed at later points in this chapter.
5.1.4.1. L protease
The L protease is a cysteine protease which is only found in aphthoviruses and cardioviruses
and is structurally similar to the papain protease found in many different organisms, from vir-
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uses to plants and animals (Guarne et al., 1998, 2000). Its catalytic activity relies on the amino
acids C51 and H148 (Roberts and Belsham, 1995) and its cleavage specificity, although not yet
completely elucidated, is in part mediated by the leucine or methionine residue at position 143
(Mayer et al., 2008). The position of L protease at the 5’end of the FMDV ORF means that two
forms of the enzyme, named Lab and Lb, are produced from the two AUG codons at the start
of the ORF. While both forms of the protease have the same activity in vitro (Medina et al.,
1993), Lb is preferentially expressed in vivo (Cao et al., 1995).
The L protease catalyses its own release from the polyprotein (Strebel and Beck, 1986) and
maintains translation from the IRES in the later stages of infection, when eIF2 is degraded
(Moral-Lopez et al., 2014). In addition to its protease activity on both the FMDV polyprotein
and on host proteins, the L protease can act as a viral deubiquitinase. This activity is central to
the L protease’s role in disrupting innate immune signalling pathways such as the Type I IFN
response, where ubiquitin is used as an activator for many of the components in the pathway,
such as Rig-I (Wang et al., 2011b).
5.1.4.2. 3C protease
The crystal structure of the serine protease 3C shows its structural similarities to chymotrypsin,
including its active site, which is contained within a peptide-binding groove (Zunszain et al.,
2010) and holds the 3C catalytic triad of H46, D84 and C163 (Grubman et al., 1995, Birtley
et al., 2005). 3C cleaves at sites which have either a glutamic acid or glutamine residue at
the P1 position (Zunszain et al., 2010) and carries out the majority of processing events on
the FMDV polyprotein (Bablanian and Grubman, 1993). Like the L protease, the 3C protease
also plays a role in blocking the host Type I IFN response. It blocks the nuclear translocation
of Stat1/Stat2, reducing the activity of interferon-stimulated regulatory elements (ISREs) and
therefore, the expression of interferon-stimulated genes (ISGs) (Du et al., 2014).
5.1.5. Selection of target sites
In this project, genome editors were designed to target host genes whose protein products are
cleaved by FMDV proteases, with an eventual aim of engineering protease-resistance into the
FMDV cleavage sites via the introduction of exogenous sequence into the genes by HDR.
Several host genes known to be cleaved by FMDV proteases are to be found in the literature,
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including eIF4G2 (Gradi et al., 2004). However, in some cases, the information given was
either not complete enough to allow for the design of genome editors or did not correspond
with the current genome and protein data for a particular species. This limited the number of
genes which could be chosen as suitable targets. The three genes selected to be targeted were
IKBKG, eIF4G1 and eIF4A1. Further details about each target gene’s protease sites is given in
Table 5.1 below;
Gene Location of cleavage site Protease Reference
IKBKG Between Q383 and R384 3C Wang et al. (2012a)
eIF4A1 Between E143 and V144 3C Li et al. (2001)
eIF4G1 Between G674 and R675 L
Kirchweger et al. (1994)
Strong and Belsham (2004)
Table 5.1.: Table showing the location of protease cleavage sites in each of the selected host
target proteins and the FMDV protease which targets each site
Given the key roles eIF4A1, eIF4G1 and IKBKG play in translation initiation and the in-
nate immune response respectively, it is unlikely that reliance on modification of the genes
by NHEJ alone would be able to produce protease-resistant alleles which maintained normal
activity levels. Therefore, once genome editors which can successfully cleave at the target
sites are developed, suitable templates for introgression by HDR would need to be designed.
Previously published work has identified point mutations which can block cleavage of these
host proteins by the FMDV proteases and could act as the basis for designing suitable HDR
templates to introduce precise alterations. These mutations are described within each protein’s
section below.
5.1.5.1. IKBKG
IKBKG (also known as Nemo or IKKg) is the regulatory subunit of the IKK complex in the
NF-kB pathway. The IKK complex also includes the kinase subunits IKKa and IKKb and
activates NF-kB through the phosphorylation of IkB proteins. More detail on the role of the
IKK complex in NF-kB signalling can be found in Israel (2010).
Cleavage of IKBKG by the 3C protease removes the C-terminal zinc finger domain which
activates the full-length protein. Loss of this domain blocks signalling from the pattern recogni-
tion receptor (PRR) Mda-5, which detects the presence of picornaviruses in the host cell (Kato
et al., 2006, Huesser et al., 2011), to both the NF-kB and IRF signalling pathways, resulting
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in the loss of IFNb expression (Wang et al., 2012a). This effect is also seen when IKBKG is
cleaved by the 3C protease of another picornavirus, hepatitis A, although the cleavage site in
this case is different to that of FMDV 3C (Wang et al., 2014a). Perturbation of the host innate
immune response is a common feature in picornavirus infection and the interactions between
the virus and host immune system have been recently reviewed by Feng et al. (2014).
Work identifying the 3C cleavage site in IKBKG also showed that mutation of glutamine 383
to an arginine residue could block cleavage of the protein in vitro (Wang et al., 2012a).
5.1.5.2. eIF4A1
The DEAD box RNA helicase eIF4A is essential for the successful initiation of translation
from both capped and uncapped mRNAs as it forms part of the cap-binding complex eIF4F,
along with eIF4G and eIF4E. The combination of eIF4A’s RNA-dependent ATPase activity, in
addition to its helicase function, allow it to unwind secondary structures found in the 5’UTRs
of transcripts, preparing the RNA strand for ribosome binding (Ray et al., 1985, Pause and
Sonenberg, 1992). There are three eIF4A isoforms; eIF4A1 and eIF4A2 show around 91% se-
quence homology at the protein level and are considered to be functionally equivalent (Nielsen
and Trachsel, 1988), while eIF4A3 appears to play an inhibitory role in translation (Li et al.,
1999). eIF4A1 is the most abundant eIF4A isoform found in the cell (Li et al., 1999).
In the early stages of FMDV infection, the FMDV IRES is recognised and bound by a com-
plex of eIF4A1 and eIF4G1 (Pilipenko et al., 2000). Work in encephalomyocarditis virus,
another picornavirus, has shown that this binding stimulates a conformational change in the
IRES, probably as a result of eIF4A1’s helicase activity (Kolupaeva et al., 2003).
Despite its importance in initiating translation from the FMDV genome, eIF4A1 is cleaved
by the 3C protease during the course of infection. This cleavage inactivates the protein by
removing an ATPase domain at the N-terminus, causing levels of both host and FMDV trans-
lation to decrease (Belsham et al., 2000, Li et al., 2001). As with other translation initiation
factors mentioned previously, it is unclear whether cleavage of eIF4A1 used for FMDV replic-
ation is an unavoidable consequence of the virus shutting down cap-dependent translation or
if it is of functional benefit to viral replication, as the removal of translating ribosomes allows
unhindered replication of the FMDV genome by the virus’ 3D polymerase. (Mahy, 2005). The
eIF4A1 double mutant A142N/V144M has been found to be resistant to cleavage by the 3C
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protease (Li et al., 2001).
5.1.5.3. eIF4G1
The two eIF4G isoforms, eIF4G1 and eIF4G2 share 46% identity in their amino acid sequences
and have been shown to be functionally interchangeable in their role as an adaptor protein
which binds the 40S ribosomal subunit (Pestova et al., 1996a, Hentze, 1997, Gradi et al., 1998).
eIF4G1 is the predominant isoform in eukaryotic cells (Gradi et al., 1998). FMDV can only
abolish cap-dependent translation in the host cell by cleaving both eIF4G isoforms (Gradi et al.,
2004).
eIF4G1 is cleaved by the FMDV L protease (Devaney et al., 1988) and can be cleaved before
the protease has self-processed from the FMDV polyprotein (Glaser et al., 2001). This cleavage
reaction occurs very rapidly after virus entry; experiments using an RRL system, which is used
to carry out cell-free translation of RNA molecules, show that the L protease can be detected
four minutes after the addition of FMDV genomic RNA to the system, while complete cleavage
of the RRL system’s eIF4G1 can be seen eight minutes after the genome is added (Glaser and
Skern, 2000). Work on other picornaviruses has suggested that this cleavage event may have
an increased efficiency when eIF4G1 is bound to eIF4E, with the binding possibly inducing a
conformational change, making eIF4G1 more favourable to cleavage (Haghighat et al., 1996).
The C-terminal residues of the L protease, while not directly involved in protein cleavage, have
been shown to be important for mediating this reaction (Glaser et al., 2001).
Cleavage of eIF4G1 removes the protein’s N-terminal eIF4E binding site, which is essential
for cap-dependent protein synthesis but not for translation from the FMDV IRES (Mader et al.,
1995, Morino et al., 2000), and a NLS (Coldwell et al., 2004). This leaves the C-terminal frag-
ment, which can bind eIF4A and eIF3, for use in FMDV replication (Ohlmann et al., 1997). As
with cap-dependent translation, the eIF4G1 fragment is necessary to bind to the 40S ribosomal
subunit to the FMDV genome (Pestova et al., 1996b).
Exchange of the L protease cleavage site in eIF4G1 for the analogous sequence of eIF4G2
(Foeger et al., 2002) can inhibit the protease’s activity however, it remains unclear whether
this also affects binding of the protease to eIF4G1. If binding is not prevented, the effects
of L protease:eIF4G1 complexes on both viral replication and host translation will need to
be evaluated. If necessary, the mutation of three additional amino acids K643A, K646A and
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R650A, which have been shown to prevent the binding of L protease (Foeger et al., 2005), may
be able to produce a fully resistant eIF4G1 allele.
Strong and Belsham (2004) demonstrated that eIF4G1 can also be cleaved by the 3C protease
at E712/T713, downstream of the L protease site. Cleavage by 3C occurs after eIF4G1 has been
cleaved by the L protease. However, eIF4G1’s sensitivity to this cleavage event varies between
species, with human eIF4G1 being resistant to the 3C protease, as it has a proline at position
713 instead of a threonine. It is also important to note that the majority of this work was
carried out in BHK cells, and that the ovine, bovine and porcine eIF4G1 protein sequences
share the P713 found in the cleavage-resistant human sequence. Therefore, it seems unlikely
that this observation has biological relevance to the livestock species which commonly suffer
from FMD.
5.2. Additional materials and methods
5.2.1. Bioinformatics
In order to find new potential targets of the FMDV proteases, the bovine and porcine proteomes
were analysed using NetPicoRNA 1.0 (http://www.cbs.dtu.dk/services/NetPicoRNA/)
(Blom et al., 1996). The bovine proteome used was release 2014_06 from Uniprot’s Know-
ledgebase and contained a total of 24207 proteins, while the porcine proteome consisted of the
26143 proteins found in Uniprot’s 2014_09 release. The ovine proteome was not analysed due
to its relatively poor annotation.
Unfortunately, NetPicoRNA does not have an algorithm for predicting potential targets of the
L protease, presumably due to the relative scarcity of literature available for predicting suitable
L protease cleavage sites. Therefore, potential targets of the 3C protease were identified us-
ing the aphthovirus 3C algorithm. Each proteome was analysed in batches of 2500 sequences.
Analysed sequences were given a cleavage score (i.e. how likely the sequence is to be recog-
nised and cleaved by 3C) and a surface score (showing how exposed that particular sequence
is on the protein) by NetPicoRNA. Scores range from 0 to 1. Candidates with both a cleavage
score and surface score greater than 0.5 were designated as potential cleavage candidates by
the software.
Following the analysis, any sequences not meeting the following criteria were removed from
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the data set to ease further analysis;
1. Sequence should been designated a ’potential’ target by Net PicoRNA
2. Sequence should have both a cleavage score and surface score above 0.75
3. Sequence should have either a glutamine or glutamic acid residue at the P1 position
Target predictions and data set cleanup were performed by Dr Zen Lu.
All uncharacterised proteins were then removed from each data set and the remaining candid-
ates sorted in descending order of cleavage score and surface score. Gene clustering was also
carried out on the final list of potential targets using PANTHER http://www.pantherdb.org
(Mi et al., 2013) as well as the original bovine and porcine proteomes to determine whether
any particular molecular functions or biological processes were enriched for in the final dataset.
Additional functional enrichment analysis was performed using ToppFun (Chen et al., 2009a)
with the p-value cutoff set at 0.05 and results grouped by the Biological Process, Molecular
Function and Pathway features.
5.3. Results
5.3.1. Comparison of target sequences from different livestock breeds
There is some evidence in the existing literature that certain breeds or individual animals can
exhibit some degree of resistance to FMDV infection (see Lei et al. (2012) and cited in Morris
(2007)). To discover if any specific bovine, ovine or porcine breeds carried polymorphisms
around the three protease cleavage sites of interest, amino acid and mRNA sequences from a
selection of breeds were aligned. The amino acid sequences are shown in Figures 5.2, 5.3 and
5.4, while the mRNA sequence alignments can be found in Appendix A.5.
Although some amino acid substitutions were observed in eIF4A1, they are not situated
in close enough proximity to the cleavage site to be considered to have a direct effect upon
cleavage by the FMDV proteases. This does not exclude the possibility that the polymorphisms
may exert a more indirect effect on protease cleavage (e.g. by affecting binding of the enzyme),
but more information on the nature of the binding between the protease and these targets is
required to determine this.
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The alignment of eIF4G1 sequences from different sheep breeds show a 6 amino acid in-
sertion/deletion between the consensus sequence, derived from the Ensembl database, and the
breed-derived sequences. As the sequence from the Texel breed is included among the breeds
analysed and the sheep genome is based on the Texel breed, it is likely that this is a result of an
inaccuracy in the consensus sequence rather than a biological feature.
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Figure 5.2.: Peptide alignments of eIF4A1 protein sequences between different bovine, porcine
and ovine breeds. The bar across the top of each set of alignments shows the degree
of conservation between the different sequences, with red indicating that all the
sequences share the same amino acid residue at that particular point. Residues
which differ from the consensus sequence are shown in a black box. The reference
sequence from the published genome of each species is the top sequence of each
alignment (Bovine eIF4A1, Porcine eIF4A1 and Ovine eIF4A1). The 3C protease
cleavage site is indicated by the purple line.
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Figure 5.3.: Peptide alignments of eIF4G1 protein sequences between different bovine, porcine
and ovine breeds. The bar across the top of each set of alignments shows the de-
gree of conservation between the different sequences, with red indicating that all
the sequences share the same amino acid residue at that particular point. Residues
which differ from the consensus sequence are shown in a black box, with the ex-
ception of the 6aa insertion/deletion between the consensus and breed sequences.
The reference sequence from the published genome of each species is the top se-
quence of each alignment (Bovine eIF4G1, Porcine eIF4G1 and Ovine eIF4G1).
The L protease cleavage site is indicated by the purple line.
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Figure 5.4.: Peptide alignments of IKBKG protein sequences between different bovine, porcine
and ovine breeds. The bar across the top of each set of alignments shows the degree
of conservation between the different sequences, with red indicating that all the
sequences share the same amino acid residue at that particular point. Residues
which differ from the consensus sequence are shown in a black box. The reference
sequence from the published genome of each species is the top sequence of each
alignment (Bovine IKBKG, Porcine IKBKG and Ovine IKBKG). The 3C protease
cleavage site is indicated by the purple line.
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5.3.2. Validation of TALENs
TALENs were designed to target the protease cleavage sites eIF4A1, eIF4G1 and IKBKG in the
porcine (Figure 5.5) and ovine (Figure 5.6) genomes and constructed as detailed in Section 2.2.
Three pairs of TALENs were designed for each gene in each species. Genomic sequences from
all three target genes were obtained from the Ensembl database (Version 70). The intention was
to initially develop active TALENs which would cleave at the protease sites and subsequently
use these TALENs to introduce modified DNA sequences to the genes by HDR. The modifica-
tions would be designed so that the protease cleavage sites became protease-resistant while the
endogenous activity of the proteins themselves remained unchanged. Validation of TALENs
was carried out by co-transfection of the TALENs and a GFP plasmid into PK15 cells or OEFs
as appropriate followed by a T7 assay.
Similar to results in previous chapters, no discernible TALEN activity was seen in any of
the transfected porcine (Figure 5.8) and ovine (Figure 5.9) cells, despite the presence of GFP
expression suggesting that the transfections had been successful. To confirm that the target
sequence for each gene was conserved between the published consensus sequence and the cells
used in the validation assay, PCR products were sequenced and, in most cases, showed that the
target sites aligned with the sequences used to design the TALENs (Figure 5.10).
The exception to this was the ovine IKBKG B left TALEN binding site. This locus was
disrupted by an ~200bp intron which had been absent from the genomic sequence originally
used to design the TALENs (Figure 5.7), but was subsequently added to a newer version of
Ensembl. This meant that the TALEN pair was not able to function as the left TALEN could
not bind to a suitable sequence and allow the FokI nucleases to dimerise. A shortage of time
and the numerous problems encountered in attempting to produce active TALENs meant that
this TALEN was not redesigned.
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Figure 5.5.: Positions of TALEN binding sites in the porcine FMDV target genes (a) eIF4A1,
(b) eIF4G1 and (c) IKBKG. Primers used for analysis are shown by green boxes
and the protease cleavage sites are indicated by red lines.
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Figure 5.6.: Positions of TALEN binding sites in the ovine FMDV target genes (a) eIF4A1, (b)
eIF4G1 and (c) IKBKG. Primers used for analysis are shown by green boxes and
the protease cleavage sites are indicated by red lines. Note that this figure shows
the genomic sequence for IKBKG taken from version 70 of Ensembl and not the
updated sequence.
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Figure 5.7.: Figure showing the disruption of the ovine IKBKG TALEN B left binding site by
a previously unidentified intron. The nucleotides originally intended to be targeted
by the B left TALEN are marked with blue boxes, while the intronic sequence is
underlined in red. The IKBKG B right TALEN binding site is shown in the orange
box, while the 3C cleavage site is indicated by the green line.
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Figure 5.8.: Transfection of eIF4A1, eIF4G1 and IKBKG TALENs into PK15 cells. In each
case, the TALEN pair was co-transfected with a GFP plasmid to indicate trans-
fection efficiency. Brightfield and GFP images are shown for transfections of (a)
eIF4A1 TALENs, (c) eIF4G1 TALENs and (e) IKBKG TALENs. Images at are
100x magnification. Gel images showing the results of T7 endonuclease digests
are shown for (b) eIF4A1, (d) eIF4G1 and (f) IKBKG. Note that no detectable
TALEN activity was seen in any of the gels.
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Figure 5.9.: Transfection of eIF4A1, eIF4G1 and IKBKG TALENs into OEFs. In each case,
the TALEN pair was co-transfected with a GFP plasmid to indicate transfection
efficiency. Brightfield and GFP images are shown for transfections of (a) eIF4A1
TALENs, (c) eIF4G1 TALENs and (e) IKBKG TALENs. Images at are 100x mag-
nification. Gel images showing the results of T7 endonuclease digests are shown
for (b) eIF4A1, (d) eIF4G1 and (f) IKBKG. Note that no detectable TALEN activ-
ity was seen in any of the gels.
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Figure 5.10.: Sequence alignments of TALEN target genes sequenced from OEF or PK15 DNA
aligned against their counterparts in the ovine or porcine genome. Areas targeted
by TALENs are highlighted in green boxes.
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5.3.3. Bioinformatic prediction of 3C protease target genes
In order to predict other potential targets of the FMDV 3C protease and find additional candid-
ates for future genome editing, bioinfomatic analysis was carried out on the bovine and porcine
proteomes using NetPicoRNA, resulting in a list of ’potential’ candidates. Table 5.2 shows how
each data set was refined from the total list of ’potential’ candidates to a list of characterised
candidates and a list of characterised candidates with a cleavage score of 0.8 or greater. This






Number of candidates with a







Table 5.2.: Table showing refinement of data sets after removal of uncharacterised proteins and
implementation of cut off points
Predicted and characterised 3C protease targets were rated by their cleavage and surface
scores. The ten highest rated genes are shown in Tables 5.3 and 5.4 while the full data sets are
shown in Appendix A.6. None of the top ten candidates are found in both species and, indeed,
there is very little evidence in the whole characterised data set of predicted targets which are
common to the two species. The two 3C targets selected from the literature for the TALEN
work, eIF4A1 and IKBKG, are also noticeably absent from both lists. Possible reasons for this
are discussed in Section 5.4.
Gene clustering using PANTHER was carried out using both the full list of characterised
candidates and the subset of candidates with a cleavage score of 0.8 or greater in addition to
the complete bovine and porcine proteomes (Figures 5.11 and 5.12). The data were visualised
as pie charts to determine if a particular molecular function or biological process is targeted
by the 3C protease. Only slight changes were observed between the data sets, such as the
decreases in protein binding transcription factor activity and structural molecule activity in the
bovine molecular function analysis and the respective increase and decrease in the stimulus
response and biological regulation categories in the porcine biological process analysis. Given
that each of the three pie charts in each analysis represents a decreasing number of genes going
from left to right, it seems unlikely that these changes have any biological significance.
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The ToppFun analysis of the bovine data (Appendix 7.1) only allowed the candidate genes
to be grouped by Pathway, and not Biological Process or Molecular Function and did not
include any pathways which are known to be linked with FMDV replication. The porcine
data is presented in Appendices 7.2, 7.3 and 7.4. Appendix 7.2 shows the potential candidates
grouped by biological process. Interestingly, TRIM26 and TRIM31 appear twice in the data
under the processes ’negative regulation of viral entry into host cell’ and ’regulation of viral
release from host cell’, suggest that they could indeed be targets of the FMDV 3C protease.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 5.11.: PantherDB pie charts showing distribution of molecular functions (top) or bio-
logical processes (bottom) across bovine candidates for cleavage by the 3C pro-
tease. Analysis of the total bovine proteome is provided for comparison and keys
are shown below their respective pie charts. The number of genes recognised by
Panther DB and the total number of hits is given below each pie chart.
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Figure 5.12.: PantherDB pie charts showing distribution of molecular functions (top) or bio-
logical processes (bottom) across porcine candidates for cleavage by the 3C pro-
tease. Analysis of the total porcine proteome is provided for comparison and keys
are shown below their respective pie charts. The number of genes recognised by
Panther DB and the total number of hits is given below each pie chart.
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5.4. Discussion
This discussion section will focus on the bioinformatics work and the potential next steps for
this work. A discussion of the validation issues with TALENs can be found in Chapter 6.
5.4.1. In silico cleavage site prediction and potential improvements
Bioinformatic analysis using NetPicoRNA was used to identify potential targets of the FMDV
3C protease in the bovine and porcine proteomes, with a view to producing a list of future
candidates for genome editing. NetPicoRNA employs a neural network algorithm which was
trained using known human targets of the FMDV 3C protease to predict potential cleavage
sites.
Subsequent analysis of the list of targets using ToppFun indicated that the E3 ubiquitin lig-
ases TRIM26 and TRIM31 may interact with the FMDV 3C protease in their roles controlling
viral entry and viral release from a host cell. TRIM31 and TRIM26 are key components in
innate immunity (Kawai and Akira, 2011), a role which renders them likely targets for de-
gradation by FMDV. According to the NetPicoRNA analysis, TRIM26 could be cleaved by
3C at E385, while TRIM31 is potentially cleaved at E467. Both cleavage sites are located
within the SPRY domains of each protein. SPRY domains are protein-interacting modules (as
reviewed by D’Cruz et al. (2013)) so it could be conceived that cleavage and loss of SPRY
from TRIM26 and TRIM31 would disrupt signalling cascades involved in the innate immune
response. It would be of great use to determine whether these proteins are indeed targeted by
the 3C protease by carrying out in vitro digests of TRIM protein with the 3C protease.
However, as stated in Section 5.3.3, none of the TALEN targets which were identified in the
literature were present in the data set produced by NetPicoRNA. This could be due to either
the algorithm itself or the relative lack of annotation in the bovine and porcine proteomes in
comparison to others, such as human, meaning that relevant targets are still uncharacterised
within the Uniprot databases and were therefore removed from the candidate list during data
cleanup.
As the NetPicoRNA program was trained on human sequences, it is possible that many of
the features that were used to create the original algorithms are not completely applicable to
sequences from livestock species. The validation of the aphthovirus 3C algorithm also does
149
not appear to be as detailed as that of the other algorithms described in Blom et al. (1996) and
there is no indication that the algorithms have been updated to include more recent data from
the published literature.
Given the large number of proteins which appear to be targeted by the L protease (discussed
further in Section 5.4.2), it would be of great use if a similar prediction algorithm could be
produced for this enzyme. Previous work on the crystal structure of L protease has identified
preferences for a leucine residue at position P2 of the cleavage site and for basic amino acids
(i.e. arginine, lysine or histidine) at positions P’1 or P’2 (Guarne et al., 1998, Seipelt et al.,
1999) as well as an inability to contain large amino acid side chains, such as phenylalanine, in
its active site (Mayer et al., 2008). Further in silico analysis has suggested that the presence
of a RKAR/RRLR motif may also indicate a potential L protease cleavage site (Pineiro et al.,
2012). Potential consensus cleavage sites could also be tested in vitro by inserting the sequence
of interest into a pro-GFP plasmid and co-transfection into cells with a plasmid containing the
L or 3C protease (Callahan et al., 2010). The expression of GFP in the transfected cells would
give a clear readout of the efficiency of cleavage.
Potential candidates could also be screened to determine the position of the predicted cleav-
age site within the protein’s secondary structures, using a tool such as PSIPRED (McGuffin
et al., 2000). Sequences situated on exposed loops are more easily accessed and cleaved by a
protease than those in an a-helix or b-strand. This could also be used to help determine whether
the predicted cleavage event removes a specific domain, as is the case in eIF4G1 cleavage by
the L protease, or simply destroys the protein, as with 3C’s cleavage of IKBKG. It will also be
important to determine that the candidate protein is expressed in epithelial cells.
5.4.2. Identification of other potential genome editing candidates from
the literature
Although only three targets were selected from the literature for genome editing in this work,
the literature shows that there are, in theory, many different proteins which could be edited
to become protease-resistant and therefore increase host resistance to FMDV infection. This
includes proteins involved in transcriptional regulation, such as Histone H3 (Falk et al., 1990),
and those in the autophagy pathway, as reviewed by Klein and Jackson (2011).
Analysis of FMDV IRES activity in a number of cell lines has shown that the presence
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of the L protease can cause an increase in IRES activity, suggesting that the protease may
have other targets than eIF4G1 that, upon cleavage, are subverted for use in virus replication
(Roberts et al., 1998). Amongst these is the Gemin5 protein, which, when intact, binds to the
FMDV IRES and exerts an inhibitory effect on FMDV translation. Cleavage by the L protease
removes this inhibition (Pineiro et al., 2012). Another target which can increase IRES activity
is the nuclear RNA binding protein Sam68 which is cleaved by the 3C protease (Lawrence
et al., 2012). Cleavage of Sam68 causes the protein to move from the nucleus to the cytoplasm,
where it interacts with the IRES. Knockdown of the protein causes a reduction in IRES activity
and in viral titre, suggesting that the cleaved product facilitates FMDV replication (Lawrence
et al., 2012).
Other targets may potentially be identified by looking at the targets of other picornaviruses
however, this does not guarantee that the protein is also targeted by FMDV. An example of
this are nucleoporin proteins, which are cleaved by rhinovirus proteases, causing inhibition
of nuclear import and subsequent mislocalisation of proteins (Walker et al., 2013). However,
analysis of FMDV-infected cells have shown only minor degradation of nucleoporin proteins
(Lawrence et al., 2012).
The TALENs described in this chapter were designed against the ovine and porcine se-
quences however, there would be great value in seeking to modify the same proteins, IKBKG,
eIF4A1 and eIF4G1, in cattle, as they appear to play a significant role in virus transmission
in mixed populations (Bravo de Rueda et al., 2014a,b). As it is unlikely that FMDV-resistant
animals from all susceptible livestock species would be developed at the same time, priority
should be placed on those species which are both known to transmit the virus easily and can
maintain a carrier status.
5.4.2.1. FMDV protease targeting of pathways involved in the innate immune
response
IKBKG is just one of many proteins involved in signalling pathways of the innate immune
response which have also been identified as targets of either FMDV or picornaviral proteases.
The L protease, in particular, appears to play a key role in the inhibition of the IFNa/b im-
mune response, suggesting that there are multiple targets affected by both the proteolytic and
deubiquitinising properties of the enzyme (Chinsangaram et al., 1999, de Los Santos et al.,
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2006). These include nuclear and cytoplasmic NF-kB protein (de Los Santos et al., 2007) as
well as the transcription factors IRF3 and IRF7 (Wang et al., 2010), resulting in a considerable
decrease in the expression of both interferon genes and genes containing ISREs, such as CCL5
(Wang et al., 2011a).
Several studies have shown that replacement of these degraded proteins by ectopic overex-
pression or use of constitutively active mutants can improve the innate immune response to
FMDV infection (Xu et al., 2014, Ramirez-Carvajal et al., 2014, Shi et al., 2015), suggesting
that preventing the cleavage of some of the affected pathway components could have a signi-
ficant effect on FMDV pathology in livestock animals. Identifying potential targets from these
pathways could prove to be an interesting avenue for future work.
5.4.3. An alternative method for engineering FMDV resistance
The transgenic chickens described in Lyall et al. (2011) could provide an alternative method
for suppressing FMDV infection by using a short hairpin RNA (shRNA) targeting part of the
FMDV genome to inhibit viral replication. shRNAs targeting the FMDV IRES or the VP1
region can reduce FMDV replication in cells and young mice (Wang et al., 2013b, Chang
et al., 2014) and could be incorporated into a expression construct and introgressed into the
host genome. However, as recent results in zebrafish have demonstrated, any candidate shRNA
would have to first be checked to ensure that it does not exert any phenotypic effects on the
host animal (Kok et al., 2015).
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6. Conclusions and discussion
6.1. Genome editor validation issues
Table 6.1 gives an overview of the genome editors used in this project. Because it was not
possible to accurately quantify the in vitro activity of the Rag1 and MSTN TALENs, due to
oversaturation of the uncut bands on the gel image, an estimation of the level of activity is
given.
The absence of detectable activity during the validation of genome editors has been a recur-
ring issue in this project. Generally, multiple TALEN pairs or sgRNAs are designed against
a single target with the expectation that at least one of the designed editors will exhibit an
acceptable level of activity. 25 TALEN pairs and eight sgRNAs were used during the course
of this work and only two TALEN pairs, Rag1 C (Figure 3.14) and MSTN (Figure 4.4), were
shown to have activity in vitro. Every target had three TALEN pairs or four sgRNAs designed
against it, as we have found this to be enough to produce at least one editor with an acceptable
cutting efficiency in our lab. However, other labs have reported designing a larger number of
editors against a single target in order to find a suitable editor to work with. It is therefore prob-
able that the design and validation of more editors, in combination with the use of new design
tools which have been developed (described in greater detail below), would have resulted in
the production of a successful editor.
However, the MSTN sgRNAs did produce an edited animal, despite not showing any in
vitro activity and repeat analysis of both the Rag1 C and MSTN TALENs failed to detect
any activity, suggesting an issue with the validation process rather than the design process.
As Rag1 C and MSTN TALEN pairs were the first to be constructed and validated for the
project, their reassessment (and resulting negative results) came at the same time that the other


























































































































































































































































































































































































































































































































































































































































for all editors used suggested that the same problem was affecting all the editors, rather than
the lack of activity in each editor being due to an individual problem. Therefore, efforts were
made to attempt to identify any problems in the construction and validation processes, rather
than redesigning new editors which may have still been affected by general construction and
validation issues.
All the destination vectors into which genome editors used in this project were cloned have
been used extensively in our lab and have been shown to function well. In order to rule out
subcloning errors as a causal factor for the loss of TALEN activity, the ELD/KKR vectors were
also sequenced to ensure that the correct heterodimer was used for the correct TALEN (Figure
4.6) and no issues were found. Based on this, the vectors were ruled out as a potential problem,
leaving the validation process itself as the only procedure common to all the editors. This was
also suggested by the production of the CRISPR-edited lamb (Figure 4.13), in spite of the fact
that the MSTN sgRNAs were never shown to be active in vitro.
Troubleshooting steps were undertaken to attempt to determine whether the validation assay
was the reason for the lack of detectable editing activity in vitro. The majority of these steps
were carried out with the Rag1 TALENs as the Rag1 C pair had previously demonstrated
specific cleavage in OEFs (Figure 3.15). The negative results from the transfections carried
out independently (Figure 3.15 (c)) and from the GFP-sorting of transfected cells indicate that
neither the transfection protocol or the level of transfection efficiency were the cause for the
loss of function. Switching from a CelI assay to a T7 assay did increase the sensitivity of
the validation procedure, as the T7 endonuclease was capable of detecting SNPs within the
transfected cells, but did not show that any of the genome editors were functional. These
results have left the true nature of the problem unclear. This is compounded by the fact that
the technology is still relatively new and few examples of non-functional editors have been
published in the literature.
It has been shown that the presence of methylated cytosine residues on the target DNA
can block TALEN binding and therefore prevented cleavage of the DNA by FokI (Kim et al.,
2013a). It is thought to be unlikely that this is the cause for the lack of activity seen here as
two target sites, Rag1 and MSTN, had been previously shown to be permissive to editing and
all of the FMDV protease target sites are located in exons of genes which are expressed in the
vast majority of cell types and would not be expected to be repressed by cytosine methylation.
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It is possible that the editors which never demonstrated activity in vitro have very poor cutting
efficiencies, below the level which can be detected by either the CelI or T7 assays. Redesigning
the editors using newly developed tools with more stringent design parameters such as SAPTA,
the Broad Institute sgRNA Designer or the CRISPR Design tool from MIT (Lin et al., 2014,
Doench et al., 2014, Hsu et al., 2013) could produce editors with an increased activity. The
MIT CRISPR Design tool in particular would be of great use for future work in the area of
genome edited large animals, as it is capable of predicting potential off-target sites in the pig
genome.
Although time constraints meant that redesigning the editors was not possible, the previously
designed sgRNAs targeted to Rag1 and MSTN were analysed using the Broad Institute sgRNA
Designer to determine their predicted efficiency. The results of this are shown in Table 6.2. The
Designer scores sgRNA candidates based on numerous features, including the GC content, the
identity of the variable nucleotide in the NGG PAM and the presence or absence of certain
nucleotides at specific positions in the sgRNA (e.g. cytosine is favoured at position 20, while
thymine is disfavoured). It should be noted that the design scoring is very stringent and that,
while a score of >0.6 is considered to be a good indicator of a highly active sgRNA, some
sgRNAs were demonstrated to be active in vitro received a score of <0.2. This means that the
design score should be taken as an indication of an sgRNA’s activity, rather than as a definitive
assessment.
The low design scores of the Rag1 sgRNAs do, indeed, suggest that these sgRNAs have a
low cutting efficiency and would benefit from being redesigned. Interestingly, the efficiencies
sgRNA name sgRNA Designer score
Ovine Rag1 F1 0.034
Ovine Rag1 F2 0.068
Ovine Rag1 R1 0.036





Table 6.2.: Table showing Broad Institute sgRNA Designer scores assigned to the four sgRNAs
designed against ovine Rag1 and the four sgRNAs designed against ovine MSTN.
The designer scores sgRNAs on their predicted efficiency from 0-1
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of two of the MSTN sgRNAs, F2 and R2, were scored relatively well. As the CRISPR-edited
lamb was injected with a mixture of all four MSTN sgRNAs, it is not possible to determine
exactly which of the sgRNAs produced the editing event, but the high scores assigned to the F2
and R2 sgRNAs suggest that they are more likely to have been the cause of the deletion seen
in the animal.
An alternative solution for the non-functional TALENs could be to construct them using
a different system, such as Platinum Gate (Sakuma et al., 2013), which has been shown to
increase the efficiency of cleavage. The Platinum Gate system differs from the Golden Gate
system used in this project as the Platinum Gate domains contain additional variations outwith
the RVD amino acids, which more closely mimics the structure of a TALE in Xanthomonas.
Other TALEN scaffold vectors are also available however a comparison of scaffolds in Xenopus
embryos indicated that the ELD/KKR heterodimeric vectors used in this project has the highest
efficiency and lowest toxicity (Nakajima and Yaoita, 2013).
A final solution to combat deficiencies in the validation procedure would be to use a different
assay to validate the editors. In vitro CRISPR/Cas9 digests using Cas9 proteins complexed
with sgRNA on amplified or plasmid DNA have been detailed in the literature (Cho et al.,
2013). These digests have been successfully carried out in our lab and would indicate if any
potential problems with the current assay system are cell- or transfection-based. It would also
be possible to try a different cell-based method, such as the traffic light reporter described
in Certo et al. (2011), which would circumvent any problems with the DNA extraction and
subsequent endonuclease assays used in the current validation protocol as the cutting efficiency
of an editor can be determined by flow cytometry.
6.2. Introduction of genome edited animals into the
agricultural industry
The TALEN- and CRISPR-edited lambs described in Chapter 4 and in the literature (Proudfoot
et al., 2014) demonstrate the potential benefits that genome editors can bring to the agricultural
industry and highlights the need for legislators to begin the process of determining how this
technology and the resulting animals will be regulated.
Uncertainties surrounding the regulation of GMOs for human or animal consumption in dif-
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ferent countries present one of the biggest barriers in developing genetic modification techno-
logy for widespread commercial use (Lusser et al., 2012). The regulation of GMOs intended for
consumption is highly variable between countries as governments can either choose to imple-
ment a regulatory framework which is process-based (i.e. that focuses on the methods used to
produce the GMO and places less emphasis on the actual modification itself) or product-based,
which looks at the effects of each new modification in an organism and is less concerned with
the method of modification, provided that the method has been previously found to be safe
(Jones, 2015). Different countries also define the term ’genetic modification’ differently. The
FDA in the United States defines GMOs as organisms which carry a transgene in their genome,
a feature that may not be routinely found in genome-edited organisms, while the European
Commission’s definition includes any DNA alterations which have not been introduced through
breeding or natural recombination of loci.
While it is clear that some form of regulation will be required for genome-edited animals
used in agriculture, the current regulation covering GMOs is not suitable for either the tech-
nology of genome editors or the use of genetically modified livestock in general. Currently,
the vast majority of GMO legislation relates to genetically modified crops rather than animals,
with the issue of containment of pollen or seeds to prevent cross-contamination being one of
the biggest issues. Unlike plants, which can spread seeds and pollen indiscriminately through
the air, containment of genetically modified animals should be easily managed by the use of
secure housing. Even if a modified animal were to escape into the surrounding environment
and successfully breed, it is unlikely that the animal would carry a modification which would
be considered detrimental in the wild population. This is in contrast to the concerns about ge-
netic drift of traits such as herbicide resistance from genetically modified crops into other plant
species.
An exception to this would be animals which contain an integrated CRISPR/Cas9 cassette in
their genome as part of multigenic chain reaction (MCR) experiments Gantz and Bier (2015).
If the integrated CRISPR/Cas9 cassette entered a wild population and spread, it is likely that
most or all animals in that population would carry mutations in both alleles of the target gene
within a few generations. Therefore, any animals involved in MCR experiments would require
a highly secure level of containment to ensure that the risk of them escaping is as minimal as
possible. However, at this moment in time, it seems unlikely that MCR will be used to produce
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edited livestock species for use in agriculture as the presence of the integrated CRISPR/Cas9
cassette in an animal’s genome would potentially pose too great a risk in the eyes of regulators.
New regulatory frameworks would also need to take into account the new possibilities presen-
ted by genome editors compared to those produced using traditional genetic modification meth-
ods, such as recombinant DNA or transgene integration using viral vectors, the current focus
of GMO regulation. The vast improvements in efficiency afforded by genome editors mean
that marker genes, such as those encoding antibiotic resistance, are no longer required. This is
in addition to the fact that genome editors allow far more subtle modifications to be produced,
such as the insertion or removal of a few nucleotides in an endogenous gene, potentially re-
flecting mutations which could naturally occur in the genome. Given the different definitions
of ’genetic modification’ used by different regulatory bodies, it is probable that, as with current
GMOs, regulation will vary internationally.
Another key issue for regulators to consider is the determination of off-target events caused
by a genome editor. Whole-genome sequencing is now at a stage where subtle differences, and
therefore potential off-target events, between isogenic cell lines can be easily detected (Veres
et al., 2014, Smith et al., 2014, Yang et al., 2014, Suzuki et al., 2014). However, it is extremely
difficult to source a suitable isogenic control for large animals such as pigs or sheep. As such,
it is almost impossible to accurately differentiate between mutations which have been induced
by a genome editor and those which have spontaneously arisen in an embryo or animal. This
will be improved by the development of assays which are able to clearly signal the presence
of off-target events, such as the assay recently published by Wang et al. (2015). Their method
uses an integrase-defective lentiviral vector to physically mark loci in the genome where a DSB
has occurred, allowing integration of the vector into the genomic DNA. Although the current
sensitivity of the assay remains an issue at present, it has the potential to clearly delineate
mutations in the genome which are caused by off-target activity and could complement whole-
genome sequencing to great effect.
Although there is currently no regulation in place which specifically mentions the use of
genome editors or of genetically modified livestock in agriculture, steps have been taken to
address this. At present, few GMOs are authorised to be grown in the EU and the area has some
of the most rigid GMO regulations globally. This makes it difficult to foresee how genome
edited livestock would be regulated, however, some progress is being made. The European
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Food Safety Authority has undertaken assessments of the safety and environmental impacts of
genetically modified animals and has made recommendations to the European Commission for
the implementation of a future regulatory framework. However, there has been little mention
of the use of genome editors (Jones, 2015) and it is currently unclear when guidance on this
will be issued.
Regulatory decisions in the United States give conflicting views about how the production
and use of genome-edited animals may be controlled. The AquAdvantage salmon (Du et al.,
1992), produced by insertion of a transgene, has long been expected to become the first ge-
netically modified animal to be approved by the FDA for human consumption. Progress has,
however, stalled numerous times since the salmon was first submitted for approval in 1996.
The FDA published a finding of ’No Significant Impact’ as the result of an environmental risk
assessment on the salmon in December 2012 (Maxmen, 2012), but has not given final approval
or commented further since then. In stark contrast to this, the US Department of Agriculture
has recently waived the need for some genome-edited crops containing targeted deletions to be
subject to regulation (Camacho et al., 2014), citing the lack of inserted genetic material as the
reason for exemption. Edited crops with genomic insertions or substitutions derived from an
exogenous template would need to be assessed on an individual basis. The extremes of these
two cases make it very difficult to predict the level of regulation which might be applied to
genome-edited livestock.
A more relaxed form of regulation for genome edited organisms in comparison to current
GMO legislation could prove beneficial for smaller biotechnology companies, who are cur-
rently hindered by the financial costs and time needed to successfully steer a newly developed
GMO through the regulatory process (Lusser et al., 2012), and would encourage the use of gen-
ome editors in more niche species, such as goats, which are not considered to be profitable, but
could be of great benefit to agriculture in the developing world. However, a complete absence
of regulation, as appears to be the current case with genome edited crops, could be harmful
to the public’s perceptions of genome editing. The debate which has surrounded genetically
modified crops since the mid 1990s has made this area very emotionally charged and an ’all or
nothing’ approach to regulated genome editing will only serve to reinforce the public’s suspi-
cions of the technology.
Genome editors clearly have the potential to be a powerful tool in combating food insecurity,
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one of the greatest problems facing society today. Increasing the productivity of livestock
either directly, as with the myostatin-edited sheep, or more indirectly, by improving disease
resistance, will help to meet an ever increasing global demand for meat and other livestock
products (Gerber et al., 2013). However, it should be recognised that the increasing demand
for meat is not only fuelled by an increasing global population, but also a rising number of
newly wealthy, middle-class citizens who aspire to the meat-based Western diet. This adoption
of the Western diet in an increasing number of developing countries is contributing a rise in
noncommunicable diseases, such as cancer and cardiovascular disease (WHO, 2011) and the
majority of countries with the highest obesity rates globally are found in the Middle East and
the Pacific Islands (Morgen and Sorensen, 2014). In conclusion, while genome edited livestock
can be used to increase the supply of livestock products, the consequences of this increased
supply should also be considered.
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A.1. PCR primers and oligos
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Ovine Rag1 forward CAAGATGCATCAGTGGGATG
61°C
Amplifies TALEN target






















region in bovine MSTN
Used with MSTN
TALEN reverse primer





Primer name Primer sequence (5’-3’) Annealing
temperature
Purpose Notes
Ovine PPT1 forward CCAAGACCCAAGAGGTGAGA
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Amplifies CRISPR target
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CACCCTGTCGTTACCCTCTAACTG Ligates MSTN CRISPR
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CACCACGACAGCATCGAGATTCTG Ligates MSTN CRISPR
sgRNA R1 into





CACCCTTCAAAATCCACAGTTAGA Ligates MSTN CRISPR
sgRNA R2 into
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On the following pages are listed the target DNA sequences and full RVD sequences for all
TALENs used in this work. DNA sequences directly bound by TALENs are shown 5’ to 3’
in blue, while spacer sequences are shown in red. Note that all right TALENs bind to com-











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Plasmid maps for all TALEN and CRISPR/Cas9 vectors used in this work are shown below.
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A.5. FMDV targets - breed mRNA alignments
On the following pages are alignments of the mRNA sequence of eIF4A1, eIF4G1 and IKBKG
in different livestock species. In each figure, the bar across the top of each set of alignments
indicates the degree of conservation between the individual sequences, with red showing that
all sequences share the same nucleotides at that particular point. The top sequence in each
alignment is the reference sequence from the genome of each species.
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Figure A.1.: Nucleotide alignments of eIF4A1 mRNA sequences from various bovine, porcine
and ovine breeds. The 3C cleavage site is indicated by the purple line.
257
Figure A.2.: Nucleotide alignments of eIF4G1 mRNA sequences from various bovine, porcine
and ovine breeds. The L protease cleavage site is indicated by the purple line
258
Figure A.3.: Nucleotide alignments of IKBKG mRNA sequences from various bovine, porcine
and ovine breeds. The 3C protease cleavage site is indicated by the purple line
259
A.6. Predicted FMDV 3C targets
On the next pages are the complete lists of targets from the FMDV protease bioinfomatics work
described in Section 5.3.3. As described previously, targets have been sorted firstly by cleavage
score, then by surface score.Targets which did not meet the cleavage score cut off point of 0.8
are shaded in green.
260





Collectin-43                                                                            P42916|CL43_BOVIN E264 0.856 0.779 DISKEGKFT Potential
TCF3 fusion partner homolog                                                             Q17QH7|TFPT_BOVIN E164 0.856 0.779 PPDKEGLSP Potential
Oxysterol-binding protein 
(Fragment)                                                    E1BA05|E1BA05_BOVIN E363 0.856 0.764 EPLKETTYT Potential
Protein DJ-1                                                                            Q5E946|PARK7_BOVIN E64 0.855 0.792 DAKKEGPYD Potential
Isoform V1 of Versican core 
protein                                                     P81282-2|CSPG2_BOVIN E1351 0.853 0.775 DARTEGPFT Potential
Versican core protein                                                                   F1N6I5|F1N6I5_BOVIN E1351 0.853 0.775 DARTEGPFT Potential
Rap guanine nucleotide 
exchange factor 2                                                F1MSG6|RPGF2_BOVIN E1390 0.848 0.775 IARKEGRYR Potential
Protein KASH5                                                                           Q2T9R2|KASH5_BOVIN E155 0.847 0.787 DPRPELPAT Potential
Neuroendocrine convertase 2                                                             Q9GLR0|NEC2_BOVIN E64 0.845 0.787 LPFAEGLYH Potential
DNA-directed RNA polymerase 
III subunit RPC8                                            F1ML03|F1ML03_BOVIN E181 0.843 0.795 LPKKEAPYT Potential
DNA-directed RNA polymerase 
III subunit RPC8                                            Q2T9X1|RPC8_BOVIN E181 0.843 0.795 LPKKEAPYT Potential
Mitochondrial import inner 
membrane translocase subunit 
Tim17-B                         F1MS17|F1MS17_BOVIN E158 0.841 0.78 LPSKEGTPG Potential
Mitochondrial import inner 
membrane translocase subunit 
Tim17-B                         Q2HJE9|TI17B_BOVIN E158 0.841 0.78 LPSKEGTPG Potential
Zinc finger with UFM1-specific 
peptidase domain protein                                 G5E563|G5E563_BOVIN E404 0.838 0.77 DAWKEGFDP Potential
Zinc finger with UFM1-specific 
peptidase domain protein                                 Q3SWY8|ZUFSP_BOVIN E404 0.838 0.77 DAWKEGFDP Potential
CDYL protein                                                                            A7MBK0|A7MBK0_BOVIN E65 0.837 0.809 EKQKEGTFT Potential
Chromodomain protein Y-like 
protein transcript variant 1                                B2XBK5|B2XBK5_BOVIN E88 0.837 0.809 EKQKEGTFT Potential
Pulmonary surfactant-
associated protein D                                               P35246|SFTPD_BOVIN E315 0.837 0.776 DTRKEGTFI Potential
Docking protein 2                                                                       A7MBB8|DOK2_BOVIN E268 0.837 0.762 LPRPESPYA Potential
Activating signal cointegrator 1 
complex subunit 3                                      E1BNG3|ASCC3_BOVIN E2017 0.835 0.759 MIEKELPAP Potential
Neuroendocrine convertase 2                                                             A7MBJ9|A7MBJ9_BOVIN E64 0.833 0.795 LPFAEGLYQ Potential
Fermitin family homolog 3                                                               Q32LP0|URP2_BOVIN E497 0.832 0.794 DASAEGLNP Potential
Fermitin family homolog 3 
(Fragment)                                                    F1MMJ5|F1MMJ5_BOVIN E107 0.832 0.794 DASAEGLNP Potential
Solute carrier family 25 
member 40                                                      Q0VCH6|S2540_BOVIN E6 0.831 0.78 DPESEGPAV Potential
MOB kinase activator 3A                                                                 Q58D63|MOB3A_BOVIN E210 0.831 0.769 EPLKEMTAR Potential
KCNJ10 protein                                                                          A2VDQ4|A2VDQ4_BOVIN E368 0.831 0.755 QAEKEGSAV Potential
Steroid 17-alpha-
hydroxylase/17,20 lyase                                                P05185|CP17A_BOVIN E505 0.83 0.759 EAQAEGSTP Potential
LMOD1 protein                                                                           A4IFK3|A4IFK3_BOVIN E175 0.828 0.817 EAGKEGPAA Potential
Cytochrome c oxidase subunit 
6B1                                                        P00429|CX6B1_BOVIN E79 0.828 0.789 DRRAEGTFP Potential
TAP binding protein (Tapasin)                                                           Q2NL04|Q2NL04_BOVIN E265 0.828 0.787 RPSQEGTYL Potential
Ankyrin repeat and SOCS box 
protein 2                                                   Q3SX45|ASB2_BOVIN E135 0.828 0.753 EPNKEGWLP Potential
High mobility group 
nucleosome-binding domain-
containing protein 3                      Q3ZBV4|HMGN3_BOVIN E73 0.827 0.808 EAGKEGTAA Potential
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Coiled-coil domain-containing 
protein 86                                                F1MM20|F1MM20_BOVIN E202 0.827 0.775 EPAREGPAP Potential
Coiled-coil domain-containing 
protein 86                                                Q2TBX7|CCD86_BOVIN E202 0.827 0.775 EPAREGPAP Potential
Calcium-binding and coiled-coil 
domain-containing protein 1                             F1N037|F1N037_BOVIN E656 0.827 0.758 PPWKECPIC Potential
Calcium-binding and coiled-coil 
domain-containing protein 1                             Q2KJ21|CACO1_BOVIN E656 0.827 0.758 PPWKECPIC Potential
Cyclic nucleotide-gated cation 
channel beta-1                                           Q28181-1|CNGB1_BOVIN E835 0.826 0.769 PPRPEPPAP Potential
Isoform CNG4C of Cyclic 
nucleotide-gated cation 
channel beta-1                          Q28181-2|CNGB1_BOVIN E826 0.826 0.769 PPRPEPPAP Potential
Isoform CNG4D of Cyclic 
nucleotide-gated cation 
channel beta-1                          Q28181-3|CNGB1_BOVIN E817 0.826 0.769 PPRPEPPAP Potential
Isoform GARP2 of Cyclic 
nucleotide-gated cation 
channel beta-1                          Q28181|CNGB1_BOVIN E1291 0.826 0.769 PPRPEPPAP Potential
DNAation factor, 45kDa, alpha 
polypeptide                                               Q0VC37|Q0VC37_BOVIN E245 0.826 0.764 LALKEKPAP Potential
BCL2/adenovirus E1B 19kD 
interacting protein like                                       Q17QP4|Q17QP4_BOVIN E150 0.825 0.77 LPRAEGLGA Potential
Visual system homeobox 1                                                                Q9GMA3|VSX1_BOVIN E299 0.825 0.752 DHLKEGSSP Potential
Inactive rhomboid protein 1                                                             A7YWH9|RHDF1_BOVIN E329 0.825 0.75 RKQKEGGAA Potential
Glutamate decarboxylase-like 
protein 1                                                  A6QM00|GADL1_BOVIN E262 0.824 0.784 EAKKEGAAP Potential
TRIO protein                                                                            A6QQZ8|A6QQZ8_BOVIN E907 0.824 0.767 CPAAEGWIP Potential
HPN protein                                                                             A1L5C6|A1L5C6_BOVIN E5 0.823 0.784 MAEKEGGRT Potential
Enoyl-CoA hydratase, 
mitochondrial                                                      Q58DM8|ECHM_BOVIN E274 0.823 0.781 EDRKEGMAA Potential
GGNBP1 protein                                                                          A6H760|A6H760_BOVIN E227 0.823 0.775 FPLKEGLPR Potential
Non-structural maintenance of 
chromosomes element 1 
homolog                             Q3T0X7|NSE1_BOVIN E163 0.823 0.772 LIEKEGEFT Potential
Non-structural maintenance of 
chromosomes element 1 
homolog (Fragment)                  F1MUB2|F1MUB2_BOVIN E117 0.823 0.772 LIEKEGEFT Potential
Regulator of microtubule 
dynamics protein 3                                             Q1JQC5|RMD3_BOVIN E172 0.822 0.806 DAESEGGYT Potential
V-type proton ATPase subunit F                                                          Q28029|VATF_BOVIN E95 0.822 0.754 IPSKEHPYD Potential
Transporter (Fragment)                                                                  F6QN23|F6QN23_BOVIN E619 0.821 0.766 TPLKEGLMA Potential
Sepiapterin reductase                                                                   Q17QK8|SPRE_BOVIN E96 0.82 0.785 LPRPEGLQR Potential
Calpain-1 catalytic subunit                                                             Q27970|CAN1_BOVIN E508 0.819 0.773 EPNKEGDFV Potential
DNA repair protein XRCC3                                                                Q08DH8|XRCC3_BOVIN E72 0.818 0.808 LLRQEGPFP Potential
RAVER1 protein                                                                          A4FUZ2|A4FUZ2_BOVIN E690 0.818 0.808 EPSPEGSYV Potential
Semaphorin-3C                                                                           A7MB70|SEM3C_BOVIN E357 0.818 0.777 FAHKEGPNH Potential
RHBDD3 protein                                                                          A6H705|A6H705_BOVIN E251 0.818 0.77 WPLSEGSAP Potential
Calsyntenin-3                                                                           Q0VCN6-2|CSTN3_BOVIN E104 0.818 0.767 EAQKEHTFT Potential
Isoform 2 of Calsyntenin-3                                                              Q0VCN6|CSTN3_BOVIN E104 0.818 0.767 EAQKEHTFT Potential
LOC508041 protein                                                                       A6QPL9|A6QPL9_BOVIN E11 0.818 0.762 RCRKELTAA Potential
CD3e molecule, epsilon 
associated protein                                               Q0VD10|Q0VD10_BOVIN E417 0.818 0.757 EPQAEGMEP Potential
Pre-miRNA 5'-monophosphate 
methyltransferase                                            Q29S19|BN3D2_BOVIN E122 0.817 0.783 RAEKECPFP Potential
Acetyl-CoA carboxylase 1                                                                E1BGH6|E1BGH6_BOVIN E1709 0.817 0.782 LARAEGIPR Potential
Acetyl-CoA carboxylase 1                                                                Q9TTS3|ACACA_BOVIN E1709 0.817 0.782 LARAEGIPR Potential
Acetolactate synthase-like 
protein                                                      A6QQT9|ILVBL_BOVIN E258 0.816 0.782 EPQPEGPLP Potential
Acetolactate synthase-like 
protein (Fragment)                                           G1K1S1|G1K1S1_BOVIN E265 0.816 0.782 EPQPEGPLP Potential
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Conglutinin                                                                             P23805|CONG_BOVIN E315 0.816 0.772 DISTEGRFT Potential
Centromere protein X                                                                    Q2NKU0|CENPX_BOVIN E58 0.816 0.757 QAQAEGLAH Potential
Probable RNA polymerase II 
nuclear localization protein 
SLC7A6OS                        Q1JQE2|S7A6O_BOVIN E101 0.815 0.779 EIRQEGRYR Potential
ASAM protein                                                                            A5D7I8|A5D7I8_BOVIN E106 0.815 0.775 KPSDEGRYT Potential
Complement factor B                                                                     P81187|CFAB_BOVIN E601 0.815 0.766 LPCTEGSIQ Potential
PHD finger protein 20-like 
protein 1                                                    A2VE56|P20L1_BOVIN E113 0.814 0.828 AINKEGTFT Potential
PHD finger protein 20-like 
protein 1                                                    E1BGZ9|E1BGZ9_BOVIN E113 0.814 0.828 AINKEGTFT Potential
Ubiquitin carboxyl-terminal 
hydrolase 10                                                A5PJS6|UBP10_BOVIN E717 0.814 0.751 EISKELLSP Potential
Radial spoke head 10 homolog 
B                                                          F1N5C9|F1N5C9_BOVIN E600 0.813 0.766 MINKELTAT Potential
Inactive ribonuclease-like 
protein 10                                                   Q70IB2|RNS10_BOVIN E58 0.812 0.807 EATKEGLAS Potential
Protein FAM188B                                                                         A1A4L4|F188B_BOVIN E245 0.812 0.778 QPHKEGSPQ Potential
Protein FAM188B                                                                         F1MGQ9|F1MGQ9_BOVIN E245 0.812 0.778 QPHKEGSPQ Potential
Interleukin-12 receptor subunit 
beta-2                                                  F1MEB5|F1MEB5_BOVIN E812 0.812 0.76 LPSHEAPIT Potential
Interleukin-12 receptor subunit 
beta-2                                                  Q9BEG2|I12R2_BOVIN E812 0.812 0.76 LPSHEAPIT Potential
Isoform 2 of Microtubule-
associated protein 4                                           P36225-3|MAP4_BOVIN E368 0.811 0.816 LASAEGTVP Potential
Isoform 3 of Microtubule-
associated protein 4                                           P36225-4|MAP4_BOVIN E368 0.811 0.816 LASAEGTVP Potential
Isoform 4 of Microtubule-
associated protein 4                                           P36225|MAP4_BOVIN E368 0.811 0.816 LASAEGTVP Potential
Microtubule-associated protein                                                          F1MAZ1|F1MAZ1_BOVIN E368 0.811 0.816 LASAEGTVP Potential
Microtubule-associated protein                                                          F1MAZ3|F1MAZ3_BOVIN E368 0.811 0.816 LASAEGTVP Potential
Microtubule-associated protein                                                          F1N0J2|F1N0J2_BOVIN E368 0.811 0.816 LASAEGTVP Potential
Microtubule-associated protein                                                          G3N2G7|G3N2G7_BOVIN E368 0.811 0.816 LASAEGTVP Potential
Microtubule-associated protein 
4                                                        P36225-2|MAP4_BOVIN E368 0.811 0.816 LASAEGTVP Potential
LMO7 protein                                                                            A8E4L8|A8E4L8_BOVIN E1024 0.811 0.79 SPDKEGTRA Potential
Protein CASC3                                                                           A5D7H5|CASC3_BOVIN E429 0.811 0.781 PPPPEGLTP Potential
FAP protein                                                                             A5D7B7|A5D7B7_BOVIN E565 0.811 0.775 LASKEGIVI Potential
DNA (cytosine-5)-
methyltransferase 1                                                    Q24K09|DNMT1_BOVIN E448 0.81 0.794 DPSPEGGIN Potential
Myocyte enhancer factor 2D                                                              F1CYZ1|F1CYZ1_BOVIN E492 0.81 0.793 EPEAEGSAV Potential
Dihydropyrimidine 
dehydrogenase [NADP(+)]                                               F1N549|F1N549_BOVIN E726 0.809 0.777 RAAKEGGAN Potential
Dihydropyrimidine 
dehydrogenase [NADP(+)]                                               Q28007|DPYD_BOVIN E726 0.809 0.777 RAAKEGGAN Potential
NBR1 protein                                                                            A6QQS9|A6QQS9_BOVIN E452 0.808 0.811 APTLEGTYT Potential
Calcium binding tyrosine-(Y)-
phosphorylation regulated                                  Q32L61|Q32L61_BOVIN E435 0.808 0.777 PPVPEGLYE Potential
Activating signal cointegrator 1 
complex subunit 1                                      Q0IIJ9|Q0IIJ9_BOVIN E292 0.807 0.804 DPNAEGRYN Potential
LOC781700 protein                                                                       A5D7L4|A5D7L4_BOVIN E225 0.807 0.796 SPSKEGRPA Potential
Immediate early response 2                                                              Q3T0B5|Q3T0B5_BOVIN E166 0.806 0.781 PAQAEGAFP Potential
Matrix-remodeling-associated 
protein 8                                                  Q148M6|MXRA8_BOVIN E283 0.806 0.779 EPADEGTYS Potential
Protein-lysine 
methyltransferase METTL21C                                               A6QP81|MT21C_BOVIN E16 0.806 0.775 RPLDEGPSP Potential
Lysosomal-associated 
transmembrane protein 4A                                           Q6QRN8|LAP4A_BOVIN E225 0.806 0.761 MPEKEPPPP Potential
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Delta-like protein (Fragment)                                                           G3X6N5|G3X6N5_BOVIN E965 0.806 0.75 LPREEGPNN Potential
PTPRR protein                                                                           A5PKF8|A5PKF8_BOVIN E226 0.805 0.783 IWSKEGFYA Potential
SPRY domain-containing 
protein 7                                                        Q2T9X3|SPRY7_BOVIN E24 0.805 0.777 IPLKEMPAV Potential
Cdc42 effector protein 1                                                                Q17QW1|BORG5_BOVIN E309 0.805 0.775 DARAEGLGA Potential
Glutamate decarboxylase-like 
protein 1                                                  F1MYA7|F1MYA7_BOVIN E262 0.805 0.758 KAKKEGAAP Potential
Pro-interleukin-16                                                                      Q0V8R5|IL16_BOVIN E449 0.804 0.789 LASQEGTIQ Potential
Zinc finger protein 512                                                                 A4FV61|ZN512_BOVIN E146 0.804 0.762 RIRKEPPAY Potential
MOB kinase activator 3B                                                                 Q29RK9|MOB3B_BOVIN E209 0.804 0.755 EPLKEMTSR Potential
AIM1L protein                                                                           A8E4N1|A8E4N1_BOVIN E228 0.803 0.782 NPRAEGSPS Potential
ULK2 protein                                                                            A6QQH7|A6QQH7_BOVIN E434 0.803 0.778 PPSLEGLVT Potential
Tuftelin-interacting protein 11                                                         F1MR60|F1MR60_BOVIN E309 0.803 0.754 PPGKEARAP Potential
Tuftelin-interacting protein 11                                                         Q29RR5|TFP11_BOVIN E309 0.803 0.754 PPGKEARAP Potential
Rho GTPase-activating protein 
10                                                        Q08DP6|RHG10_BOVIN E386 0.802 0.785 IPRPEGSAQ Potential
Reticulon                                                                               G3MZ35|G3MZ35_BOVIN E224 0.802 0.779 QPKAEGICP Potential
Reticulon-3                                                                             G3N1F7|G3N1F7_BOVIN E128 0.802 0.779 QPKAEGICP Potential
Alpha-aminoadipic 
semialdehyde dehydrogenase                                            E1BFG0|E1BFG0_BOVIN E391 0.802 0.76 EAKKEGGTV Potential
Alpha-aminoadipic 
semialdehyde dehydrogenase                                            Q2KJC9|AL7A1_BOVIN E391 0.802 0.76 EAKKEGGTV Potential
LMAN2 protein                                                                           A6QP36|A6QP36_BOVIN E101 0.801 0.756 ERSKEGSIW Potential
Bucentaur-2                                                                             A0JBZ9|A0JBZ9_BOVIN E196 0.801 0.75 PPRSEGGQH Potential
Ubiquitin carboxyl-terminal 
hydrolase                                                   E1BGW4|E1BGW4_BOVIN E855 0.801 0.75 ERRKEGRAE Potential
Replication protein A2, 32kDa                                                           Q2KI86|Q2KI86_BOVIN E223 0.8 0.753 CPRPEGLNF Potential
Mitogen-activated protein 
kinase kinase kinase 12                                       F1N791|F1N791_BOVIN E679 0.8 0.75 TPPSEGSAP Potential
Oral-facial-digital syndrome 1 
isoform 1                                                F1MB20|F1MB20_BOVIN E642 0.799 0.783 NASAEGSSP Potential
V-type proton ATPase 116 kDa 
subunit a isoform 2                                        O97681|VPP2_BOVIN E364 0.799 0.78 IPTKETPPT Potential
MARVELD3 protein                                                                        A6H721|A6H721_BOVIN E120 0.799 0.755 PLRKEGLGR Potential
BTB (POZ) domain containing 
12                                                          F1N7Q0|F1N7Q0_BOVIN E1680 0.799 0.754 PASQESTAT Potential
Lysosome-associated 
membrane glycoprotein 1                                             Q05204|LAMP1_BOVIN E307 0.798 0.816 PDAKEGSFT Potential
RNA guanylyltransferase and 5'-
phosphatase                                              Q2KHX7|Q2KHX7_BOVIN E82 0.798 0.785 DIEKEGIKY Potential
Transcription factor NF-E2 45 
kDa subunit                                               Q5EAD3|NFE2_BOVIN E49 0.798 0.771 EPSFEPPAP Potential
Ras-related protein Rab-6B                                                              A6QR46|RAB6B_BOVIN E186 0.798 0.765 EKSKEGMID Potential
CTF18, chromosome 
transmission fidelity factor 18 
homolog                               E1B8Q4|E1B8Q4_BOVIN E30 0.798 0.758 LAELEGSAA Potential
FRS3 protein                                                                            A6H792|A6H792_BOVIN E217 0.797 0.805 QPLPEGRAP Potential
MAP2K2 protein                                                                          Q17QH2|Q17QH2_BOVIN E20 0.797 0.799 PAIAEGPSP Potential
Zinc finger SWIM domain-
containing protein 8                                            A7E305|ZSWM8_BOVIN E693 0.797 0.759 TPRPEGKVP Potential
Zinc finger SWIM domain-
containing protein 8                                            E1BCX3|E1BCX3_BOVIN E1115 0.797 0.759 TPRPEGKVP Potential
E3 ubiquitin-protein ligase 
TRIM56                                                      E1BD59|TRI56_BOVIN E239 0.797 0.75 LAEKEALAR Potential
E3 ubiquitin-protein ligase 
TRIM56                                                      G5E5F1|G5E5F1_BOVIN E239 0.797 0.75 LAEKEALAR Potential
Transcription factor ETV6                                                               Q0VC65|ETV6_BOVIN E261 0.797 0.75 SPRQEGTRV Potential
Transcription factor ETV6 
(Fragment)                                                    F1MQT2|F1MQT2_BOVIN E206 0.797 0.75 SPRQEGTRV Potential
Beta-casein                                                                             P02666|CASB_BOVIN E123 0.796 0.801 PKHKEMPFP Potential
Clathrin heavy chain 
(Fragment)                                                         F1MPU0|F1MPU0_BOVIN E1374 0.796 0.789 DAWKEGQFK Potential
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Clathrin heavy chain 1                                                                  P49951|CLH1_BOVIN E1388 0.796 0.789 DAWKEGQFK Potential
Type 2 phosphatidylinositol 4,5-
bisphosphate 4-phosphatase                              Q3SZ48|TM55A_BOVIN E37 0.796 0.786 SPRAELPPP Potential
CLEC11A protein                                                                         A5D7L1|A5D7L1_BOVIN E249 0.796 0.77 DRRAEGLYL Potential
Endonuclease/exonuclease/ph
osphatase family domain-
containing protein 1                 Q3MHJ7|EEPD1_BOVIN E550 0.795 0.759 WTRKEGPRS Potential
MGC159566 protein                                                                       A6QQ29|A6QQ29_BOVIN E279 0.795 0.754 AALKEGSTW Potential
PTPN5 protein                                                                           A6QQD4|A6QQD4_BOVIN E23 0.794 0.811 LDQAEGPAA Potential
Platelet-activating factor 
acetylhydrolase 2, cytoplasmic                               P79106|PAFA2_BOVIN E163 0.794 0.756 EALKEEWIP Potential
DPYSL3 protein                                                                          A7MBI5|A7MBI5_BOVIN E82 0.794 0.75 RPGAEGDTP Potential
Heat shock factor protein 1                                                             Q08DJ8|HSF1_BOVIN E311 0.794 0.75 SPRAEGASP Potential
Kinesin-like protein KIF2A                                                              F1N034|F1N034_BOVIN E50 0.793 0.789 EPSPETPPP Potential
Kinesin-like protein KIF2A                                                              G3N277|G3N277_BOVIN E77 0.793 0.789 EPSPETPPP Potential
Kinesin-like protein KIF2A                                                              Q2NL05|KIF2A_BOVIN E50 0.793 0.789 EPSPETPPP Potential
Tyrosine-protein kinase 
receptor (Fragment)                                             F1MQH1|F1MQH1_BOVIN E621 0.793 0.784 EAFMEGIFT Potential
TCEB3 protein                                                                           A6QPU3|A6QPU3_BOVIN E109 0.793 0.774 EAEIEGDYP Potential
von Willebrand factor                                                                   F1N0R5|F1N0R5_BOVIN E781 0.793 0.755 NPRAEGLEC Potential
von Willebrand factor 
(Fragment)                                                        P80012|VWF_BOVIN E783 0.793 0.755 NPRAEGLEC Potential
Keratin 10 (Epidermolytic 
hyperkeratosis; keratosis 
palmaris et plantaris)              A6QNZ7|A6QNZ7_BOVIN E378 0.793 0.752 LAETEGRYC Potential
Keratin, type I cytoskeletal 10                                                         P06394|K1C10_BOVIN E378 0.793 0.752 LAETEGRYC Potential
Solute carrier family 27 (Fatty 
acid transporter), member 4                             Q0VCQ2|Q0VCQ2_BOVIN E604 0.793 0.752 ELQKEGFDP Potential
Ribosomal RNA processing 1 
homolog (S. cerevisiae)                                      Q148H9|Q148H9_BOVIN E332 0.792 0.818 QALAEGLFP Potential
Optic atrophy 3 protein 
homolog                                                         Q05B66|OPA3_BOVIN E181 0.792 0.763 TPRDEGPPD Potential
Fibroblast growth factor-
binding protein 1                                              Q9MZ06|FGFP1_BOVIN E26 0.791 0.773 EAKKEGRNR Potential
AP-3 complex subunit delta-1                                                            Q865S1|AP3D1_BOVIN E1034 0.791 0.765 LARPEGSSV Potential
UNC5B protein                                                                           A5PJP9|A5PJP9_BOVIN E595 0.79 0.816 LPLSEGTQT Potential
CCCTC-binding factor (Zinc 
finger protein)                                              Q08DH9|Q08DH9_BOVIN E145 0.79 0.77 EVSKEGLAE Potential
SAMD14 protein                                                                          A6QL51|A6QL51_BOVIN E132 0.79 0.756 TASHEGLAA Potential
Annexin                                                                                 F1MU06|F1MU06_BOVIN E210 0.789 0.797 LKQAEGPST Potential
Annexin A9                                                                              Q3ZC08|ANXA9_BOVIN E210 0.789 0.797 LKQAEGPST Potential
Radial spoke head 10 homolog 
B                                                          Q1JPG1|RS10B_BOVIN E600 0.789 0.79 IINKELTAT Potential
T-complex protein 1 subunit 
beta                                                        Q3ZBH0|TCPB_BOVIN E482 0.789 0.782 LDMKEGTIG Potential
Paraspeckle component 1                                                                 Q1LZD9|PSPC1_BOVIN E57 0.789 0.781 RPADEGGFT Potential
CD97 antigen                                                                            F1MCN3|F1MCN3_BOVIN E144 0.789 0.751 CINTEGSYT Potential
Fibulin-1                                                                               F1MYN5|F1MYN5_BOVIN E332 0.789 0.751 CINTEGSYT Potential
DnaJ homolog subfamily C 
member 3                                                       F1N036|F1N036_BOVIN E281 0.788 0.823 ELIKEGRYT Potential
DnaJ homolog subfamily C 
member 3                                                       Q27968|DNJC3_BOVIN E281 0.788 0.823 ELIKEGRYT Potential
Cathepsin K                                                                             Q5E968|CATK_BOVIN E112 0.788 0.758 IPDWEGRAP Potential
RING finger protein 112                                                                 E1BFZ5|E1BFZ5_BOVIN E201 0.787 0.779 LASGEGSWP Potential
RING finger protein 112                                                                 Q08DF2|RN112_BOVIN E201 0.787 0.779 LASGEGSWP Potential
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 
5                                   Q02379|NDUS5_BOVIN E89 0.787 0.769 KLIKEGKYT Potential
LOC407171 protein                                                                       A5D7Q0|A5D7Q0_BOVIN E164 0.787 0.767 LLSKEGAAH Potential
Trafficking protein particle 
complex subunit 9                                          F1MTG7|F1MTG7_BOVIN E1118 0.787 0.763 GPSKELPPS Potential
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Trafficking protein particle 
complex subunit 9                                          Q32PH0|TPPC9_BOVIN E1118 0.787 0.763 GPSKELPPS Potential
Protein arginine N-
methyltransferase 7                                                  A6QQV6|ANM7_BOVIN E597 0.786 0.806 PIHAEGTIE Potential
Protein arginine N-
methyltransferase 7                                                  F1MQX7|F1MQX7_BOVIN E597 0.786 0.806 PIHAEGTIE Potential
Angiotensin-converting enzyme 
(Fragment)                                                F1MQJ0|F1MQJ0_BOVIN E1154 0.786 0.773 SARLEGPFV Potential
LIM domain only protein 3                                                               Q2KIA3|LMO3_BOVIN E138 0.786 0.773 GLMKEGYAP Potential
Gap junction alpha-4 protein                                                            A4IFL1|CXA4_BOVIN E271 0.786 0.769 LPMSEGPSS Potential
Gap junction protein                                                                    G1K1Q0|G1K1Q0_BOVIN E271 0.786 0.769 LPMSEGPSS Potential
DDB1- and CUL4-associated 
factor 15                                                     Q3SZD5|DCA15_BOVIN E378 0.785 0.788 PPAAEAPAP Potential
Microspherule protein 1                                                                 Q08E44|Q08E44_BOVIN E381 0.785 0.775 DLSLEGPAW Potential
Calcitonin gene-related peptide 
type 1 receptor                                         A6QP74|CALRL_BOVIN E358 0.785 0.771 PWRPEGKIA Potential
Calcitonin gene-related peptide 
type 1 receptor                                         G3N3V9|G3N3V9_BOVIN E359 0.785 0.771 PWRPEGKIA Potential
Calcitonin gene-related peptide 
type 1 receptor                                         G3X6P6|G3X6P6_BOVIN E358 0.785 0.771 PWRPEGKIA Potential
Peroxisomal carnitine O-
octanoyltransferase                                             G5E5R3|G5E5R3_BOVIN E119 0.785 0.77 WPPKEGTQL Potential
Peroxisomal carnitine O-
octanoyltransferase                                             O19094|OCTC_BOVIN E118 0.785 0.77 WPPKEGTQL Potential
A disintegrin and 
metalloproteinase with 
thrombospondin motifs 2                        P79331|ATS2_BOVIN E959 0.784 0.789 DARPEGRRA Potential
Plastin-3                                                                               A7E3Q8|PLST_BOVIN E101 0.784 0.779 INRKEGICA Potential
Plastin-3                                                                               F1MSB7|F1MSB7_BOVIN E101 0.784 0.779 INRKEGICA Potential
AP2-associated protein kinase 1                                                         F1MH24|AAK1_BOVIN E318 0.784 0.767 LLKKECPIP Potential
AP2-associated protein kinase 1 
(Fragment)                                              H2XJE8|H2XJE8_BOVIN E263 0.784 0.767 LLKKECPIP Potential
Inositol polyphosphate 1-
phosphatase                                                    P21327|INPP_BOVIN E256 0.784 0.76 NPSSEGSCR Potential
E3 ubiquitin-protein ligase 
RNF34                                                       Q5E9J6|RNF34_BOVIN E56 0.783 0.816 PASAEGPNI Potential
Tensin-4                                                                                F1MN94|F1MN94_BOVIN E429 0.783 0.816 TASPEGPAR Potential
Tensin-4                                                                                Q32PJ7|TENS4_BOVIN E429 0.783 0.816 TASPEGPAR Potential
Coronin                                                                                 F1MFD6|F1MFD6_BOVIN E666 0.783 0.811 EPLQEGPGP Potential
Coronin-7                                                                               Q0V8F1|CORO7_BOVIN E666 0.783 0.811 EPLQEGPGP Potential
Autophagy-related protein 13                                                            Q08DY8|ATG13_BOVIN E270 0.783 0.757 VPGKEGGVP Potential
Coatomer subunit gamma-2                                                                A2VE21|COPG2_BOVIN E462 0.782 0.821 LLGKEGPRT Potential
EXOC4 protein                                                                           A6QLD1|A6QLD1_BOVIN E797 0.782 0.766 PLAKEGNYA Potential
Fibulin 5                                                                               Q2KJ89|Q2KJ89_BOVIN E148 0.782 0.762 CINTEGGYT Potential
Fibulin-5                                                                               Q5EA62|FBLN5_BOVIN E148 0.782 0.762 CINTEGGYT Potential
LOC510340 protein (Fragment)                                                            A6QPC7|A6QPC7_BOVIN E177 0.781 0.806 PASPEGLAE Potential
Protein sprouty homolog 2                                                               Q08E39|SPY2_BOVIN E188 0.781 0.796 CKCKECTYP Potential
Basal cell adhesion molecule                                                            Q9MZ08|BCAM_BOVIN E460 0.781 0.787 QPKAEGSWT Potential
Matrix metalloproteinase-23                                                             F1N5K7|F1N5K7_BOVIN E368 0.781 0.784 NAINEGTYT Potential
Matrix metalloproteinase-23                                                             Q2TBM7|MMP23_BOVIN E368 0.781 0.784 NAINEGTYT Potential
ST3 beta-galactoside alpha-2,3-
sialyltransferase 2                                      Q6H8M9|Q6H8M9_BOVIN E63 0.781 0.772 RLSKEGLAG Potential
Leucine rich repeat neuronal 5                                                          Q58DI7|Q58DI7_BOVIN E301 0.781 0.763 WARAEGLSS Potential
Transmembrane 7 superfamily 
member 3                                                    Q08DX3|Q08DX3_BOVIN E553 0.781 0.752 LAQIEGLFQ Potential
Mitochondrial uncoupling 




AMP lyase (cyclizing)            A0JN77|A0JN77_BOVIN E128 0.78 0.775 QARAEGIPV Potential
Bifunctional ATP-dependent 
dihydroxyacetone kinase/FAD-
AMP lyase (cyclizing)            Q58DK4|DHAK_BOVIN E128 0.78 0.775 QARAEGIPV Potential
Inhibin beta A chain                                                                    P07995|INHBA_BOVIN E143 0.78 0.773 EISKEGSDL Potential
Protein MMS22-like                                                                      E1BGH8|MMS22_BOVIN E982 0.78 0.77 QQEKELPAP Potential
Alpha-ketoglutarate-dependent 
dioxygenase alkB homolog 2                                F1N437|F1N437_BOVIN E62 0.78 0.767 RIRAEGLNC Potential
Alpha-ketoglutarate-dependent 
dioxygenase alkB homolog 2                                Q58DM4|ALKB2_BOVIN E62 0.78 0.767 RIRAEGLNC Potential
Fibrinogen alpha chain                                                                  A5PJE3|A5PJE3_BOVIN E52 0.78 0.758 SACKETGWP Potential
Fibrinogen alpha chain                                                                  P02672|FIBA_BOVIN E52 0.78 0.758 SACKETGWP Potential
C2 calcium-dependent domain-
containing protein 4A                                       Q2KJ18|C2C4A_BOVIN E279 0.779 0.791 LLRAEGPAG Potential
C2 calcium-dependent domain-
containing protein 4A 
(Fragment)                            G3N1Z1|G3N1Z1_BOVIN E268 0.779 0.791 LLRAEGPAG Potential
Prenylated Rab acceptor 
protein 1                                                       Q1RMH4|PRAF1_BOVIN E14 0.779 0.79 DAEAEGLSA Potential
Polymerase (DNA-directed), 
delta interacting protein 3                                  A7YW33|A7YW33_BOVIN E266 0.779 0.783 EPPKELPPA Potential
Serine beta-lactamase-like 
protein LACTB, mitochondrial                                 P83095|LACTB_BOVIN E464 0.779 0.783 SWDKEGKYA Potential
Histidine ammonia-lyase                                                                 A7YWP4|HUTH_BOVIN E301 0.779 0.764 LKPKEGLAL Potential
Fibronectin                                                                             P07589|FINC_BOVIN E657 0.778 0.763 DRWKEATIP Potential
S1PR3 protein                                                                           A6QR17|A6QR17_BOVIN E304 0.778 0.755 LASKEMRRA Potential
Transcription factor E3                                                                 E1BHE4|E1BHE4_BOVIN E17 0.777 0.828 EASAEGPRA Potential
Transcription factor E3                                                                 Q05B92|TFE3_BOVIN E17 0.777 0.828 EASAEGPRA Potential
LOC539976 protein                                                                       A4FUY3|A4FUY3_BOVIN E247 0.777 0.806 RALCEGPYD Potential
Ameloblastin                                                                            Q9XSX7|AMBN_BOVIN E302 0.777 0.789 LANPEGNIP Potential
Tetratricopeptide repeat 
protein 30A                                                    A2VE45|TT30A_BOVIN E166 0.777 0.75 LLYKEGHYE Potential
Tetratricopeptide repeat 
protein 30B                                                    A6H739|TT30B_BOVIN E166 0.777 0.75 LLYKEGHYE Potential
Hydroxysteroid (17-beta) 
dehydrogenase 1                                                Q1JQD0|Q1JQD0_BOVIN E105 0.776 0.787 EAHKEGSVD Potential
EIF2AK3 protein                                                                         A5D791|A5D791_BOVIN E1015 0.776 0.779 LILFELLYP Potential
CC2D1A protein                                                                          A5PKI6|A5PKI6_BOVIN E934 0.776 0.768 EAAKEALYR Potential
IQ domain-containing protein C                                                          F1N4P6|F1N4P6_BOVIN E51 0.776 0.768 LQWTEGWIP Potential
Isoform 2 of IQ domain-
containing protein C                                             Q2TBI7|IQCC_BOVIN E51 0.776 0.768 LQWTEGWIP Potential
Leucine zipper transcription 
factor-like protein 1                                      Q3ZBL4|LZTL1_BOVIN E143 0.776 0.759 APLHEGGAA Potential
Leucine zipper transcription 
factor-like protein 1 (Fragment)                           F1MNG7|F1MNG7_BOVIN E101 0.776 0.759 APLHEGGAA Potential
TTLL11 protein                                                                          A7E2Z5|A7E2Z5_BOVIN E273 0.776 0.755 LASKENPPH Potential
Oxidation resistance protein 1                                                          A5PKL1|OXR1_BOVIN E424 0.776 0.753 MPTKEGDQA Potential
Oxidation resistance protein 1 
(Fragment)                                               F1MR28|F1MR28_BOVIN E323 0.776 0.753 MPTKEGDQA Potential
Thrombomodulin                                                                          F1N6M2|F1N6M2_BOVIN E388 0.775 0.81 CICAEGFAP Potential
Thrombomodulin (Fragment)                                                               P06579|TRBM_BOVIN E166 0.775 0.81 CICAEGFAP Potential
PDK3 protein                                                                            A6QLG3|A6QLG3_BOVIN E265 0.775 0.803 EDRKEGYPA Potential
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Galectin                                                                                G5E5J2|G5E5J2_BOVIN E192 0.775 0.8 LPTMEGPPA Potential
Galectin-4                                                                              Q3T0D6|LEG4_BOVIN E192 0.775 0.8 LPTMEGPPA Potential
Targeting protein for Xklp2                                                             A6H6Z7|TPX2_BOVIN E435 0.775 0.771 PEKKELPIT Potential
Targeting protein for Xklp2                                                             F1MJB6|F1MJB6_BOVIN E435 0.775 0.771 PEKKELPIT Potential
Pyruvate dehydrogenase 
protein X component                                              P22439|ODPX_BOVIN E272 0.775 0.768 QPNVEGTFT Potential
Cholesterol side-chain cleavage 
enzyme, mitochondrial                                   P00189|CP11A_BOVIN E114 0.775 0.754 LFKFEGSYP Potential
Cholesterol side-chain cleavage 
enzyme, mitochondrial 
(Fragment)                        F1N060|F1N060_BOVIN E25 0.775 0.754 LFKFEGSYP Potential
Matrix metalloproteinase-9                                                              F1MF56|F1MF56_BOVIN E626 0.775 0.753 LPRPEGKVL Potential
Matrix metalloproteinase-9                                                              P52176|MMP9_BOVIN E626 0.775 0.753 LPRPEGKVL Potential
Putative UDP-galactose 
translocator                                                     Q8SPM1|Q8SPM1_BOVIN E254 0.774 0.824 LWWAEGTAV Potential
UDP-galactose translocator                                                              F1MZI7|F1MZI7_BOVIN E254 0.774 0.824 LWWAEGTAV Potential
UDP-galactose translocator                                                              Q58DA6|S35A2_BOVIN E254 0.774 0.824 LWWAEGTAV Potential
Neurotrimin                                                                             Q58DA5|NTRI_BOVIN E110 0.774 0.77 DVYDEGPYT Potential
Opioid-binding protein/cell 
adhesion molecule                                           G5E5Q3|G5E5Q3_BOVIN E110 0.774 0.77 DVYDEGPYT Potential
Opioid-binding protein/cell 
adhesion molecule                                           P11834|OPCM_BOVIN E110 0.774 0.77 DVYDEGPYT Potential
Arrestin domain containing 2                                                            A2VDR7|A2VDR7_BOVIN E370 0.774 0.762 DMSMEGPFF Potential
SF4 protein                                                                             A4FV64|A4FV64_BOVIN E536 0.773 0.777 KALKEGREP Potential
Cadherin-13                                                                             Q3B7N0|CAD13_BOVIN E247 0.773 0.774 PIFREGPYI Potential
Cadherin-13 (Fragment)                                                                  F1MKP6|F1MKP6_BOVIN E197 0.773 0.774 PIFREGPYI Potential
GA-binding protein subunit 
beta-2                                                       Q0V8G2-2|GABP2_BOVIN E320 0.773 0.772 EESKEGTER Potential
Isoform 2 of GA-binding protein 
subunit beta-2                                          Q0V8G2|GABP2_BOVIN E349 0.773 0.772 EESKEGTER Potential
Trafficking protein particle 
complex subunit 11                                         A6QLC7|TPC11_BOVIN E486 0.773 0.766 DYRSEGWWT Potential
Trafficking protein particle 
complex subunit 11                                         F1MXL8|F1MXL8_BOVIN E486 0.773 0.766 DYRSEGWWT Potential
60S ribosomal protein L23a                                                              Q24JY1|RL23A_BOVIN E8 0.773 0.765 KAKKEAPAP Potential
Carboxypeptidase Q                                                                      Q17QK3|CBPQ_BOVIN E167 0.773 0.758 GPDAEGKIV Potential
SEC14L1 protein                                                                         A7MBE2|A7MBE2_BOVIN E616 0.772 0.757 LICKEGESV Potential
Dispatched homolog 1 
(Drosophila)                                                       Q2T9Q5|Q2T9Q5_BOVIN E44 0.771 0.833 LACKEAPRT Potential
Protein arginine N-
methyltransferase 5                                                  A7YW45|ANM5_BOVIN E499 0.771 0.776 EAQFEMPYV Potential
Protein arginine N-
methyltransferase 5                                                  F1N443|F1N443_BOVIN E499 0.771 0.776 EAQFEMPYV Potential
Angiomotin-like protein 1                                                               E1BEQ5|AMOL1_BOVIN E233 0.771 0.76 KARTEGRPT Potential
Cytosolic carboxypeptidase 3                                                            E1B9D8|CBPC3_BOVIN E515 0.771 0.753 QKSKEGTGR Potential
Cytosolic carboxypeptidase 3                                                            G3N121|G3N121_BOVIN E515 0.771 0.753 QKSKEGTGR Potential
Cytosolic carboxypeptidase 3                                                            G5E5V2|G5E5V2_BOVIN E520 0.771 0.753 QKSKEGTGR Potential
Olfactory receptor                                                                      G5E5M2|G5E5M2_BOVIN E100 0.771 0.752 LISFEGCMT Potential
Polynucleotide 5'-hydroxyl-
kinase NOL9                                                  E1BPN0|NOL9_BOVIN E478 0.77 0.772 DEEKEGPVM Potential
Cytochrome c oxidase subunit 
1                                                          P00396|COX1_BOVIN E40 0.77 0.759 LIRAELGQP Potential
Cytochrome c oxidase subunit 
1                                                          Q6QTG9|Q6QTG9_BOVIN E40 0.77 0.759 LIRAELGQP Potential
Collagen alpha-2(XI) chain                                                              F1MRP6|F1MRP6_BOVIN E696 0.77 0.753 HPGKEGPPG Potential
Collagen alpha-2(XI) chain                                                              Q32S24|COBA2_BOVIN E696 0.77 0.753 HPGKEGPPG Potential
Melanoma-associated antigen 
D4                                                          A6QLI5|MAGD4_BOVIN E204 0.769 0.834 EAAAEGPST Potential
REEP3 protein                                                                           A6QQT6|A6QQT6_BOVIN E206 0.769 0.814 DEEAEGPYS Potential
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LRRTM2 protein                                                                          A6H701|A6H701_BOVIN E492 0.769 0.808 EPTHEGPFI Potential
General transcription factor IIE 
subunit 1                                              A6QLI8|T2EA_BOVIN E297 0.769 0.77 EEMKEGGID Potential
General transcription factor IIE 
subunit 1                                              F1MGT5|F1MGT5_BOVIN E298 0.769 0.77 EEMKEGGID Potential
Endothelin converting enzyme                                                            Q28868|Q28868_BOVIN E713 0.769 0.76 ESSHEGLIT Potential
Endothelin-converting enzyme 
1                                                          P42891|ECE1_BOVIN E709 0.769 0.76 ESSHEGLIT Potential
Nuclear receptor subfamily 1 
group D member 1                                           Q08E02|NR1D1_BOVIN E397 0.769 0.753 YPAPEGEAP Potential
TNFRSF6B protein                                                                        A6QPW7|A6QPW7_BOVIN E244 0.768 0.751 PPLREGRAA Potential
Collagen alpha-1(IV) chain                                                              G1K238|G1K238_BOVIN E1365 0.767 0.804 LPGPEGPAG Potential
Aggrecan core protein                                                                   F1N367|F1N367_BOVIN E1334 0.767 0.774 LPSGEGPEV Potential
Aggrecan core protein                                                                   F1N368|F1N368_BOVIN E1334 0.767 0.774 LPSGEGPEV Potential
Aggrecan core protein                                                                   P13608-2|PGCA_BOVIN E1333 0.767 0.774 LPSGEGPEV Potential
Isoform 2 of Aggrecan core 
protein                                                      P13608|PGCA_BOVIN E1333 0.767 0.774 LPSGEGPEV Potential
RSPRY1 protein                                                                          A4IFG8|A4IFG8_BOVIN E424 0.767 0.769 PCWKEGDTV Potential
Cyclic AMP-responsive element-
binding protein 3                                         Q8SQ19|CREB3_BOVIN E136 0.767 0.766 LLEKEGLTL Potential
Importin subunit alpha                                                                  Q3SYV6|Q3SYV6_BOVIN E354 0.767 0.764 NIQKEATWT Potential
ETS1 protein                                                                            A5PJG9|A5PJG9_BOVIN E151 0.767 0.76 PPYPESRYT Potential
GPR182 protein (Fragment)                                                               A6QPN2|A6QPN2_BOVIN E403 0.766 0.8 IITKEGIQP Potential
Polo-like kinase 3 (Drosophila)                                                         Q0VCE7|Q0VCE7_BOVIN E389 0.766 0.787 DARPEAPAA Potential
Vesicular, overexpressed in 
cancer, prosurvival protein 1                               A6QNZ8|VOPP1_BOVIN E30 0.766 0.769 CWYFEGLYP Potential
Cell division cycle protein 27 
homolog                                                  A7Z061|CDC27_BOVIN E789 0.766 0.754 LPDDEEPIT Potential
Cyclic GMP-AMP synthase                                                                 E1BGN7|CGAS_BOVIN E84 0.765 0.823 EDQAEGPAA Potential
ABI3 protein                                                                            A4FUD5|A4FUD5_BOVIN E262 0.765 0.778 PPAPELPMP Potential
Protein LTV1 homolog                                                                    Q0VC06|LTV1_BOVIN E198 0.765 0.77 DDEKEGGSD Potential
RECQL4 protein                                                                          A5D786|A5D786_BOVIN E877 0.765 0.755 PPEQEGSRS Potential
Insulin-like 3                                                                          E1BAS5|E1BAS5_BOVIN E210 0.764 0.797 LIAQEGPFF Potential
Chaperone activity of bc1 
complex-like, mitochondrial                                   Q29RI0|ADCK3_BOVIN E113 0.763 0.811 AAGSEGPAP Potential
Matrix metallopeptidase 19                                                              Q08DI9|Q08DI9_BOVIN E199 0.763 0.797 ELWTEGTYR Potential
Putative sodium-coupled 
neutral amino acid transporter 
7                                A7E3U5|S38A7_BOVIN E229 0.763 0.786 WPDKEMTPA Potential
Zinc finger FYVE domain-
containing protein 21                                           Q05B78|ZFY21_BOVIN E195 0.763 0.78 RPAAEGGNA Potential
Zinc finger FYVE domain-
containing protein 21 
(Fragment)                                F1MHW4|F1MHW4_BOVIN E149 0.763 0.78 RPAAEGGNA Potential
SALL2 protein                                                                           A6QQL8|A6QQL8_BOVIN E82 0.763 0.766 EPRPEGHSS Potential
Citrate synthase, mitochondrial                                                         Q29RK1|CISY_BOVIN E117 0.762 0.828 EPLPEGLFW Potential
Serpin peptidase inhibitor, 
clade A (Alpha-1 
antiproteinase, antitrypsin), 
member 7     Q3SYR0|Q3SYR0_BOVIN E22 0.762 0.767 PNSCEGKIT Potential
Thyroxine-binding globulin                                                              Q9TT36|THBG_BOVIN E22 0.762 0.767 PNSCEGKIT Potential
Ribonucleoside-diphosphate 
reductase                                                    F1MSF1|F1MSF1_BOVIN E229 0.762 0.762 DDSIEGIYD Potential
Collagen alpha-2(I) chain                                                               P02465|CO1A2_BOVIN E814 0.762 0.758 PAGKEGLRG Potential
Coatomer subunit beta'                                                                  P35605|COPB2_BOVIN E743 0.761 0.757 DACLELLIR Potential
Cystic fibrosis transmembrane 
conductance regulator                                     F1MN01|F1MN01_BOVIN E620 0.76 0.777 LILHEGSIY Potential
Cystic fibrosis transmembrane 
conductance regulator                                     P35071|CFTR_BOVIN E620 0.76 0.777 LILHEGSIY Potential
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Rho GTPase-activating protein 
36                                                        A7MB27|RHG36_BOVIN E180 0.76 0.762 LAELEGGAL Potential
SNF8, ESCRT-II complex 
subunit, homolog (S. cerevisiae)                                 Q08DR7|Q08DR7_BOVIN E219 0.76 0.755 HLLKEGLAW Potential
Protein S100-A12                                                                        P79105|S10AC_BOVIN E40 0.759 0.795 LITKELPKT Potential
Protein S100-A12 (Fragment)                                                             G3N2H5|G3N2H5_BOVIN E43 0.759 0.795 LITKELPKT Potential
Cyclic nucleotide-gated cation 
channel beta-1                                           F1MTS6|F1MTS6_BOVIN E840 0.759 0.782 PPAPEPPAP Potential
Cyclic nucleotide-gated cation 
channel beta-1                                           F1MTS7|F1MTS7_BOVIN E1282 0.759 0.782 PPAPEPPAP Potential
Cyclic nucleotide-gated cation 
channel beta-1                                           F1N3J4|F1N3J4_BOVIN E826 0.759 0.782 PPAPEPPAP Potential
Cyclic nucleotide-gated cation 
channel beta-1                                           G3MZY3|G3MZY3_BOVIN E836 0.759 0.782 PPAPEPPAP Potential
Cyclic nucleotide-gated cation 
channel beta-1                                           G3N2E6|G3N2E6_BOVIN E817 0.759 0.782 PPAPEPPAP Potential
Actin-related protein 2/3 
complex subunit 1B                                            Q58CQ2|ARC1B_BOVIN E312 0.759 0.761 KASSEGSAA Potential
Rab-like protein 6                                                                      Q08DA0|RABL6_BOVIN E512 0.759 0.76 KPRPEGPSG Potential
Drebrin 1                                                                               Q1RMT6|Q1RMT6_BOVIN E531 0.759 0.758 LPAGEGSAN Potential
Transporter                                                                             E1BHC0|E1BHC0_BOVIN E561 0.759 0.755 PLRQEKPYP Potential
LIM and senescent cell antigen-
like-containing domain protein 
2                         Q2KJ33|LIMS2_BOVIN E52 0.758 0.828 RPFPEGLFY Potential
Asparagine synthetase 
[glutamine-hydrolyzing]                                           Q1LZA3|ASNS_BOVIN E514 0.758 0.813 PKTKEGYYY Potential
Cullin-associated NEDD8-
dissociated protein 1                                           A7MBJ5|CAND1_BOVIN E813 0.758 0.808 ACPKEGPAV Potential
Fatty acid synthase                                                                     F1N647|F1N647_BOVIN E1340 0.758 0.801 AALKEGGFL Potential
Fatty acid synthase                                                                     Q71SP7|FAS_BOVIN E1340 0.758 0.801 AALKEGGFL Potential
Beta-1,3-N-
acetylglucosaminyltransferase 
lunatic fringe                                 Q2KJ92|LFNG_BOVIN E109 0.758 0.766 RPLAEPLAP Potential
Alpha-2-macroglobulin                                                                   Q7SIH1|A2MG_BOVIN E612 0.758 0.752 RPEAELSAA Potential
MARCKS-related protein                                                                  G3MY11|G3MY11_BOVIN E119 0.758 0.751 RNRKEGGGD Potential
MARCKS-related protein                                                                  G3MZA0|G3MZA0_BOVIN E111 0.758 0.751 RNRKEGGGD Potential
MARCKS-related protein                                                                  Q0VBZ9|MRP_BOVIN E111 0.758 0.751 RNRKEGGGD Potential
FTS and Hook-interacting 
protein                                                        A7YY62|F16A2_BOVIN E838 0.757 0.8 LDWTEGPAA Potential
FTS and Hook-interacting 
protein (Fragment)                                             F1MLL5|F1MLL5_BOVIN E730 0.757 0.8 LDWTEGPAA Potential
Solute carrier family 3 (Cystine, 
dibasic and neutral amino acid 
transporters, activator of 
cystine, dibasic and neutral 
amino acid transport), member 
1 Q3SZF7|Q3SZF7_BOVIN E644 0.757 0.777 LASGEGLIL Potential
MGC148449 protein                                                                       A4IFQ5|A4IFQ5_BOVIN E16 0.757 0.775 LPGKEDPPA Potential
Keratin, type II cuticular Hb3                                                          A4FUZ0|KRT83_BOVIN E161 0.757 0.773 EPLFEGYIE Potential
Short transient receptor 
potential channel 5                                            F1MTE6|F1MTE6_BOVIN E863 0.757 0.758 EPSSEPMYT Potential
Zinc finger C2HC domain-
containing protein 1B                                           Q32KN7|ZC21B_BOVIN E102 0.756 0.786 LAIKEGRPL Potential
Stress-70 protein, 
mitochondrial                                                        Q3ZCH0|GRP75_BOVIN E352 0.756 0.771 RAQFEGIVT Potential
COP9 signalosome complex 
subunit 6                                                      A6QQ21|CSN6_BOVIN E100 0.756 0.763 IIDKEYYYT Potential
COP9 signalosome complex 
subunit 6                                                      F1MG10|F1MG10_BOVIN E100 0.756 0.763 IIDKEYYYT Potential
Peptidyl-glycine alpha-
amidating monooxygenase                                          F1MZB4|F1MZB4_BOVIN E611 0.756 0.759 PKSKEGPLL Potential
Peptidyl-glycine alpha-
amidating monooxygenase                                          F1MZN4|F1MZN4_BOVIN E611 0.756 0.759 PKSKEGPLL Potential
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Peptidyl-glycine alpha-
amidating monooxygenase                                          P10731|AMD_BOVIN E611 0.756 0.759 PKSKEGPLL Potential
Transmembrane emp24 
domain-containing protein 5                                         Q2KJ84|TMED5_BOVIN E77 0.756 0.757 LASPEGKTL Potential
Sine oculis-binding protein 
homolog                                                     A7XYH9|SOBP_BOVIN E7 0.755 0.814 EMEKEGRPP Potential
Sine oculis-binding protein 
homolog                                                     G5E5M4|G5E5M4_BOVIN E7 0.755 0.814 EMEKEGRPP Potential
MAPK-interacting and spindle-
stabilizing protein-like                                   Q5E9L3|MISSL_BOVIN E120 0.755 0.76 MPFPELPRP Potential
Butyrophilin subfamily 1 
member A1                                                      E1BHI7|E1BHI7_BOVIN E197 0.754 0.805 NPDEEGLFT Potential
Butyrophilin subfamily 1 
member A1 (Fragment)                                           F1MZQ4|F1MZQ4_BOVIN E199 0.754 0.805 NPDEEGLFT Potential
Disintegrin and 
metalloproteinase domain-
containing protein 10                          Q10741|ADA10_BOVIN E533 0.754 0.79 DCAKEGICN Potential
Armadillo repeat-containing 
protein 2                                                   F1MJ05|F1MJ05_BOVIN E752 0.754 0.784 LILKEGGGI Potential
Armadillo repeat-containing 
protein 2                                                   P0C6R2|ARMC2_BOVIN E754 0.754 0.784 LILKEGGGI Potential
Protein FAM110B                                                                         E1BF54|E1BF54_BOVIN E111 0.754 0.772 GAKSEGGAP Potential
Protein FAM110B                                                                         Q2KJ38|F110B_BOVIN E111 0.754 0.772 GAKSEGGAP Potential
DNA-(apurinic or apyrimidinic 
site) lyase 2                                             F1MSK4|F1MSK4_BOVIN Q495 0.754 0.77 CARPQGPPT Potential
DNA-(apurinic or apyrimidinic 
site) lyase 2                                             Q5E9N9|APEX2_BOVIN Q495 0.754 0.77 CARPQGPPT Potential
Methionine aminopeptidase 2                                                             F1N4Q2|F1N4Q2_BOVIN E58 0.754 0.765 EPDKEAGAS Potential
Methionine aminopeptidase 2                                                             Q3ZC89|MAP2_BOVIN E58 0.754 0.765 EPDKEAGAS Potential
Histone H2A                                                                             Q1LZ92|Q1LZ92_BOVIN E168 0.754 0.754 DSDKEGTSN Potential
FGD1 protein                                                                            A5D7I5|A5D7I5_BOVIN E128 0.753 0.831 EPHPEGPQR Potential
Protein-methionine sulfoxide 
oxidase MICAL3                                             G3MWR8|MICA3_BOVIN E1366 0.753 0.785 LPAAEGAQP Potential
Nitric oxide synthase                                                                   F1MYR5|F1MYR5_BOVIN E614 0.753 0.771 LMLKELTNT Potential
Nitric oxide synthase, inducible                                                        Q27995|NOS2_BOVIN E614 0.753 0.771 LMLKELTNT Potential
KRT82 protein                                                                           A3KMY1|A3KMY1_BOVIN E168 0.753 0.756 EPIFEGYIS Potential
LIX1L protein                                                                           A2VE91|A2VE91_BOVIN E311 0.753 0.756 LAGKELRFH Potential
PAIP1 protein                                                                           A5PKG2|A5PKG2_BOVIN E257 0.753 0.756 DAWKEKGKT Potential
Ubiquitin carboxyl-terminal 
hydrolase                                                   E1BKF4|E1BKF4_BOVIN E968 0.753 0.752 PSPKEGPSA Potential
HLA-B associated transcript 4                                                           Q0P5E9|Q0P5E9_BOVIN E274 0.753 0.75 GPRGEGRAN Potential
Vacuolar protein sorting-
associated protein 35                                          Q2HJG5|VPS35_BOVIN E787 0.752 0.814 SPESEGPIY Potential
Oxidative stress induced 
growth inhibitor 1                                             Q2KIN7|Q2KIN7_BOVIN E441 0.752 0.798 TIHQEGLYA Potential
Neural cell adhesion molecule 1                                                         P31836|NCAM1_BOVIN E567 0.752 0.783 EASMEGIVT Potential
Neural cell adhesion molecule 1 
(Fragment)                                              F1MMJ2|F1MMJ2_BOVIN E567 0.752 0.783 EASMEGIVT Potential
DNA repair protein RAD51 
homolog 1                                                      Q2KJ94|RAD51_BOVIN E163 0.752 0.764 YIDTEGTFR Potential
Gamma-aminobutyric acid 
receptor subunit alpha-4                                        P20237|GBRA4_BOVIN E199 0.752 0.76 YPKSEMIYT Potential
ATF6B protein                                                                           A4FUY2|A4FUY2_BOVIN E290 0.751 0.772 RVQPEGPTP Potential
Vesicular glutamate 
transporter 2                                                       A6QLI1|VGLU2_BOVIN E14 0.751 0.769 TPGKEGLKN Potential
LOC530205 protein                                                                       A4FUB1|A4FUB1_BOVIN E303 0.751 0.765 HPKPEGLAA Potential
HERC3 protein                                                                           A2VDP7|A2VDP7_BOVIN E757 0.751 0.764 LLLKELLNP Potential
SH3RF2 protein                                                                          A4IFR5|A4IFR5_BOVIN E46 0.751 0.763 KAHKELRCP Potential
Pentatricopeptide repeat-
containing protein 2, 
mitochondrial                            Q3SZ55|PTCD2_BOVIN E89 0.751 0.757 LILKEELRT Potential
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ETS homologous factor                                                                   Q32LN0|EHF_BOVIN E183 0.751 0.754 LPIAESPDT Potential
Protein NDRG1                                                                           F1MS38|F1MS38_BOVIN E170 0.75 0.812 NPCAEGWMD Potential
Protein NDRG1                                                                           Q3SYX0|NDRG1_BOVIN E170 0.75 0.812 NPCAEGWMD Potential
Mitochondrial peptide 
methionine sulfoxide reductase                                    P54149|MSRA_BOVIN E61 0.75 0.805 EPFPEGTQM Potential
Trifunctional enzyme subunit 
beta, mitochondrial                                        O46629|ECHB_BOVIN E449 0.75 0.802 RLRKEGGQY Potential
39S ribosomal protein L45, 
mitochondrial                                                F1MEP0|F1MEP0_BOVIN E103 0.75 0.793 SLSKEGLAQ Potential
39S ribosomal protein L45, 
mitochondrial                                                Q3T142|RM45_BOVIN E103 0.75 0.793 SLSKEGLAQ Potential
Cathelicidin-1                                                                          P22226|CTHL1_BOVIN E108 0.75 0.786 LKRCEGTVT Potential
ZW10 interactor                                                                         F1N7G9|F1N7G9_BOVIN E98 0.75 0.781 EQWKELKAT Potential
ZW10 interactor                                                                         Q2TBH8|ZWINT_BOVIN E98 0.75 0.781 EQWKELKAT Potential
UPF0488 protein C8orf33 
homolog                                                         Q2KID8|CH033_BOVIN E169 0.75 0.772 RPRPEGRSK Potential
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Protein name Uniprot identifer P1 amino acid Cleavage score
Surface 
score Predicted cleavage site
Likelihood of cleavage 
site
Oxysterol-binding protein 
(Fragment)                                                    I3LKX6|I3LKX6_PIG   E305 0.856 0.764 EPLKETTYT Potential
Neuroendocrine convertase 2                                                             F1SBI5|F1SBI5_PIG   E64 0.845 0.787 LPFAEGLYH Potential
Neuroendocrine convertase 2                                                             Q03333|NEC2_PIG E64 0.845 0.787 LPFAEGLYH Potential
Aquaporin 6                                                                             B2MUK1|B2MUK1_PIG   E263 0.844 0.757 EPQKEGSQA Potential
Sodium channel protein                                                                  F1RSK2|F1RSK2_PIG   E1764 0.842 0.782 APEKEGLIA Potential
Oxysterol-binding protein                                                               F1RY89|F1RY89_PIG   E60 0.841 0.798 PPRDEGPPT Potential
Lysoplasmalogenase                                                                      F1RMN2|TM86B_PIG   E6 0.839 0.777 DPGKEGLPR Potential
Complement component MASP3                                                              D5L7X4|D5L7X4_PIG E580 0.836 0.828 RPEPEGPAP Potential
Sodium channel protein                                                                  F1SJS7|F1SJS7_PIG E665 0.834 0.768 DPFAELTIT Potential
Integrin beta-1-binding protein 2                                                       Q462R2|ITBP2_PIG    E76 0.832 0.819 APQPEGPAT Potential
Galectin                                                                                I3LGZ8|I3LGZ8_PIG   E181 0.83 0.777 LPSMEGSPT Potential
1-phosphatidylinositol 4,5-
bisphosphate phosphodiesterase 
delta-4                       Q8SPR7|PLCD4_PIG    E657 0.826 0.77 DDSKEGSIV Potential
Sialoadhesin                                                                            A7LCJ3|SN_PIG    E1236 0.825 0.763 RPSDEGLYS Potential
Dihydropyrimidine dehydrogenase 
[NADP(+)]                                               F1S550|F1S550_PIG   E650 0.823 0.767 RAAKEGGAD Potential
Dihydropyrimidine dehydrogenase 
[NADP(+)]                                               Q28943|DPYD_PIG     E726 0.823 0.767 RAAKEGGAD Potential
V-type proton ATPase subunit F                                                          F1SMN6|F1SMN6_PIG E95 0.822 0.754 IPSKEHPYD Potential
Calpain-1 catalytic subunit                                                             P35750|CAN1_PIG E506 0.819 0.773 EPNKEGDFV Potential
Aminopeptidase N                                                                        F1SK03|F1SK03_PIG   E493 0.818 0.769 DLFKEGLAS Potential
Aminopeptidase N                                                                        P15145|AMPN_PIG     E493 0.818 0.769 DLFKEGLAS Potential
Heat shock protein beta-1                                                               Q5S1U1|HSPB1_PIG E65 0.814 0.771 PPAIEGPAA Potential
Interleukin-12 receptor subunit 
beta-2                                                  F1S826|F1S826_PIG   E812 0.812 0.76 LPSHEAPIT Potential
Interleukin-12 receptor subunit 
beta-2                                                  K7GQN9|K7GQN9_PIG   E726 0.812 0.76 LPSHEAPIT Potential
Interleukin-12 receptor subunit 
beta-2                                                  Q8MJS1|I12R2_PIG    E812 0.812 0.76 LPSHEAPIT Potential
Calpain-7                                                                               A0FKG7|CAN7_PIG     E794 0.811 0.79 LPKQEGPFF Potential
Calpain-7                                                                               I3LBF0|I3LBF0_PIG   E794 0.811 0.79 LPKQEGPFF Potential
Annexin                                                                                 F1SS97|F1SS97_PIG   E213 0.809 0.806 LKRAEGPST Potential
Major histocompatibility complex, 
class II, DM alpha                                    A5D9K9|A5D9K9_PIG   E117 0.809 0.752 GPLFEGKIP Potential
Major histocompatibility complex, 
class II, DM alpha                                    Q9BEA4|Q9BEA4_PIG   E117 0.809 0.752 GPLFEGKIP Potential
Nitric oxide synthase, endothelial                                                      Q28969|NOS3_PIG Q29 0.807 0.771 LCGKQGPAT Potential
4-trimethylaminobutyraldehyde 
dehydrogenase                                             F1S232|F1S232_PIG   E473 0.805 0.771 PKLKEGYYM Potential
Gastrokine-3                                                                            D2XPP7|GKN3_PIG     E150 0.805 0.753 QQQKEGTAL Potential
Interleukin 16                                                                          Q76EI9|Q76EI9_PIG   E457 0.804 0.789 LASQEGTIQ Potential
WAP four-disulfide core domain 
protein 2                                                Q8MI69|WFDC2_PIG    E76 0.803 0.798 PNEKEGSCP Potential
Mitochondrial uncoupling protein 2                                                      O97562|UCP2_PIG     E264 0.8 0.762 MLQKEGPRA Potential
Mitogen-activated protein kinase 
kinase kinase                                          F1SFP4|F1SFP4_PIG   E646 0.8 0.75 TPPSEGSAP Potential
Mitogen-activated protein kinase 
kinase kinase 12                                       I3L8B0|I3L8B0_PIG   E679 0.8 0.75 TPPSEGSAP Potential
V-type proton ATPase subunit a                                                          F1RFL9|F1RFL9_PIG   E364 0.799 0.78 IPTKETPPT Potential
Isoform 3 of Sterol regulatory 
element-binding protein cleavage-
activating protein      Q5MNU5|SCAP_PIG     E948 0.799 0.759 TPEDEGSFP Potential
Sterol regulatory element-binding 
protein cleavage-activating protein                   F1SNT3|F1SNT3_PIG   E949 0.799 0.759 TPEDEGSFP Potential
GNAS complex locus                                                                      A5GFT7|A5GFT7_PIG  R242 0.796 0.766 SPSKRGPIP Potential
Endothelin B receptor                                                                   P35463|EDNRB_PIG    E92 0.796 0.763 PPPCEGPIE Potential
Hermansky-Pudlak syndrome 6 
protein                                                     A5A775|A5A775_PIG   E400 0.795 0.785 LPSAEGLVF Potential
Olfactory receptor (Fragment)                                                           I3LFY3|I3LFY3_PIG   E232 0.795 0.775 MPSAEGRAK Potential
Tyrosine-protein kinase receptor 
(Fragment)                                             F1S3X9|F1S3X9_PIG   E621 0.793 0.784 EAFMEGIFT Potential
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Tyrosine-protein kinase receptor 
(Fragment)                                             K7GQT6|K7GQT6_PIG   E699 0.793 0.784 EAFMEGIFT Potential
Protein delta homolog 2                                                                 B2LW77|DLK2_PIG E132 0.793 0.755 CERKEGPCE Potential
von Willebrand factor                                                                   K7GNN0|K7GNN0_PIG   E568 0.793 0.755 NPRAEGLEC Potential
von Willebrand factor (Fragment)                                                        F1SL22|F1SL22_PIG   E606 0.793 0.755 NPRAEGLEC Potential
von Willebrand factor (Fragment)                                                        Q28833|VWF_PIG E458 0.793 0.755 NPRAEGLEC Potential
Wee1-like protein kinase 2                                                              A4PES0|WEE2_PIG E109 0.791 0.768 PPHCESPFT Potential
Tissue factor pathway inhibitor                                                         F1SFC1|F1SFC1_PIG E42 0.791 0.764 LPPDEGPCR Potential
Iodotyrosine dehalogenase 1                                                             Q6TA49|IYD1_PIG E271 0.791 0.758 YPSKEATVP Potential
Microtubule-associated protein                                                          F1SLI3|F1SLI3_PIG E479 0.79 0.776 PPNKELPPS Potential
Chaperonin containing TCP1, 
subunit 2 (Beta)                                            D0G0C8|D0G0C8_PIG   E482 0.789 0.782 LDMKEGTIG Potential
XK-related protein                                                                      F1STN1|F1STN1_PIG   E258 0.789 0.764 DPCSEWLYR Potential
Fibulin-1                                                                               F1SM61|F1SM61_PIG   E335 0.789 0.751 CINTEGSYT Potential
GH3 domain-containing protein                                                           E9KYT5|E9KYT5_PIG E433 0.788 0.79 LDSSEGSAP Potential
Xaa-Pro aminopeptidase 2                                                                Q95333|XPP2_PIG     E547 0.787 0.816 IPMAEGMFT Potential
Protein S100-A12                                                                        K7GR24|K7GR24_PIG   E40 0.787 0.791 LITKELPNT Potential
Protein S100-A12                                                                        P80310|S10AC_PIG   E40 0.787 0.791 LITKELPNT Potential
Oxytocin receptor                                                                       E3V2E8|E3V2E8_PIG   E24 0.786 0.78 PPEAEGNRT Potential
Oxytocin receptor                                                                       P32306|OXYR_PIG     E24 0.786 0.78 PPEAEGNRT Potential
LIM domain only 3                                                                       A9ED84|A9ED84_PIG   E138 0.786 0.773 GLMKEGYAP Potential
Phosphoinositide phospholipase C                                                        F1RQ08|F1RQ08_PIG   E999 0.785 0.775 QARAEGRCR Potential
Calcitonin gene-related peptide 
type 1 receptor                                         Q8WN93|CALRL_PIG    E358 0.785 0.771 PWRPEGKIA Potential
Phosphoacetylglucosamine mutase                                                         F1RQM2|F1RQM2_PIG E81 0.785 0.759 DPLGEMLAP Potential
Prolactin receptor                                                                      Q6JTA8|PRLR_PIG   E581 0.785 0.757 EPTKETPPS Potential
Prolactin receptor (Fragment)                                                           K7GKV2|K7GKV2_PIG E596 0.785 0.757 EPTKETPPS Potential
Coronin                                                                                 F1RK53|F1RK53_PIG   E673 0.783 0.811 EPLQEGPGP Potential
Autophagy-related protein 13 
(Fragment)                                                 F1SIA3|F1SIA3_PIG   E341 0.783 0.757 VPGKEGGVP Potential
Coatomer subunit gamma                                                                  F1SNE9|F1SNE9_PIG E462 0.782 0.821 LLGKEGPRT Potential
Apolipoprotein M                                                                        Q2LE37|APOM_PIG    E58 0.782 0.765 APTKEELAT Potential
Toll-like receptor 8                                                                    B3XXC2|B3XXC2_PIG   E1000 0.781 0.796 NPKAEGLFW Potential
Pulmonary surfactant-associated 
protein D                                               Q9N1X4|SFTPD_PIG    E120 0.781 0.77 PAGKEGPSG Potential
Bifunctional ATP-dependent 
dihydroxyacetone kinase/FAD-AMP 
lyase (cyclizing)            F1RKQ4|DHAK_PIG     E128 0.78 0.775 QARAEGIPV Potential
Inhibin beta A chain                                                                    F1SSD8|F1SSD8_PIG   E143 0.78 0.773 EISKEGSDL Potential
Inhibin beta A chain                                                                    P03970|INHBA_PIG   E143 0.78 0.773 EISKEGSDL Potential
Iron-responsive element-binding 
protein 2                                               B3VKQ2|IREB2_PIG    E838 0.78 0.75 LYQKEGIPL Potential
Prenylated Rab acceptor protein 1                                                       F1RMX2|F1RMX2_PIG E14 0.779 0.79 DAEAEGLSA Potential
Prenylated Rab acceptor protein 1                                                       Q52NJ0|PRAF1_PIG    E14 0.779 0.79 DAEAEGLSA Potential
Histidine ammonia-lyase                                                                 F1SQR7|F1SQR7_PIG   E301 0.779 0.764 LKPKEGLAL Potential
Glutathione S-transferase omega-1                                                       Q9N1F5|GSTO1_PIG E21 0.777 0.753 GPVPEGLIR Potential
Coiled-coil and C2 domain 
containing 1A                                                 F1SD63|F1SD63_PIG   E934 0.776 0.768 EAAKEALYR Potential
Histone acetyltransferase                                                               F1RIR8|F1RIR8_PIG E32 0.776 0.752 NAAVEGTAP Potential
Histone acetyltransferase                                                               K7GPZ7|K7GPZ7_PIG   E32 0.776 0.752 NAAVEGTAP Potential
Eosinophil peroxidase                                                                   K7GNQ2|K7GNQ2_PIG   E21 0.774 0.794 AWSCEGTAP Potential
Eosinophil peroxidase (Fragment)                                                        F1RSB4|F1RSB4_PIG E26 0.774 0.794 AWSCEGTAP Potential
Phosphoinositide phospholipase C 
(Fragment)                                             I3LCQ7|I3LCQ7_PIG   E295 0.774 0.753 EPSKEGQEK Potential
Protein arginine N-
methyltransferase 5                                                  C3RZ98|C3RZ98_PIG   E499 0.771 0.776 EAQFEMPYV Potential
POU domain protein                                                                      F1RM14|F1RM14_PIG   E58 0.771 0.764 LARAEALAA Potential
POU domain protein                                                                      I3L5L7|I3L5L7_PIG E61 0.771 0.764 LARAEALAA Potential
POU domain protein                                                                      I3LTT4|I3LTT4_PIG E59 0.771 0.764 LARAEALAA Potential
POU domain protein (Fragment)                                                           F1RS67|F1RS67_PIG E18 0.771 0.764 LARAEALAA Potential
Olfactory receptor                                                                      I3LKS3|I3LKS3_PIG E232 0.771 0.757 MKSKEGRIK Potential
Olfactory receptor                                                                      F1RMQ7|F1RMQ7_PIG   E100 0.771 0.752 LISFEGCMT Potential
Myosin-1                                                                                F1SS64|F1SS64_PIG   E900 0.77 0.788 QAEAEGLAD Potential
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Myosin-2                                                                                Q9TV63|MYH2_PIG     E900 0.77 0.788 QAEAEGLAD Potential
Cytochrome c oxidase subunit 1                                                          O79876|COX1_PIG E40 0.77 0.759 LIRAELGQP Potential
Acyl-CoA desaturase                                                                     K7GKT7|K7GKT7_PIG   E63 0.769 0.814 YQDKEGPRP Potential
Acyl-CoA desaturase                                                                     Q6RWA7|Q6RWA7_PIG   E63 0.769 0.814 YQDKEGPRP Potential
Acyl-CoA desaturase (Fragment)                                                          K7GNB9|K7GNB9_PIG E25 0.769 0.814 YQDKEGPRP Potential
Adenosine monophosphate 
deaminase 1 isoform M                                           B5SYT7|B5SYT7_PIG   E227 0.767 0.76 AASKEEPKP Potential
Olfactory receptor                                                                      I3LIR8|I3LIR8_PIG   E230 0.766 0.798 IPSAEGRAK Potential
Olfactory receptor                                                                      I3LL29|I3LL29_PIG   E230 0.766 0.798 IPSAEGRAK Potential
Serine/threonine-protein kinase 
PLK                                                     F1S348|F1S348_PIG   E389 0.766 0.787 DARPEAPAA Potential
Polymeric immunoglobulin 
receptor                                                       F1SEY8|F1SEY8_PIG   E71 0.766 0.757 LISSEGYIS Potential
Insulin-like 3                                                                          F1SMC2|F1SMC2_PIG   E213 0.764 0.797 LIAQEGPFF Potential
Transporter                                                                             I3L6B0|I3L6B0_PIG   E570 0.763 0.767 LCQTEGPFL Potential
Transporter (Fragment)                                                                  F1SPI3|F1SPI3_PIG   E573 0.763 0.767 LCQTEGPFL Potential
Citrate synthase, mitochondrial                                                         P00889|CISY_PIG     E117 0.762 0.828 EPLPEGLFW Potential
Diacylglycerol kinase (Fragment)                                                        I3LQV4|I3LQV4_PIG E814 0.762 0.794 DVRAEGTPA Potential
Caspase                                                                                 I3L9A3|I3L9A3_PIG   E126 0.762 0.793 EPRPEAPRP Potential
Taste receptor type 2                                                                   I3LB59|I3LB59_PIG   E170 0.762 0.771 NPFKEMPPL Potential
Ribonucleoside-diphosphate 
reductase                                                    I3LEK6|I3LEK6_PIG   E60 0.762 0.762 DDSIEGIYD Potential
2-amino-3-carboxymuconate-6-
semialdehyde decarboxylase 
(Fragment)                       F1S0C2|F1S0C2_PIG   E101 0.759 0.754 RCVKELGFP Potential
Asparagine synthetase                                                                   D0G0C6|D0G0C6_PIG  E514 0.758 0.813 PKTKEGYYY Potential
Isoform 2 of Large proline-rich 
protein BAG6                                            A5D9M6|BAG6_PIG     E989 0.758 0.774 PPAPEGGSR Potential
Large proline-rich protein BAG6                                                         A5D9M6-2|BAG6_PIG E988 0.758 0.774 PPAPEGGSR Potential
Large proline-rich protein BAG6                                                         F1RQX8|F1RQX8_PIG E989 0.758 0.774 PPAPEGGSR Potential
Liver X receptor alpha                                                                  Q4TU03|Q4TU03_PIG   K86 0.757 0.806 QKRKKGPAP Potential
Syntaxin-binding protein 2                                                              F1SCI9|F1SCI9_PIG   E53 0.757 0.771 DILAEGITI Potential
Syntaxin-binding protein 2 
(Fragment)                                                   Q29268|STXB2_PIG    E53 0.757 0.771 DILAEGITI Potential
Stress-70 protein, mitochondrial                                                        F1RGJ3|F1RGJ3_PIG E352 0.756 0.771 RAQFEGIVT Potential
COP9 signalosome complex subunit 
6                                                      A7TX81|CSN6_PIG     E99 0.756 0.763 IIDKEYYYT Potential
Ubiquitin-conjugating enzyme E2L 
6                                                      F4ZS20|F4ZS20_PIG   E17 0.755 0.758 DLQKELPRY Potential
One cut domain family member                                                            F1SDH9|F1SDH9_PIG E394 0.755 0.755 RPSKEMQVT Potential
Histone H2A (Fragment)                                                                  I3LQZ2|I3LQZ2_PIG E146 0.754 0.754 DSDKEGTSN Potential
DNA repair protein RAD51                                                                B0M1M6|B0M1M6_PIG   E163 0.752 0.764 YIDTEGTFR Potential
Galectin-4                                                                              Q29058|LEG4_PIG     E183 0.75 0.819 LPCMEGAPT Potential
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A.7. ToppFun analysis
Results from the ToppFun analysis of potential FMDV 3C targets in the bovine and porcine
proteomes are presented here. As described in Chapter 5, no information for either Biological
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Abstract Genome editing tools enable efficient and
accurate genome manipulation. An enhanced ability to
modify the genomes of livestock species could be
utilized to improve disease resistance, productivity or
breeding capability as well as the generation of new
biomedical models. To date, with respect to the direct
injection of genome editor mRNA into livestock
zygotes, this technology has been limited to the
generation of pigs with edited genomes. To capture the
far-reaching applications of gene-editing, from
disease modelling to agricultural improvement, the
technology must be easily applied to a number of
species using a variety of approaches. In this study, we
demonstrate zygote injection of TALEN mRNA can
also produce gene-edited cattle and sheep. In both
species we have targeted the myostatin (MSTN) gene.
In addition, we report a critical innovation for
application of gene-editing to the cattle industry
whereby gene-edited calves can be produced with
specified genetics by ovum pickup, in vitro fertiliza-
tion and zygote microinjection (OPU-IVF-ZM). This
provides a practical alternative to somatic cell nuclear
transfer for gene knockout or introgression of desir-
able alleles into a target breed/genetic line.
Keywords Livestock  TALEN  Myostatin 
Zygote  Genetic engineering
Introduction
The ability to generate gene knockouts is an extremely
powerful tool for the analysis of gene function and for
the generation of animals with biotechnological or
breeding applications (Fahrenkrug et al. 2010). In
livestock species this process traditionally involves
the generation of a knock-out cell line generated
utilising homologous recombination followed by
somatic cell nuclear transfer (SCNT). This remains
the method of choice for many applications (Kurome
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et al. 2013), however, application of SCNT strategies
requires a high-level of technical expertise, reliable
supply of oocytes and a large recipient herd, features
not available in many areas where gene-editing might
have the greatest impact.
The advent of highly efficient genome editors has
driven a renaissance in livestock genetic modification
by embryo microinjection (Tan et al. 2012; Lillico
et al. 2013). Whereas pronuclear injection, the original
method for creation of transgenic livestock, is rarely
performed nowadays due to the low frequency of
transgenic offspring (Clark and Whitelaw 2003; Clark
et al. 2007; Ivics et al. 2014) cloning strategies are still
widely utilised and in combination with zinc finger
nucleases have been used to generate edited cattle (Liu
et al. 2014), pigs (Hauschild et al. 2011), sheep (Zhang
et al. 2014) and goats (Boulanger et al. 2014). In
comparison to cloning, cytoplasmic injection of
zygotes with editor mRNA is both technically simple
and efficient (Geurts et al. 2009; Carbery et al. 2010;
Carlson et al. 2012). In this study, we build on our
recent success of gene-editing in pigs (Lillico et al.
2013) to derive the first genome edited sheep and
cattle. As with our swine study, the editing events were
the result of direct injection of TALEN mRNA into
zygotes followed by transfer into synchronized recip-
ients. Another critical innovation in this study is that
bovine embryos were prepared by ovum pickup,
in vitro fertilisation and zygote microinjection
(OPU-IVF-ZM). OPU-IVF is widely used in the cattle
industry to rapidly produce a number of offspring from
a single cow of elite genetics, up to 50–100 offspring
per year (Leeuw 2006). Thus, in vitro produced
embryos from either in vitro or in vivo matured
oocytes can be used for rapid introgression of gene-
edits into defined populations.
Materials and methods
TALEN design and construction
Design and construction of the btGDF83.1L?83.1NR
is described in Carlson et al. 2012 using the RCIscript-
GoldyTALEN transcription vector (Addgene ID
38142). Messenger RNA was synthesized using the
mMessage Machine T3 Kit (Ambion) as previously
described (Carlson et al. 2012) prior to polyadenyla-
tion using the Poly(A) tailing kit (Ambion) according
to the manufacturers recommendations. To test the
activity of the TALEN pair, 1 lg of mRNA was
transfected (NeonTM, Life Technologies; 1800 V,
20 ms, 1 pulse) into 106 primary bovine and ovine
fibroblasts. The cells were allowed to recover at 30 C
for 3 days before being harvested and the extent of
genome modification assessed by Surveyor nuclease
assay. The primer pair MSTN For (50-
GTCAAGGTAACAGACACACC-30) and MSTN
Rev (50-CACCCACAGCGATCTACTAC-30) was
used to amplify a 359 base pair region both the bovine
and ovine Surveyor assays.
Bovine oocyte collection and manipulation
Oocytes were collected from Nellore cows under
ultrasound guidance (Aloka 500 and a vaginal guide
probe) with a 17 gauge needle connected via a Cook
pump set at 72 psi. Oocytes were rinsed with pre-
warmed TL Hepes (0.3 % BSA) ? Gentamicin
(50 lg/ll) supplemented with 10 IU/ml of Heparin
and placed into maturation medium. In vitro fertiliza-
tion was conducted in pre-equilibrated modified
Tyrode-lactate medium supplemented with 250 lM
sodium pyruvate, 1 % P/S, 6 mg/ml BSA Fatty Acid
free (Sigma), 20 lM Penicillamine, 10 lM Hypotau-
rine, 1 lM Epinephrine and 10 lg/ml Heparin (Sigma)
at 38.5 C, 5 % CO2 in an air humidified incubator.
Frozen semen from a Nelore bull was thawed at 35 C
then separated by centrifugation at 2009g in a density
gradient medium (Isolate, Irvine Scientific, Santa
Ana, CA, USA) 50 % upper/90 % lower. The sperm
pellet was re-suspended in 2 ml of modified Tyrodes
medium and centrifuged at 2009g for 10 min to wash.
This was repeated once more before the sperm pellet
was removed and placed into a warm 0.65 ml micro-
tube (VWR Scientific, Pittsburgh, PA., USA). Fertil-
ization was conducted in a Nunclon 4-well multi-dish
(VWR) containing up to 50 matured oocytes per well
and a concentration of 1.5 9 106 sperm/ml ? 20 lg/
ml heparin. Presumptive zygotes, 20–22 h post fertil-
ization, were vortexed and further cleaned with a
stripper pipette (125 lm diameter) prior to placing in
Hanks 199 ? 10 % FBS ? Gentamicin for an injec-
tion of either 2 or 5 ng/ll TALEN mRNA. Injections
were conducted under positive pressure until a slight
expansion of the cell membrane was observed. All
injected zygotes were placed in Evolve ? 4 mg/ml




incubator at 38.5 C. On day 2 post IVF, all non-
cleaved embryos were removed leaving the remainder
to culture undisturbed until day 7. At 7 days post IVF
viable embryos were washed through Vigro Holding
Medium (Bioniche), loaded and transferred into syn-
chronized cross-bred recipients.
Ovine oocyte manipulation and transfer
Ovine ovaries were collected from the abattoir and the
follicles aspirated with pre-warmed phosphate buf-
fered saline at 38 C. Oocytes were washed three
times in oocyte wash medium before transfer to
maturation medium for 22 h (38.5 C, 5 % CO2). The
oocytes are then washed twice in fertilisation medium
before being transferred to a Nunclon 4-well multi-
dish (VWR) with each well containing 450 ul of
fertilisation medium and approximately 40 oocytes.
1 9 106 sperm was added to each well and incubated
for 24 h (38.5 C, 5 % CO2). The fertilized oocytes
were then washed in SOFaaBSA to remove sperm and
any remaining cumulus cells. The zygotes were
subjected to a single 2–5pl injection of 2 ng/ul
TALEN mRNA before being returned to 4 well plates
containing 800 ul SOFaaBSA medium per well and
cultured in groups of approximately 40 zygotes. The
zygotes were incubated (5 % CO2, 5 % O2, 90 % N2,
38.5 C) for 6–7 days at which point blastocysts were
transferred to recipient ewes. Progesterone sponges
(Chronogest sponges) were inserted into ewes for a
period of between 11 and 15 days. After removal of
the sponges the ewes showed estrus 36–48 h later.
Schedules were arranged such that day 6 blastocysts
were transferred to recipient ewes 6 days post estrus
under general anaesthesia, following a mid-line lap-
arotomy to expose the uterus. A Drummond pipette
was used to transfer two or three blastocysts into the
uterine horn.
Genotyping
Gene editing events were characterized by PCR,
Surveyor assays and sequencing as described previ-
ously (Carlson et al. 2012). Analysis of bovine samples
utilized the primer pair btGDF8 forward (50-CCTT
GAGGTAGGAGAGTGTTTTGGG-30) and btGDF8
reverse (50-CTCATGAACACCCACAGCGATCTA
C-30). The lambs were analysed using the primer pair
MSTN For (50-GTCAAGGTAACAGACACACC-30)
and MSTN Rev (50-CACCCACAGCGATCTACTAC-
30).
Results and discussion
The aim of this paper was to determine the potential of
genome editors as a tool for introducing desired
mutations in sheep and cattle species. The MSTN gene
(McPherron et al. 1997) was considered an attractive
target as mutations have been found naturally in both
cattle (Grobet et al. 1997) and sheep (Clop et al. 2006).
MSTN or growth and differentiation factor 8 (GDF-8)
is a member of the transforming growth factor b
family and is a negative regulator of muscle growth.
An 11 bp deletion in the bovine MSTN gene at position
821 has been shown to result in muscular hypertrophy
or the ‘double muscle’ phenotype characterised by a
20 % increase in muscle mass (Grobet et al. 1997).
Mutations in the MSTN gene that result in either
inactivation or reduction of functional protein also
result in a marked increase in muscle mass (McPher-
ron and Lee 1997). Indel formation induced by
TALEN activity would be ideal for attempting to
replicate the double muscle phenotype and proving the
functionality or editors in sheep and cattle. In this
particular example, we hypothesized that the easy
calving of Nelore cattle will reduce the management
burden of dystocia that is common in other cattle
breeds with double muscling breeds (Ménissier 1976).
For sheep, higher survivability of offspring derived
from a terminal Texel (MSTN-KO) sire (Leymaster
and Jenkins 1993) would be more beneficial in
alternative breeds of sheep. Gene editing represents
a rapid methodology to introgress MSTN inactivating
alleles into naive breeds.
We have previously demonstrated activity of
TALENs that targeted a region of the bovine MSTN
gene between positions 815 and 872 relative to the
start codon (NM_001001525; Fig. 1a) (Carlson et al.
2012). The left TALEN recognises 23 base pairs and
the right TALEN recognises 19 base pairs. Compar-
ison of the bovine and ovine (NM_001009428)
sequences showed there to be a SNP at base 8 of the
binding site of the left TALEN monomer (Fig. 1a).
We have observed that at least one mismatch between
the TALENs and the target sequence can be tolerated
(Tan et al. 2013), so we hypothesized that the bovine




Indeed, transient transfection of TALEN mRNA into
bovine and ovine fibroblasts and subsequent Surveyor
nuclease assay showed similar levels of activity in
both species (Fig. 1b).
Bovine zygote injections and transfers
Two rounds of OPU-IVF were conducted using Nelore
donors in parallel to the same procedure with abattoir
oocytes (TransOva Genetics, Sioux Center, IA). After
IVF, presumptive zygotes were injected with 2 or
5 ng/ll of TALEN mRNA. Embryos were scored for
blastocyst formation on day 7 and a portion of
embryos were analysed for gene-edits to evaluate
performance of the approach. For embryos derived
from abattoir oocytes, 4/13 (31 %) and 17/30 (57 %)
were edited for the 2 and 5 ng/ll injections, respec-
tively. Four of the six Nelore blastocysts included in
this analysis were edited. In total, 20 Nelore embryos
were transferred to 11 outbred recipients resulting in
two full term twin-pregnancies (Table 1). The first set
of twins birthed naturally resulting in a bull (bull #1)
and heifer calf (Fig. 2a). Unfortunately, the second
recipient went into labour shortly after a routine check
and the birth was unattended. Both bull calves were
born dead due to calving difficulties associated with
twinning. Sequence analysis revealed that each of the
three bull calves was edited whereas no edits were
observed in the heifer. A total of 3 unique alleles were
sequenced from bull # 1. The predominant genotype
844del1 (70 % of sequenced alleles, n = 13) is a
frame shift mutation that results in a stop codon within
four amino acids. A second mutant allele, DR283, was
also observed twice as was the wild type sequence
(Fig. 3). This suggests that the TALENs were active
for more than one cell division, an observation made
previously by analysis of pre-implantation embryos
(Carlson et al. 2012). The DR283 mutation has not
been characterized previously, and since it is not a
frame-shift it is expected to produce a protein, but with
Fig. 1 The MSTN
TALENs. a 359 bp of the
bovine MSTN gene
sequence showing the
TALEN binding sites (red
boxes) and the primers
(green boxes) used to
amplify the region for the
surveyor nuclease assay.
The base coloured blue
dictates the position of the
mismatch in the ovine
sequence in which it is G
rather than A. b The
surveyor nuclease assay
results for the TALEN
transfected bovine and ovine
fibroblasts. gDNA extracted
from transfected cells was






unknown functionality. Regardless, a phenotypic
difference between bull #1 and the wild-type heifer
is readily observed (Fig. 2b). Given that this bull is
mosaic, without segregation it is difficult to differen-
tiate whether hypermuscularity in the Nelore bull
derives from haploinsufficiency, from homozygosity
of 844del1 knockout allele, or heterozygosity 844del1
and DR283 alleles. The potential of DR283 as a
hypomorphic allele will be evaluated in subsequent
generations due to the desire to identify myostatin
Table 1 The development and editing frequency of bovine and ovine zygotes
Dose Species Oocytes Cleaved (%) Blastocysts (%) Transferred Preg (%) Edited (%)
C Transova 83 62 (74) 27 (33) –
TE Transova 119 89 (75) 24 (20) –
2 ng/ll Transova 45 34 (76) 12 (27) –
Nelore 21 17 (81) 6 (29) 4 0/2 –
Sheep 113 61 (54) 27 (24) 26 8/9 (89) 1/9 (11)
5 ng/ll Transova 308 234 (76) 44 (14) –
Nelore 166 112 (67) 13 (8) 16a 2/9 (22) 3/4 (75)
A comparison of the zygote data, pregnancy rates and editing frequencies
C uninjected controls, TE TE injected controls
a 9 of the transferred were morulae
Fig. 2 MSTN edited animals. a The live born bull (bull #1: left) and heifer calf (right). b The readily observed phenotypic difference
between bull #1 (right) and the wild-type heifer (left). c The edited lamb
Fig. 3 The MSTN editing
events. An alignment of the
bovine and ovine WT
sequences and the alleles
present in each of the edited
animals. The TALEN
binding sites are highlighted









genotypes that balance enhanced muscle hypertrophy
with calving ease (Keele and Fahrenkrug 2001).
Future analysis will also measure the effect of the
mosaicism on germline transmission of the editing
events from the Nelore bull. Given this, a full analysis
of the degree of mosaicism in different tissues, to
assess whether or not it is lower in muscle, has been
ruled out at this stage.
Ovine zygote injections and transfers
Ovine oocytes were collected from abattoir-derived
material and subjected to in vitro maturation and
in vitro fertilisation (Ritchie et al. 2008) before
receiving a single 2–5pl injection of TALEN mRNA
at 2 ng/ll. The zygotes were subsequently cultured for
a further 6–7 days before transfer of blastocysts to
synchronised recipient ewes. The sheep zygotes
showed a good blastocyst development rate of 24 %,
despite an initially poorer than expected cleavage rate
(Table 1). In total 26 blastocysts were transferred to 9
recipient ewes (2 or 3 blastocysts per ewe) resulting in
8 pregnancies and 12 live births. Three of these lambs
died within 24 h post-partum and carcasses were
disposed of before samples could be acquired for
analysis.
Of the 9 live births one was shown to be edited
(Fig. 2c) as a heterozygote DR283 (Fig. 3), demon-
strating cross-species application and surprisingly an
identical genotypic outcome of TALENs designed
against the bovine myostatin gene. As with bull #1, the
sequence context does not enable definitive identifi-
cation as to which three bases have been deleted from
the MSTN gene. For example, in Fig. 3, the three
deleted bases have been marked as those coding for
R283, alternatively, the three-base deletion could
equally have started 1 or 2 bases downstream.
However, in all three scenarios the resulting nucleo-
tide and amino acid sequences would be the same.
Conclusion
This study further exemplifies the utility and ease with
which TALENs can be used to engineer the genome of
livestock. Specifically we demonstrate that sheep and
cattle can be added to the growing list of species for
which genome editing is now practical. It is antici-
pated that these tools will accelerate the utilisation of
engineered livestock for biomedical and agricultural
applications. Genome edited livestock differ from
traditional GM animals in that no recombinant DNA
(transgene) is integrated into the animal genome.
Combined with the ability to mimic desirable or pre-
existing mutations, genome editing overcomes many
of the issues associated GM animals increasing the
likelihood for societal acceptance. Furthermore, the
advent of this technology is extremely timely given the
global challenge of food security; targeted mutagen-
esis and allele introgression has the potential to
accelerate genetic advancement of agriculturally
important traits. The deployment of gene editing using
industry-standard reproductive technologies demon-
strates several practical approaches to advancing
livestock genetics and biotechnology.
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